Handbook of clinical allergology by Vykhrystenka, L. R. & Yanchanka, U. V.
VITEBSK STATE MEDICAL UNIVERSITY
Vykhrystsenka L.R., Yanchanka U.V. 
Edited by Novikov D.K.
HANDBOOK OF 
CLINICAL ALLERGOLOGY
Textbook for students o f high medical educational establishments
VITEBSK  STATE M EDICAL UNIVERSITY PRESS
2008
УДК 616: 57.083.32(07)
ББК52.523я7
V94
Reviewed by:
M R. Conorev, Professor of Hospital Therapy, Vitebsk State Medical University
Contributors (autors):
Vykhrystsenka L.R.
V94 Handbook of clinical allergology: Handbook / Vykhrystsenka L.R., Yanchanka U.V., 
edited by Novikov D.K., for students of high medical educational establishments, - Vitebsk 
VSMU, 2008.-147 p.
The content of «Handbook of clinical Allergology» is update, believed to be 
reliable coben checked coith sourceo and is in accordance coith simple language and in 
stepcoise manner, cobich coil create interest -  and enthusiasm to ceam and develop the 
concept in clinical Allergology.
This book gives a new arientation to the subject of Allergology so that the 
student appreciate the great importance and significance of application of allergology to 
medicine.
Authors welcome comments and suggestion from faculty students and other 
readers to make improvement in the next edition.
УДК 616: 57.083.32 (07) 
Б Б К  52.523я7
Издательство Витебского 
государственного медицинского 
университета, 2008
ISBN 978-985-466-254-1
C O N T E N T S  Pages
Symbol and abbreviations....................................................................................... 4
CHAPTER 1. IMMUNOLOGY OF ALLERGIC DISORDERS....................................... 6
CHAPTER 2. ALLERGENS...................................................................................................11
CHAPTER 3. THE ATOPIC DISEASES: APPROACH TO DIAGNOSIS.................. 18
CHAPTER4. ANAPHYLAXIS..............................................................................................41
CHAPTERS. ASTHMA........................................................................................................ 49
CHAPTER 6. ALLERGIC RHINITIS................................................................................. 79
CHAPTER 7. ALLERGIC CONJUNCTIVITIS.................................................................88
CHAPTERS. SINUSITIS.........................................................................................................89
CHAPTER 9. FOOD ALLERGY..........................................................................................90
CHAPTER 10. ATOPIC DERMATITIS............................................................................. ,99
CHAPTER 11. CONTACT DERMATITIS (HYPERSENSITIVITY)...........................108
CHAPTER 12. DRUG ALLERGY........................................................................................ 112
CHAPTER 13. LATEX ALLERGY......................................................................................122
CHAPTER 14. ANGIOEDEMA............................................................................................ 126
CHAPTER 15. URTICARIA................................................................................................ 131
QUESTIONS AND ANSWERS............................................................................................137
3
Symbols and abbreviations
ADA adenosine deaminase
ANA anti-nuclear antibody
ANCA anti-neutrophil cytoplasmic antibody
APC antigen-presenting cell
APGS autoimmune polyglandular syndrome
APS anti-phospholipid syndrome
BAL bronchoalveolar lavage
BCG bacille Calmette-Guerin
Td twice a day
BM bone marrow
cAMP cyclic adenosine monophosphate
C-ANCA cytoplasmic ANCA
CIDP chronic inflammatory
demyelinating polyneuropathy 
CK creatine kinase
CMI cell-mediated immunity
CMV cytomegalovirus
CNS central nervous system
ConA concanavalin A
COPD chronic obstructive
pulmonary disease
CPD continuing professional development
Cr & E creatinine and electolytes
CRF chronic renal failure
CRP C-reactive protein
CSF cerebrospinal fluid
CSF-1 colony-stimulating factor-1
CSS Churg-Strauss syndrome
CT computed tomography
CTD connective tissue disease
CTL cytotoxic T lymphocyte
CTLp cytotoxic T-lymphocyte precursor
CV coefficient of variation
CVA cerebrovascular accident
CyA cyclosporin A
DAF decay accelerating factor
dATP deoxyadenosine triphosphate
DBPC double-blind, placebo-controlled
DCT direct Coombs test
DH dermatitis herpetiformis
DIC disseminated
intravascular coagulation 
DIF direct immunofluorescence
DM dermatomyositis
DNA deoxyribonucleic acid
DNA-PK.cs DNA protein kinase catalytic subunit 
DRL drug-related lupus
dsDNA double-stranded DNA
DTH delayed-type hypersensitivity
DV designated value
DVT deep vein thrombosis
EA early antigen
EAA extrinsic allergic alveolitis
EBNA EBV nuclear antigen
EBV Epstein-Barr virus
ECG electrocardiogram
ECP eosinophil cationic protein
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EIA enzyme-linked immunoassay
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
ENA
ENT
EPD
FAST
FCAS
FcR
FIA
FISH
F1TC
G-CSF
GGT
G1
GLP
GM-CSF
GN
GP
GPC
G6PD
GPI
GS-ANA
HAE
H & E
HANE
Hb
HBsAg
HCV
HEP
HEp-2
HGV
HHV
Hib
HIGE
H1GM
HIT
HIV
HLA
Hsp
HSP
HSV
5-HT
HTLp
HUV
1CAM
1COS
ID
IDDM
IDT
IEF
IF
IFN
lg
IIF
IL
IM
IMIg
IPF
U
IU
IV
JCA
extractable nuclear antigen 
ear, nose, and throat 
enzyme-potentiated desensitization 
fluorescent allergosorbent test 
familial cold autoinflammatory 
syndrome 
Fc receptor
fluorescent immunoassay 
fluorescent in situ hybridization 
fluorescein isothiocyanate 
granulocyte colony stimulating factor 
gammaglutamyt transferase 
gastrointestinal 
good laboratory practice 
granulocyte-macrophage colony 
stimulating factor 
glomerulonephritis 
glycoprotein 
gastric parietal cell 
glucose 6-phosphate dehydrogenase 
glucosylphosphatidylinositol 
granulocyte anti-nuclear antibody 
hereditary angioedema 
haematoxylin and eosin 
hereditary angioneurotic oedema 
haemoglobin
hepatitis В surface antigen 
hepatitis C virus 
histamine equivalent potency 
human epithelial cell line 
hepatitis G virus 
human herpesvirus 
Haemophilus influenzae type b 
hyper-1 gE syndrome 
hyper-IgM
heparin-induced thrombocytopenia 
human immunodeficiency virus 
human leucocyte antigen 
heat-shock protein 
Henoch-Schonlein purpura 
herpes simplex virus 
5-hydroxyttyptamine (serotonin) 
helper-T lymphocyte precursor 
hypocomplementaemic urticarial 
vasculitis
intercellular adhesion molecule 
inducible co-stimulator 
intradermal
insulin-dependent diabetes mellitus
intradermal test
Immunoelectrophoresis
intrinsic factor
interferon
immunoglobulin
indirect immunofluorescence
interleukin
intramuscular(ly)
intramuscular immunoglobulin
idiopathic pulmonary fibrosis
intensive care unit
international units
intravenously)
juvenile chronic arthritis
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JDF Juvenile Diabetes Foundation Pr3 proteinase 3
KIR killer-cell Ig-like receptors PrP prion protein
LAC lupus anticoagulant PRU Protein Reference Unit
LAD leucocyte adhesion defect PSS progressive systemic sclerosis
LAK lymphokine-activated killer cell PUPP pruritic urticaria and plaques of
LDH lactate dehydrogenase pregnancy
LE lupus erythematosus PV pemphigus vulgaris
LFA lymphocyte function antigen RANA rheumatoid-associated nuclear
LFT liver function test antibodies
IG lymphomatoid granulomatosis RAST radioallergosorbent test
LPS lipopolysaccharide RBCs red blood cells
mAbs monoclonal antibodies RFT respiratory function tests
МАО I monoamine oxidase inhibitor RhA rheumatoid arthritis
MAST multiple allergosorbent tests RhF rheumatoid factor
MBL mannan-binding lectin RIA radioimmunoassay
MBP mannan-binding protein RID radial immunodiffusion
MCP macrophage chemotactic peptide RNA ribonucleic acid
MDP muramyl dipeptide RNP ribonucleoprotein
MPA microscopic polyarteritis rRNP ribosomal ribonucleoprotein
MPGN membranoproliferative SC subcutaneous(ly)
glomerulonephritis SCID severe combined immunodeficiency
MPO myeloperoxidase SCIg subcutaneous immunoglobulin
MRA magnetic resonance angiography Scl scleroderma
MS multiple sclerosis SIRS systemic inflammatory response
MTX methotrexate syndrome
NARES non-allergic rhinitis with eosinophilia SLA soluble liver antigens
NB nota bene SLE systemic lupus erythematosus
NBT nitroblue tetrazolium test SPT skin-prick test
NCAM neuronal cell adhesion molecule SSc systemic sclerosis
NF-AT nuclear factor of activated T cells ssDNA single-stranded DNA
NK natural killer T3 triiodothyronine
NRL natural rubber latex T4 thyroxine
NSAIDs nonsteroidal anti-inflammatory drugs TAME tosyl-L-arginine methyl ester
OCP oral contraceptive pill ТВ tuberculosis
od once a day Ter T-cell receptor
P450 sec P450 side-chain cleavage enzyme TdT terminal deoxytransferase
PA pernicious anaemia TFT thyroid function tests
PACNS primary angiitis of the CNS TGF T-cell growth factor
PAF platelet-activating factor TGS1 thyroid growth stimulating antibody
PAN polyarteritis nodosa Thl T helper-1
P-ANCA perinuclear ANCA Th2 T helper-2
PBC primary biliary cirrhosis TIA transient ischaemic attack
PCNA proliferating cell nuclear antigen TNF tumour necrosis factor
PCP Pneumocystis carinii pneumonia TPMT thiopurine methyltransferase
PCR polymerase chain reaction TPN total parenteral nutrition
PDC pyruvate dehydrogenase complex TPO thyroid peroxidase
PDGF platelet-derived growth factor TRAB thyrotropin receptor antibody
PE pulmonary embolism or TRAPS TNF-receptor-associated periodic
phycoerythrin syndrome
PEFR peak expiratory flow rate TREC T-cell receptor excision circle
PFAPA periodic fever with aphthous TSH thyroid stimulating hormone
ulcers, pharyngitis, and cervical TSH-R thyroid stimulating hormone receptor
adenopathy TSI thyroid stimulating antibody
PGE2 prostaglandin E2 TTP thrombotic thrombocytopenic
PHA phytohaemagglutinin purpura
PM polymyositis uc ulcerative colitis
PMR polymyalgia rheumatica uv ultraviolet
PNH paroxysmal nocturnal VCA viral capsid antigen
haemoglobinuria VCAM vascular celt adhesion molecule
PNP purine nucleoside phosphorylase VCF velocardiofacial syndrome
PNU protein nitrogen units VEGF vascular endothelial growth factor
PPD purified protein derivative (of 
tuberculin)
VIP vasoactive intestinal polypeptide
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1. IMMUNOLOGY OF ALLERGIC DISORDERS
Hypersensitivity indicates a heightened or exaggerated immune response that develops after 
more than one exposure to a given antigen. Hypersensitivity is usually considered synonymous with 
allergy. An antigen responsible for an allergic reaction is an allergen. The term allergy was 
introduced by Clemens Von Pirquet in 1906 to designate an altered reactivity to a foreign substance 
after prior experience with the same material, whether this response was helpful or harmful to the 
host. This concept of allergy, popularized by Gell and Coombs, may have merit in that it permits an 
organized and systematic approach to the pathogenesis of immunologic diseases. Nevertheless, the 
term allergy, as commonly used in clinical practice, indicates an adverse reaction and describes the 
pathophysiologic responses that result from the interaction of an allergen with antibodies and/or 
lymphocytes in a patient previously exposed and sensitized to that allergen. This immunologic 
definition of allergy is accepted by most but not all allergists, as nonimmune processes can influence 
the pathogenesis of allergic diseases with recognized immune etiologies.
The terms atopy and atopic are frequently used in reference to allergic diseases. Derived from 
the Greek word meaning "strange,” they were introduced by Coca and Cooke in 1923 to describe 
allergic diseases, such as asthma, allergic rhinitis (hay fever), and atopic dermatitis (infantile 
eczema), that showed a familial predilection and an implied genetic predisposition. Other allergic 
diseases, such as contact dermatitis and serum sickness, showed no familial tendency and were 
referred to as nonatopic. It was also recognized that serum from these allergic individuals contained 
a factor subsequently described as a skin-sensitizing antibody. This heat-labile serum factor could 
passively sensitize the skin of a nonsensitive individual and, after imradermal challenge with a 
specific allergen, the passively sensitized skin showed a positive wheal-and-flare reaction within 20 
minutes. This passive transfer test, also known as the Prausnitz-Kustner, or PK, test, provided 
documentation of the presence of a specific serum antibody important in the pathogenesis o f allergic 
diseases. More than 90% of these antibodies are now identified as immunoglobulin (Ig) E. Many 
allergists use the term atopic instead of allergic to identify those families and patients with hereditary 
predisposition toward asthma, hay fever, and/or infantile eczema.
CLASSIFICATION OF IMMUNOLOGIC REACTIONS IN ALLERGIC DISEASES
The manifestations and expressions of allergic disease are dependent on many variables, which 
include the genetic constitution of the sensitized individual, the nature of the allergen involved, the 
route o f allergen administration to the sensitized subject, the biologic properties of the antibodies or 
sensitized cells, and the local tissue response to the allergen-antibody interaction. If a suspected 
allergen is applied to or injected into the skin of a previously sensitized allergic subject, several 
different responses occur. The allergic or hypersensitivity cutaneous reactions can be classified as 
immediate hypersensitivity (IgE early- and late-phase) reactions and T-cell (48 hours) 
hypersensitivity reactions.
IMMEDIATE HYPERSENSITIVITY RESPONSES
The immediate cutaneous hypersensitivity reaction usually develops within 20 minutes of 
challenge with the antigen and is manifested as a wheal-and-flare skin response. Studies have 
demonstrated that an antibody (typically IgE immunoglobulin) present in either serum or tissues 
binds to the specific antigen and initiates secretion of mediators of inflammation and cytokines that 
are responsible for the immediate hypersensitivity response.
Biopsy and microscopic examination of an immediate cutaneous hypersensitiviiy reaction at 15 
to 30 minutes reveals little cellular infiltrate - perhaps a few neutrophils and occasional eosinophils 
and some local edema. It is the immediate hypersensitivity reaction that is the basis for much of the 
allergy skin testing performed by clinical allergists and immunologisls.
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LATE PHASE AND DELAYED RESPONSES
Depending on IgE antibody and allergen concentrations, a subset o f allergy patients shows a 
late (2 to 6 hours) cutaneous allergic IgE response in addition to the immediate (15 to 30 minute) 
reaction. Biopsy of the late-phase IgE reaction reveals moderate cellular inflammation and an 
increased number of neutrophils and lymphocytes, with many basophils and eosinophils.
The T-cell-mediated cutaneous delayed hypersensitivity reaction typically peaks 48 to 72 hours 
after antigen challenge and is characterized by local erythema and induration. This delayed reaction 
is not dependent on a serum antibody but rather on a cell-mediated immune reaction involving 
sensitized T-lymphocytes. Microscopic examination of a cutaneous biopsy o f delayed 
hypersensitivity skin reaction reveals moderate mononuclear cellular infiltrate, consisting primarily 
of small lymphocytes. These different IgE- and T-cell-mediated cutaneous manifestations are not 
mutually exclusive and may be elicited in the same host, depending on the variables listed 
previously.
GELL AND COOMBS CLASSIFICATION SCHEMA
To better comprehend the concepts o f allergy, including the cutaneous immediate and delayed 
hypersensitivity reactions, Gell and Coombs proposed a classification of the immunopathologic 
mechanisms. They separated the reactions by which a specific antigen can induce cellular and tissue 
injury into four groups: Type I (immediate or anaphylactic), Type II (cytotoxic or cytolytic), Type III 
(antigen-antibody complex), and Type IV (delayed or cell mediated) (Fig. 1-1). These four reactions 
patterns are not mutually exclusive; often, more than one of them occurs in the same patient. Hence, 
some immunologists do not accept or utilize this schema. For example, there may be several allergic 
immune reactions to penicillin. Urticaria may develop, representing a Type I response involving IgE. 
In other patients, a hemolytic anemia can result from the formation of an immune complex 
composed of penicillin, IgG antibody, and complement (Type III). Further, contact dermatitis, 
mediated by sensitized T-lymphocytes reacting to the penicillin (Type IV), may also arise. 
Appreciating that these inconsistencies exist, the authors feel that this classification is helpful for the 
clinician in understanding the pathogenesis o f allergic and immunologic diseases.
Figure 1-4. Summary of the four types of hypersensitivity reactions. Type I: Mast cells bind 
immunoglobulin E (IgE) via Fc receptors. On the encountering antigen, the IgE becomes cross- 
linked, inducing degranulation and release of mediators. Type II: Antibodies are directed against 
antigens on an individual’s own cells (target cells). This may lead to complement-mediated lysis or 
cytotoxic action by killer cells. Type III: Immune complexes are deposited in the tissues, 
complement is activated, and polymorphs are attracted to the site of antigen deposition, causing 
local damage. Type IV: Antigen-sensitized T-cells release lymphokines following a secondary 
contact with the same antigen. Lymphokines induce inflammatory reactions, activating and 
attracting macrophages, which release mediators.
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Type I Reaction
The Type i reaction of Gell and Coombs is referred lo as the immediate, anaphylactic, or 
homocytotropic antibody reaction. This reaction might also be called an atopic phenomenon, and it is 
responsible for many of the common allergic diseases. Clinical examples include asthma, hay fever, 
urticaria, angioedema, and anaphylaxis.
In the Type I reaction, mast cells or peripheral blood basophil leukocytes are passively 
sensitized by homocytotropic IgE antibodies, which are synthesized by plasma cells on stimulation 
by appropriate allergens. The binding of IgE to the mast cells involves the Fc portion of the IgE 
molecule and a receptor on the cell surface. During this initial sensitization phase, there is no overt 
deleterious host reaction. On subsequent challenge, however, this same allergen combines with its 
specific IgE antibody at the cell membrane of the sensitized mast cell and/or the blood basophil. This 
combination of allergen and antibody results in a sequence of energy-dependent enzyme reactions, 
with alteration of the cell membrane that initiates the synthesis and release of the specific 
pharmacologic mediators of the Type I immediate hypersensitivity reaction. These mediators may be 
preformed and stored in the mast cell granules or generated from phospholipids of the mast cell or 
basophil membrane. The preformed mediators include histamine and eosinophil chemotactic factor 
(ECF-A). The newly synthesized mediators of anaphylaxis include metabolites of arachidonic acid, 
especially including the prostaglandins, which are products of the cyclo-oxygcnase pathway, and the 
leukotrienes, which are the result of the lipoxygenase pathway.
The Type I reaction usually occurs within minutes of exposure to an appropriate antigen but 
may be sustained for 2 to 6 hours without additional antigen contact as a late-phase IgE reaction. 
After the mast cells and basophils have been through a refractory period of several hours, they 
resynthesize the pharmacologic mediators of hypersensiliviiy and once again become capable of 
responding to a specific allergen.
The specific intracellular biochemical events that occur during the Type I response arc not 
entirely understood on a molecular level, but in vitro studies suggest that mediator release is 
promoted by those processes that decrease intracellular cyclic adenosine monophosphate (cAMP). It 
has been noted that adrenergic agents, especially the more selective beta-adrenergic agents, increase 
intracellular cyclic adenosine monophosphate and thereby inhibit histamine release. Cyclic 
adenosine monophosphate is normally catabolized by phosphodiesterase; if phosphodiesterase is 
inhibited by a phosphodiesterase inhibitor, intracellular cyclic adenosine monophosphate is 
increased, and less histamine and other mediators may be released. Theophylline, a methylxanthine 
derivative, is a phosphodiesterase inhibitor. Calcium and magnesium appear to be essential to the 
release of histamine from sensitized mast cells and basophils in vitro.
Interaction of IgE antibodies and an allergen at the mast cell membrane does not appear to be 
capable of activating the complement sequence by the classic pathway; however, complement 
activation by the alternative pathway may occur. In most situations, the immunologic effectors of the 
Type I immediate hypersensitivity allergic reaction have been shown to be IgE antibodies; it should 
be emphasized, however, that it is the inflammatory mediators (e g., histamine, prostaglandins, and 
leukotrienes) that are responsible lor the pathophysiologic changes observed in the patient.
Type II Reaction
The Type II reaction as described by Gell and Coombs is referred to as the cytotoxic or 
cytolytic reaction. In this allergic situation, circulating IgG and IgM antibodies react with antigens 
that may actually be portions o f cells, such as erythrocytes and their membranes, or with an unrelated 
antigen, such as a drug that has become associated with these cells. The fact that the antigen is a cell 
or a cell constituent indicates that this reaction may be expressed as a form of autoimmunization or 
isoimmunization in clinical situations. In most cases, both IgM and IgG are involved in this reaction, 
as is the complement system. The complement-activated mediators are responsible for an 
inflammatory reaction. The cell that functions as the antigen or carries the appropriate antigenic 
determinant is usually destroyed or altered; there may be injury to erythrocytes, leukocytes, and 
platelets, and other cytotoxic reactions may be involved in this mechanism. Clinical examples of
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Type II reactions include autoimmune hemolytic anemia; transfusion reactions; hemolytic disease of 
the newborn; Goodpasture's syndrome; and drug-induced, antibody-dependent hemolytic anemia, 
leucopenia, and thrombocytopenia. It is the destruction or alteration of a target cell that differentiates 
this type of immunologic injury.
Type III Reaction
The Type III reaction is referred to as immune-complex injury or tissue damage. In this 
immunopathologic reaction, serum IgG antibodies interact with an antigen but not necessarily at a 
cell surface or membrane. Antigen-antibody complexes are formed, usually in moderate antigen 
excess, when antigen and antibody concentrations are appropriate. These microprecipitates or com­
plexes aggregate in and near blood vessels. They induce inflammation in the tissues in which they 
are deposited, which leads to vascular damage and thrombosis. Frequently, these antigen-antibody 
complexes are formed in areas of high blood flow, with deposition occurring in such tissues as the 
kidneys, lungs, and walls of small blood vessels.
The antigen-antibody complexes activate the complement system, and components C5, C6, and 
C7 attract polymorphonuclear leukocytes to the reaction site. Phagocytosis of the complexes by these 
leukocytes, as well as other macrophages, result in the release of enzymes, cytokines, and other 
mediators responsible for the observed inflammation and tissue destruction. Clinical examples of this 
Type III reaction include serum sickness syndrome, acute poststreptococcal glomerulonephritis, and 
certain collagen vascular diseases, especially systemic lupus erythematosus.
Type IV Reaction
The Type IV reaction of Gell and Coombs is the T-cell-mediated immune response or delayed 
hypersensitivity reaction. The immunopathologic response in the Type IV reaction appears to be 
dependent on sensitized small T-lymphocytes and their cytokines; serum antibodies to the 
appropriate antigens have not been implicated in the pathogenesis of this immune reaction. Many of 
these cytokines are identified as interleukins. There is no apparent interaction of the antigen with 
humoral antibodies, either at the cell membranes or in tissues, and it has been proposed that the 
antigens react directly with the sensitized lymphocytes.
After challenge with an antigen, the cell-mediated immune reaction results in the 
accumulation of mononuclear cells at the site of tissue inflammation within 24 to 48 hours. 
Activation of dendritic cells, local proliferation of lymphocytes, and additional release of cytokines 
are important in the development of the delayed hypersensitivity, cell-mediated immune reaction.
Complement does not appear to be involved in this reaction. Cell-mediated delayed 
hypersensitivity represents the pathophysiologic basis for contact dermatitis, as well as for many 
aspects o f organ transplant and skin graft rejection phenomena. In certain pulmonary diseases (e.g., 
tuberculosis, fungal diseases, and sarcoidosis), the observed tissue damage and inflammation appear 
to be due to cell-mediated, delayed hypersensitivity responses of the host to various antigens.
IMMUNOGENETIC ASPECTS OF ALLERGIC (ATOPIC) REACTIONS
The familial nature o f allergic diseases has been recognized for years, and a positive family 
history of atopic disease has been reported in approximately 75% of allergic patients. Though the 
tendency for developing allergic disease is clearly familial, the specific clinical allergic reaction is 
not directly inherited, since the host response is dependent on the appropriate environmental 
exposure. If there is no exposure to the allergen, there is no allergic disease, regardless of familial 
predisposition Family studies comparing the allergic high-IgE phenotype to the nonallergic low-IgE 
phenotype suggest a recessive inheritance for high-lgE levels. However, studies of IgE levels in 
monozygotic and dizygolic twins were not conclusive. Although a major portion of the variation in 
IgE levels is genetic, other environmental factors are likely to be involved.
Investigations of inbred animals suggested that specific antibody synthesis to a well- 
characterized antigen is controlled, in part, by immune response (Ir) genes linked to the major tissue 
histocompatibilily locus antigen (HLA). Analogous Ir genes linked to HLA have been described in
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humans. Ragweed hay fever symptoms and a positive skin test for the purified ragweed antigen E 
correlated highly wilh a particular HLA haplotype in successive generations of allergic families. The 
observed haplotype varied from family to family, suggesting that the Ir genes for this response were 
linked to (not associated with) HLA. The responses to complex multiple allergens, such as those 
used in clinical practice, may be dominated by the general level of IgE production rather than by the 
presence of specific HLA-linkcd Ir genes. Recently, a dominant autosomal trait was uncovered in 
allergic families, through use of restrictive enzymes, and the IgE immune response gene has been 
linked to chromosome 11. However, these results were not universal in other populations, and other 
studies suggest the gene is located on chromosome 5. In the past 10 years, there have been other 
linkage and association studies examining genetic susceptibility to allergic disease. A mullifactorial 
mode of inheritance also has been proposed, and many investigators feel that several loci are 
involved in the expression o f allergic disease; interaction with environmental exposures is also 
important.
Parents often become concerned with the risk of having allergic children if one or both of them 
have allergic problems or if they already have an affected child. Retrospective family studies suggest 
that when both parents are affected, allergic disease is present in about 60% of the offspring, and 
when only one parent is affected, about 30% of the children are allergic. When environmental 
exposure is probably the same for siblings in a given family, the risk of developing allergic disease is 
probably the same for each pregnancy, unless the family initiates preventive tactics to reduce antigen 
exposure. Many clinicians suggest breastfeeding during the first year o f life to reduce the possibility 
o f cow's milk allergy. It remains to be proven that avoidance of inhalant allergens during infancy 
reduces the incidence of respiratory allergy.
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2. ALLERGENS
Allergens are those antigens responsible for clinical allergic diseases. They are usually 
proteins or glycoproteins capable of inducing synthesis o f immunoglobulin (Ig) E antibodies, 
thereby sensitizing the potentially allergic person. Upon reexposure to the same allergen, the 
previously sensitized patient manifests the signs and symptoms of allergy, as the allergen reacts 
with cell-related IgE tissue antibody, and the cells generate the mediators of inflammation.
As shown in Box 2-1, allergens can be classified on the basis o f the nature or manner in which the 
patient is exposed.
Box 2-1. Classification of allergens according to the route through which they enter the
body
Inhalants
• Outdoor
• Indoor
Ingestants
Contactants
Injectants
Those allergens responsible for allergic respiratory diseases, including allergic asthma and 
allergic rhinitis, are principally inhalants. These aeroallergens, which can be present outdoors or 
indoors, are responsible for the majority o f all allergic diseases. Foods and other ingestants, 
including drugs, are also important, especially for allergic gastrointestinal and skin diseases. The 
contactants are principally responsible for allergic contact dermatitis. In addition to drugs, the 
injectant group includes the venom and saliva of insects. This chapter is limited to a discussion of 
the inhalant allergens, as the other allergens are described in the separate chapters on food allergy, 
drug allergy, contact dermatitis, and anaphylaxis. The inhalant allergens can be grouped as outlined 
in Box 2-2.
Box 2-2. Classification of inhalant allergens
Pollen
Fungi (molds)
Animal products
•  Mammalian
•  Arthropod
Dusts
Algae
Pollens were the earliest known causes of allergic respiratory diseases, being identified as 
such in the 19th century. They remain the most commonly recognized today. The spores of fungi, 
often referred to as molds by clinicians, are especially important when airborne in those 
environments in which the humidity supports their growth. Animal products, both mammalian and 
arthropod, have been increasingly recognized during the 20th century as being causative factors in 
allergic diseases, as have other organic and inorganic dusts to which sufferers are exposed in the 
home and workplace. Algae are relatively uncommon inhalant allergens.
ALLERGEN DETECTION
The detection and quantification of aeroallergens have provided the clinician with the basis for 
understanding the etiology of allergic respiratory illnesses. The methods o f aeroallergen detection 
and measurement are listed in Table 2-1.
An environmental survey based on the history given by the patient or visual inspection o f the 
environment provides valuable information regarding potential aeroallergen sources and can
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provide clues as to the source of the allergen. Direct microscopic examination is the most widely 
employed means of detecting and counting pollen and fungal spores. The quantification of pollens 
has been traditionally performed by collecting the pollen grains onto greased microscope slides 
using the Durham gravity system. Only during the past two to three decades have impact samplers 
(Rotorod) and suction samplers (Burkard, Kramer-Collins and Andersen) been used, providing truly 
quantitative ways of measuring these allergens. Recently, immunochemical techniques have been 
developed that can identify the soluble allergen constituents of ragweed pollen, as well as other 
allergens such as dust mites. These types of studies have become very important in finding other 
amorphous airborne allergens that cannot be identified using microscopy. Propagation of viable 
microorganisms in culture media can be used depending on the material under study and the type of 
data desired.
Table 2-1. Aeroallergen detection and measurement
Methods Application
Visual inspection or retrospective Clinical environment survey (no sampling 
device)
Microscopic analysis Identification and enumeration of pollen grains 
and fungal spores
Immunoassay Specific allergen detection and measurement
Propagation (culture) Identification of viable microorganisms
ALLERGEN NOMENCLATURE
The Allergen Nomenclature Committee of the International Union of Immunological Societies 
(IUIS) has devised a unified nomenclature system for purified allergens. Allergens are 
phenotypically designated by the first three letters of the genus followed by a space, the first letter 
of the species, another space, and finally, an Arabic number; occasionally an additional letter must 
be added to either the genus or the species, designation. Allergens are genotypically designated with 
italics; for example, the two genes encoding the two polypeptide chains of the major house cat 
(Felis domesticus) allergen Fel d  /  are designated Fel d  IA and Fel d  IB. A complete and updated 
Internet-based listing of purified allergens is maintained by the IUIS.
POLLENS
Pollens are the viable male germinal cells that are essential for the reproduction of most seed 
plants. The sources of pollens include trees, grasses, and weeds. Because of this seasonal variation 
in atmospheric pollen, the patient who develops pollen allergy manifests a seasonal 
symptomatology. In some tropical and subtropical regions of the world, however, climatic 
conditions show little annual variation, and pollen prevalence may be perennial. Guidelines for the 
characterization of those pollens that can become potent allergens were initially postulated by 
Thommen in 1931 (Box 2-3).
Box 2-3. Factors that contribute to the allergenicity of pollens
Wind-borne (anemophilous)
Buoyant (of small particle size)
Produced in large quantity
Potent antigen
In general, pollens that are wind-borne (anemophilous) are of greater clinical relevance than 
those carried by insects (entomophilous). Thus, the pollens of attractive, brightly colored flowering 
plants are infrequently the cause of allergic diseases. These insect-borne pollens tend to be heavy, 
sticky, and less numerous. For example, the pollens of roses and goldenrod are often incorrectly 
incriminated as important inhalant allergens, since their flowers bloom in temperate climates at the
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height o f the grass pollen and ragweed pollen seasons, respectively. However, florists, landscapers, 
hobbyists, and others whose occupational or recreational pursuits increase their exposure do 
become sensitized to the pollens of flowering plants.
The buoyancy, relative size, and density of a pollen can contribute to its dispersion. Ragweed 
pollen has a long wind-borne range and has been detected many miles offshore of lakes and oceans. 
Certain plants are widely distributed and produce large amounts of pollen - a single ragweed plant 
may release a million pollen grains in one day. Trees, especially conifers such as pine, may release 
clouds o f pollen, but these are generally less allergenic than ragweed.
Typically, the onset of pollination for many pollens is predictable to within a margin of a 
week or less, a characteristic that is important for clinical diagnosis. Clinicians should know the 
most prevalent pollen allergens in their area of the world, as well as their seasonal occurrence. Even 
though the seasonal appearance of the pollen is predictable, the amount produced in a given season 
varies, depending on climatic conditions. Extended dry periods during plant development and 
growth reduce the eventual pollen production. Also, a rainy day during the pollen season reduces 
the amount of airborne pollen on that day, whereas a dry, windy day increases the airborne 
concentration.
In addition to allergen exposure, the allergenicity of the pollen is another important factor. It is 
not known what accounts for certain pollens being more potent-sensitizing allergens than others. 
Only a subset (10% to 20%) o f the population become sensitized and show allergic symptoms, even 
though the entire community is exposed to the allergens.
WEEDS
The pollens o f weeds are common causes o f seasonal allergic rhinitis. The most prevalent 
allergenic ragweeds are the short (Ambrosia artemisiifolia) and giant ragweeds (Ambrosia trifida); 
the latter can reach a stately 12 feet (3.7 m) in height. Its pollen is released in temperate areas from 
mid-August to mid-September. In the southern and southwestern states, ragweed pollen can be 
airborne throughout the spring, summer, and fall.
Botanically, ragweed is a member o f the same Asteraclae composite family as many 
flowering plants, including chrysanthemums, marigolds, asters, some daisies, and sunflowers. 
These others, however, are only bothersome to those such as florists or gardeners who handle them 
regularly. Pyrethrum is an insecticide made form the flower heads of certain chrysanthemums, and 
inhalation of this compound can provoke symptoms in ragweed-allergic patients. The major 
allergens o f ragweed have been isolated and characterized as Amb a I  (antigen E) and Amb a II 
(antigen K). Commercial extracts o f ragweed pollen used in clinical allergy testing and 
immunotherapy are now required by the U.S. Food and Drug Administration (FDA) to be 
standardized to Amb a I  content.
The most common weeds throughout the world are similar. These include nettle, plantain, 
dock, sage, mugwort, lamb's quarter, and pigweed. Depending on the climate and the local 
geography, the pollination of weeds frequently coincides with that o f grasses in many temperate 
areas o f the world.
GRASSES
In Europe, South America and North America, Asia, and Africa grasses are the most 
important causes o f pollen allergy. Allergic rhinitis was described initially in England in 1889 by 
Blackley as hay fever because of the association of nasal symptoms with the harvesting of the 
forage grass, timothy, which is used to make hay. Most of the grasses are cultivated either 
agriculturally or ornamentally and are prevalent where people live. The pollens of the different 
grasses vary in size from 20 to 40 pm, and they all have a single germinal pore, which makes them 
difficult to distinguish microscopically.
Only about a dozen of the more than 5000 species o f grass are important allergens, as many of 
the grasses do not produce abundant pollen. The bulk of the airborne grass pollen in the Northern 
Hemisphere, United States, Canada, Europe, and northern Asia is present in the late spring and
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height o f the grass pollen and ragweed pollen seasons, respectively. However, florists, landscapers, 
hobbyists, and others whose occupational or recreational pursuits increase their exposure do 
become sensitized to the pollens of flowering plants.
The buoyancy, relative size, and density of a pollen can contribute to its dispersion. Ragweed 
pollen has a long wind-borne range and has been detected many miles offshore of lakes and oceans. 
Certain plants are widely distributed and produce large amounts of pollen - a single ragweed plant 
may release a million pollen grains in one day. Trees, especially conifers such as pine, may release 
clouds of pollen, but these are generally less allergenic than ragweed.
Typically, the onset o f pollination for many pollens is predictable to within a margin of a 
week or less, a characteristic that is important for clinical diagnosis. Clinicians should know the 
most prevalent pollen allergens in their area of the world, as well as their seasonal occurrence. Even 
though the seasonal appearance of the pollen is predictable, the amount produced in a given season 
varies, depending on climatic conditions. Extended dry periods during plant development and 
growth reduce the eventual pollen production. Also, a rainy day during the pollen season reduces 
the amount o f airborne pollen on that day, whereas a dry, windy day increases the airborne 
concentration.
In addition to allergen exposure, the allergenicity of the pollen is another important factor. It is 
not known what accounts for certain pollens being more potent-sensitizing allergens than others. 
Only a subset (10% to 20%) of the population become sensitized and show allergic symptoms, even 
though the entire community is exposed to the allergens.
WEEDS
The pollens o f weeds are common causes of seasonal allergic rhinitis. The most prevalent 
allergenic ragweeds are the short (Ambrosia artemisiifolia) and giant ragweeds (Ambrosia trifida); 
the latter can reach a stately 12 feet (3.7 m) in height. Its pollen is released in temperate areas from 
mid-August to mid-September. In the southern and southwestern states, ragweed pollen can be 
airborne throughout the spring, summer, and fall.
Botanically, ragweed is a member of the same Asteraclae composite family as many 
flowering plants, including chrysanthemums, marigolds, asters, some daisies, and sunflowers. 
These others, however, are only bothersome to those such as florists or gardeners who handle them 
regularly. Pyrethrum is an insecticide made form the flower heads of certain chrysanthemums, and 
inhalation of this compound can provoke symptoms in ragweed-allergic patients. The major 
allergens o f ragweed have been isolated and characterized as Amb a I  (antigen E) and Amb a II 
(antigen K). Commercial extracts of ragweed pollen used in clinical allergy testing and 
immunotherapy are now required by the U S. Food and Drug Administration (FDA) to be 
standardized to Amb a I  content.
The most common weeds throughout the world are similar. These include nettle, plantain, 
dock, sage, mugwort, lamb's quarter, and pigweed. Depending on the climate and the local 
geography, the pollination of weeds frequently coincides with that o f grasses in many temperate 
areas of the world.
GRASSES
In Europe, South America and North America, Asia, and Africa grasses are the most 
important causes o f pollen allergy. Allergic rhinitis was described initially in England in 1889 by 
Blackley as hay fever because o f the association of nasal symptoms with the harvesting of the 
forage grass, timothy, which is used to make hay. Most o f the grasses are cultivated either 
agriculturally or ornamentally and are prevalent where people live. The pollens of the different 
grasses vary in size from 20 to 40 pm, and they all have a single germinal pore, which makes them 
difficult to distinguish microscopically.
Only about a dozen of the more than 5000 species of grass are important allergens, as many of 
the grasses do not produce abundant pollen. The bulk of the airborne grass pollen in the Northern 
Hemisphere, United States, Canada, Europe, and northern Asia is present in the late spring and
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early summer from May to July. Whereas in the Southern Hemisphere, including Australia, South 
America, southern Asia, and South Africa the seasons are reversed. The important early grasses 
include sweet, vernal, and orchard, which are followed by timothy, biuegrass, fescue, redtop, and 
perennial ryegrass. All of these grasses show considerable allergen cross-reactivity, but they are 
allergenically distinct from the southern grasses. In the subtropical and tropical areas of the world, 
including the southern United States, Bermuda grass is found nearly all year round, and Johnson 
and salt grasses also have long seasons. In southern Europe and the Mediterranean areas, grasses 
may pollinate from February to October.
TREES
Tree pollens are prevalent worldwide, but because of a shorter pollen season in most 
countries, they do not produce as much allergic disease as do the grasses and weeds. The fruit- 
bearing trees, such as apple, pear, and peach, are insect pollinated, and their entomophilian pollens 
are not relevant in most clinical allergy. In much of North America, Europe, and temperate areas of 
the world, the pollen seasons for trees typically precede those of the weeds and grasses, sometimes 
making these early-onset symptoms easy to relate to the tree pollens. There is less antigenic cross­
reactivity among the tree pollens than among the grass pollens.
In the Mediterranean region and southern Europe, cypress and hazel tree pollens can appear as 
early as January, whereas in the northeastern forests of North America and Europe, the earliest tree 
pollens appear in March and April, with the release of pollen from birch, elm, maple, ash, alder, and 
hazel trees. Birch is a major allergen in Scandinavian countries. Oak trees shed more pollen than 
many other plants and are present in all of Europe and North America except Alaska, Hawaii, and 
other hot, tropical, or very cold climates. In the Northern Hemisphere, airborne oak pollens are 
present in April and May, whereas in the Southern Hemisphere, these and others can initially appear 
during August and September. In general, conifer (pine) trees produce large amounts o f pollen but 
cause modest allergic symptoms, with the exception of the mountain cedar in Texas and the 
Japanese cedar in California, Japan, and other parts of Asia.
FUNGI (MOLDS)
Fungi are saprophytic organisms that are present throughout most of the world. Most fungi 
produce airborne spores that can become important inhalant allergens. As allergens, fungi can be 
detected both outdoors and indoors and may show seasonal or perennial presence. Their numbers 
increase in the air during the warm months and decrease when hard frost prevents growth, and they 
are absent when the ground is snow covered. In those areas of the world without a winter season, 
outdoor fungi spores can be perennial aeroallergens. Alternaria and Cladosporium 
(Hormodendrum) species are the most numerous in late summer and early fall in the Northern 
Hemisphere. These molds are saprophytic fungi and grow on decaying leaves and dead plants. They 
are often increased atmospherically in the daytime. Some, such as Drechslera (Helminthosporium), 
grow abundantly on grasses and cereal crops and in the soil and are more numerous in subtropical 
climates.
Water (humidity) is the primary controlling factor for fungal growth, both outdoors and 
indoors. In cool weather, warmer moist indoor air diffuses through walls and on contact with cold 
vapor barriers forms condensation with growth of fungi. In this fashion, molds such as Aspergillus, 
Penicillium, and Stachybotrys can grow indoors with a humidity lower than 85%. These are the 
organisms most typically found in sheds, bams, and homes, especially in basements and 
crawlspaces. Aspergillus is also commonly found in bams associated with stored grains or 
vegetables. Penicillium is the green "mildew" seen typically on items stored in damp basements. 
Stachybotrys is often referred to as the "black mold." Epicoccum can be found both in storage areas 
and outdoors as a seasonal aeroallergen. Fungi can also often be found in damp bathrooms and on 
houseplants. Vaporizers, humidifiers, and air conditioners that have water storage units can be 
contaminated with fungi and then become a source of aerosolized mold spores. The potential of
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fungal allergy should not be ignored, as recent studies have indicated that many asthmatics in large 
cities had positive immediate skin tests to Alternaria and Penicillin.
Unfortunately there are no generally accepted standards for interpretation of fungal levels in 
indoor or outdoor air. At present, the best approach to indoor fungal control is moisture control in 
the indoor environment.
INDOOR ALLERGENS
Airborne indoor allergens are important causes of clinical allergy. It has been known for years 
that indoor exposure to dusts, either through household or occupational exposure, can provoke 
respiratory allergy (Box 2-4).
Box 2-4. Selected indoor allergens
Acarids
Dust mites
Mammals
Cat, dog, rabbit, ferret, guinea pig, gerbil, mouse, rat
Insect
Cockroach (Blatella germanica, Periplaneta Americana,Blatta orientalis)
Fungi
Aspergillus, epicoccum
For years, the source of the allergen in house dust was debated, but in 1967, its principal 
allergenic component was shown to be a mite. House dust or mattress mites (Dermatophygoides), as 
well as other mite species, are found worldwide. D. pteronyssius is more common in Europe, along 
with Euroglyphus maynei, D. farinae, and D. pteronyssius, which are both found in the United 
States and Japan.
The tropical mite Blomia tropkalis has been detected in Brazil, Venezuela, Puerto Rico, and 
Florida and is probably present in many tropical areas. These eight-legged, sightless arthropods 
cannot be observed without magnification, but they can be identified microscopically with lower- 
power lenses.
They feed on human or animal epithelium and other high-protein debris found in human 
environmental dusts. The highest concentrations of mites have been found in mattresses, pillows, 
rugs, upholstered furniture, and vacuum sweepings. Mites do not search for or drink water but 
absorb water from ambient humidity. For optimal propagation, mites require temperatures o f 25°C 
to 30°C and humidity greater than 50%. In temperate climates, they attain their maximal numbers in 
early fall, but they can survive for many months at lower temperatures and humidity as well. 
Temperatures greater than 130°F (54°C) or less than 32°F (0°C) can kill the mites. They are rarely 
found in arid or arctic climates or at high altitudes.
The major mite allergen has been found in the spherical mite fecal particles. Their shape and 
size (10 to 35 pm in diameter) make these particles comparable to many pollens. Moderate amounts 
of mite allergen are found in the body cuticle. The two major allergens in dust mites have been 
purified and are identified as D. pteronyssius allergen I (Der p  1) and Der p  2 and D. farinae (Der f  
I and Der f  2). These purified Der p  1 allergens have homology with cysteine proteinases with 
enzyme activity and are cross-reacting allergens with Der f  I. However, these purified Der p  and 
Der f  allergens only partially cross-react with the tropical dust mite (B. tropicalis). In the United 
States and England, 10% of the population and 80% to 90% of allergic asthmatics have positive 
immediate skin tests to the purified dust mite allergen. Reductions in mite exposure by reducing the 
environment concentration of mites lead to lower levels of specific IgE antibody and fewer allergic 
symptoms. About 10% of allergic patients who are symptomatic indoors in the United States do not 
react to skin testing with dust mites; they are reactive to another allergenic constituent in their 
environmental house dust.
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Another important indoor aeroallergen is the cockroach, which can introduce important 
aeroallergens into the household dusts o f certain environments. Studies comparing air samples in 
crowded New York tenements versus suburban middle-class homes showed comparable concen­
trations of house dust mite allergen but remarkably higher- levels of German cockroach allergen in 
the older urban apartments, with a significant association of cockroach IgE antibodies with asthma. 
As with the dust mite, the major cockroach allergens are related to the gastrointestinal tract or the 
feces and are greater than 10 pm in size.
MAMMALIAN ANIMAL ALLERGENS
Domestic pets are a very common source of indoor inhalant allergens that provoke significant 
respiratory complaints and disease in many patients with asthma and allergic rhinitis. Allergic 
symptoms can occur not only in owners, family, and friends of dogs, cats, or other pets but also in 
veterinarians and farmers, as well as laboratory workers exposed to horses, cattle, sheep, and 
rodents, including rabbits, rats, mice, and guinea pigs. The desquamated epithelium, also known as 
dander, that is attached to the hair becomes aerosolized and is the potent allergen. Epithelial 
desquamation is a constant process in mammals and is a continual source of aerosolized, highly 
allergenic proteins, as well as body excretions (Table 2-2).
Table 2-2. Common inhalant allergens from animal sources
Epidermal Excretions
Dander (desquamated epithelium) Saliva
Cuticle (body) Urine
Feces
It is common for animal-allergic individuals to develop urticaria at sites where they have been 
licked by a cat or dog or scratched by its claws or teeth. Among the house pets, cats seem to cause 
the more prominent symptoms. However, dogs do spend more time out of doors and are less 
frequently kept in bedrooms or beds and may be groomed more frequently than cats. Recent studies 
have shown that cat allergens are found in the skin, saliva, and sebaceous glands of the skin. It has 
also been suggested that cat urine can become aerosolized from litter pans, and urinary proteins can 
act as allergens. Dog allergens have been shown on fur and in dander, salivą and serum proteins. It 
has been suggested that some breeds of dog are less allergenic than others, but this may be more 
quantitative than qualitative and related to frequency of grooming.
The main cat allergen, Fel d  1, has been purified from both cat washing solutions and pelt. 
The allergens prepared from pelt extracts are thought to be less representative of natural exposure 
because they contain a relatively large concentration of cat tissue proteins (e g., albumin). When 
cats are washed repeatedly, the allergen recovered decreases progressively. These observations lead 
to the clinical recommendation that washing cats is a method of reducing exposure to allergen in 
cat-allergic patients. However, not all cats tolerate washing, and this effect is short lived - less than 
a week. To be effective, washing of cats or dogs needs to be repeated frequently, at least once a 
week. The major dog allergen (Canfl) has also been purified. Identification of the major cat and dog 
allergens has enabled specific environmental immunoassays. Using these assays, significant levels 
of both cat and dog allergens have been documented, not only in homes of pet owners but also in 
dust from schools. Recent reports suggest that persistent daily exposure to the allergens from dogs 
or cats from early infancy may result in statistically less allergic inhalant symptoms than 
intermittent or daily exposure as an older child or adult. These observations need to be confirmed 
and may provide future means to induce immune tolerance to animal allergens.
OTHER ENVIRONMENTAL DUSTS
A variety o f inhalant airborne allergens include organic dusts, such as baker's flour, grain mill 
dust, and enzymes used in laundry detergents, as well as trimellitic anhydride, plicatic acid from
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wood dust, toluene di-isocyanate, and the salts of nickel, chrome, and platinum. Kapok, a plant fiber 
from the Kapok tree, is very resilient and has been used in pillows and upholstered furniture. It is 
impervious to water, making it a useful material for boat cushions and lifejackets. When pulverized 
and airborne, kapok is a potent allergen. It is being replaced by various synthetic polymers in 
pillows and cushions.
Occasionally, foods become aerosolized allergens during booking. If inhaled by a sensitive 
person, certain food allergens may provoke severe respiratory allergy. However, most food-allergic 
individuals manifest their reactions, which can include respiratory symptoms, after ingestion of the 
specific food.
Many clinicians feel that respiratory complaints related to our environment have increased in 
the past several decades. Terms such as sick building syndrome have been coined to describe 
allergies that might be related to exposure to inhaled substances from closed environments with 
inadequate ventilation. Such nonantigenic irritants, which can exacerbate allergic respiratory 
disease, include sulfur dioxide, cigarette smoke, cold air, auto exhaust fumes, hairsprays, perfumed 
aerosols, and solvent vapors.
These substances may directly provoke the activation of mediators o f inflammation, such as 
histamine or leukotrienes, which then cause respiratory symptoms without any mediation by an IgE 
antibody and allergen reaction. If combined with exposure to an allergen such as dust mites or 
fungi, these nonallergic irritants can potentiate or exacerbate an allergic respiratory disease.
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3. THE ATOPIC DISEASES: APPROACH TO DIAGNOSIS
Introduction
Allergic diseases are common: it has been estimated that 15% of the population will suffer 
from some sort o f allergic reaction during their lifetime. It is clear that there has been an increase in 
atopic diseases since the Second World War. The precise cause of this change is unknown but 
undoubtedly reflects changes in lifestyle, in particular 'improvements' in housing, rendering houses 
more heavily colonized with dust mites. A reduction in breastfeeding may also have contributed, 
particularly to atopic eczema. The evidence for air pollution, particularly car exhaust fumes, 
contributing to the increase is conflicting. It is also likely that the improvements in public health, 
leading to elimination in the Western world of parasitic infections, may contribute through a lack of 
physiological function for the IgE-mast cell axis. This has been formalized in the hygiene 
hypothesis ('dirt is good for you!’).
The atopic diseases are processes mediated by or related to IgE-immediate hypersensitivity. 
(The terms atopic and allergic are frequently interchanged. In its broadest sense, the term allergy 
has been used in the past to describe any immunologic alteration in the capacity to react following 
contact with a foreign substance. Atopic, on the other hand, characterizes conditions produced only 
by the action o f IgE.)
Genetic factors play an important role in the susceptibility to these diseases. The association 
of the atopic diathesis with the inheritance of histocompatibility (HLA) antigen haplotypes in 
families has been demonstrated and suggests that immune-response genes associated with the major 
histocompatibility complexes may genetically determine or define the atopic state. An IgE response 
occurs normally in all individuals, but the presence of immune-response genes may be needed for 
antigen specificity and clinical manifestations of the atopic state. The expression of this potential 
response may clearly be altered by factors such as dose, route, and timing of antigen exposure, drug 
therapy, and concomitant illnesses.
I. Anaphylaxis, the most dramatic and devastating form of atopic disease, is the systemic 
manifestation of immediate hypersensitivity. The implicated antigen is often introduced parenterally 
such as by injection of penicillin or a bee sting. Oral exposure may also produce anaphylaxis, 
although less frequently. The activation and degranulation of mast cells systemically, with massive 
mediator release, results in the clinical picture of bronchospasm, urticaria, and anaphylactic shock.
II. Allergic rhinoconjunctivitis is the most common atopic disorder, affecting approximately 
15% of the United States population. Like anaphylaxis, allergic rhinoconjunctivitis is a well- 
documented model of immediate hypersensitivity pathophysiology. It is mediated by IgE produced 
locally under the mucosal surfaces of the nose and eye. Airborne antigen comes into contact with 
mast cells sensitized by the locally produced IgE and produces mast cell degranulation, with the 
resulting picture o f "local anaphylaxis" of the nasal or conjunctival membranes, or both.
III. Urticaria and angioedema. Immediate hypersensitivity may express itself in a cutaneous 
form of disease: urticaria, or angioedema, or both. Allergic urticaria-angioedema is often self­
limited, lasting less than 6 weeks, and is frequently related to the ingestion or administration of 
foods or drugs. If urticaria persists longer than 6 weeks, the causative agent is not often determined.
IV. Asthma is the expression of immediate hypersensitivity reactions in the lung. Inhaled 
intact pollens, deposited heavily in the nose and pharynx, probably do not reach the small or even 
the large airways. Although bronchial challenge studies may provoke bronchospasm, they employ 
large doses o f antigen (e g., aerosolized aqueous extract o f pollen). On the other hand, 
bronchospasm develops after natural exposure to pollen antigens. The definite role of inhaled 
antigens has not been completely elucidated.
The antigens may also be ingested in the mucous membrane of the oropharynx, their active 
allergens eluted and subsequently absorbed, with hematogenous spread producing symptoms. 
Pulmonary manifestations alone, without cutaneous or nasal symptoms, may follow antigen 
exposure. The reason for this differential expression of target organs in atopic patients is unknown .
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V. Gastrointestinal allergy. The gastrointestinal tract is an unusual site for the expression of 
localized immediate hypersensitivity disease. Nausea, abdominal cramps, vomiting, and diarrhea 
may follow food exposure within a matter of minutes to hours, but these reactions are usually not 
mediated by IgE. Although the gastrointestinal tract contains large numbers o f IgE-forming plasma 
cells, there is little documented evidence to support the common belief that IgE-mediated 
hypersensitivity reactions occur there frequently. The presence o f increased numbers of eosinophils 
in the small intestine on biopsy after food challenge is suggestive, but not definite, evidence of 
immediate hypersensitivity.
VI. Atopic dermatitis is an eczematous cutaneous eruption associated with the previously 
mentioned atopic disorders of asthma and allergic rhinitis. The incidence in the general population 
is up to 10%. Several features suggest its classification as an atopic disorder: familial association 
with allergic rhinitis and asthma; markedly elevated serum levels of IgE; frequent hypersensitivity 
to environmental allergens; eosinophilia; evidence for a beta adrenergic-receptor defect in atopic 
dermatitis patients similar to that described in asthmatic patients; and the association of allergic 
rhinitis and asthma in patients with atopic dermatitis. In contrast, the presence of atopic dermatitis 
does not correlate with immediate hypersensitivity skin tests and antigen exposure, does not 
respond to immunotherapy, and has histopathologic features that do not resemble those of the usual 
atopic states.
Approach to the Patient
I. Allergic history. A comprehensive allergy history produces the best data base for the 
diagnosis and management of patients with allergic disease. A standardized allergic 
history form (Table 3-1) allows the physician to obtain a comprehensive picture of 
the patient's problem as it relates to allergic disease and exposures.
Table 3-1. Allergy history guidelines
I. Name:_____________ Date:___________________  Age: ______  Sex:______ _
//. Clinical Illness
A. Present illness
1. Nature of illness
2. Age of onset
3. Frequency of attacks
4. Duration o f attacks
5. Changes in nature, frequency, or duration of attacks
6. Previous evaluation and treatment
7. Present treatment
B. Family history
C. Past medical history
III. Environmental Reactions
A. Time of year and day of symptoms
B. What produces symptoms?
C. What relieves symptoms?
D. Symptoms at home, work, vacation
E. Reactions to dusty or moldy environments, pets, odors, foods, medicines, insects, colds, 
change in weather, smoke, exercise, emotion, mowing lawn
IV. Environmental Survey
A. Occupation, where employed, unusual exposures
B. Place and type of residence, basement, heating, air conditioning, etc. C Carpets or rugs in 
home, type and matting
D. Pillow, blanket, and mattress, type and age
E. Exposure to bams, dead leaves, or other moldy environments
F. Pets in home (indoors and/or outdoors), number and type
G. Exposure to chemicals, insecticides, etc.
H. Hobbies
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I. Medications
J. Cigarettes
The principles of history taking are similar to those for any medical history, but certain 
aspects of the history require particular attention and expansion, namely, noting the temporal and 
spatial relationships of symptoms as related to possible allergen exposures.
Historical details should include the following:
A. The time relationships of symptoms should include the time of day, time of the 
week (all week or weekends only), and time of the year, as well as the duration of 
symptoms.
B. Do the symptoms occur at home, at work, or on vacation, when the patient is away 
from his or her work or home environment?
C. Does sensitivity occur to known allergens (e g., dust, animals, grass cuttings) in 
addition to possible exposures to unsuspected allergens (e g., room humidifiers, jute carpet 
pads)?
D. Do symptoms relate to physical changes (cold, heat, dampness) or activities (e g., 
smoking, exercise, or painting)?
E. Does past or current use or abuse of antiallergic therapy (medication, im­
munotherapy, environmental controls) change allergic symptoms?
F. Since atopic diseases have a strong propensity for familial incidence, a careful 
history to detect possible atopic disorders in other family members is necessary.
G. The patient should estimate the degree of difficulty or impairment experienced 
from the allergic symptoms. This is the primary factor in determining the extent of 
further evaluation and treatment.
H. The presence of any concomitant medical conditions should be noted, since these 
conditions may mimic allergic disease or alter its expression (e.g., pregnancy, 
hypothyroidism).
II. Physical examination. A complete physical examination is mandatory. Specific attention 
should be directed to areas where atopic diseases are manifested: the skin, the conjunctiva, the 
nasopharynx, and the lungs. A more complete discussion of the physical findings in each specific 
atopic disorder is found in subsequent chapters. However, certain principles bear emphasis at this 
time.
A. The entire skin should be examined for important physical changes (e g., lichenification in 
the flexor areas or other chronic alterations of the skin) that may not be mentioned by the patient 
who feels that they are unimportant, unrelated, or embarrassing.
B. The conjunctiva should be carefully examined for hyperemia and edema (chemosis) 
involving both the palpebral and bulbar membranes. The presence of increased or abnormal- 
appearing secretions in the palpebral fissures should be noted. The fundus should be examined, 
because cataracts are often associated with both atopic disease and corticosteroid treatment.
C. The middle ear is often a site of secondary complications of allergic disease, such as 
serous or infectious otitis media. Similarly, the frontal and maxillary sinuses should be examined by 
palpation and transillumination.
D. The nose is the most accessible area to observe the physical alterations resulting from the 
pathophysiologic features of immediate hypersensitivity disease.
I. A transverse line across the top of the nose, the allergic crease, may occur as a 
result of chronic upward nose rubbing (allergic salute), especially in children.
2. The interior of the nose should be assessed using adequate illumination and 
exposure as provided by a head mirror and nasal speculum. An otoscope with a large 
speculum provides an alternative method. The examiner must be careful not to distort the 
anatomy o f the nasal vestibule.
a. The mucosa and the structures it overlies (septum, turbinates) should be examined 
carefully.
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b. The quantity and quality of nasal secretions should be assessed.
c. The presence of polyps or foreign bodies should be noted.
d. The patency of the nasal passages is assessed by having the patient sniff through 
one nostril with the other lightly occluded.
E. The mouth and oropharynx are examined with a bright light source and tongue blade. 
Because the mucosa of the oropharynx is continuous with the nasal mucosa, in allergic rhinitis the 
posterior lateral pharynx and uvula may often be erythematous, or edematous, or both. A narrow, 
high-arched palate, narrow chin, and elongated maxilla with overbite occasionally result from 
chronic allergic disease in childhood (allergic facies).
F. The chest should be examined by visual inspection, palpation, percussion, and auscultation. 
The findings in allergic disease vary from normal during symptom-free intervals to marked 
hyperinflation, accessory muscle use, and marked wheezing during acute asthma attacks. The 
changes of chronic lung disease (e.g., increased anteroposterior diameter) may result from severe 
asthma or may be a complication of repeated infections or immune injury (e.g., hypersensitivity 
pneumonitis).
III. Diagnostic tests of allergic and clinical immunologic disordes
The results o f laboratory studies do not make the diagnosis of allergic disease. They 
strengthen or weaken various diagnostic possibilities suggested by the history and physical findings. 
They are also an aid in patient management - in monitoring both the complications of allergic 
disease and the effects o f therapy.
A. Complete blood count with differential. The white blood cell count is usually normal 
except during states o f increased catecholamine input (endogenous or exogenous) or intercurrent 
infection. Eosinophil percentages between 5 and 15% are nonspecific but do suggest atopic disease. 
Corticosteroids cause eosinopenia and may mask eosinophilia.
1. Moderate eosinophilia (15-40% of peripheral blood leukocytes) may be found in 
allergic disorders, but other causes should be considered, namely, parasitic infections, drug 
exposure, malignancy, and immunodeficiencies. Radiation therapy, congenital heart disease, 
peritoneal dialysis, cirrhosis, periarteritis nodosa, and dermatitis herpetiformis also are 
associated with moderate eosinophilia
2. Exaggerated eosinophilia (50-90% of peripheral blood leukocytes) is commonly 
observed in visceral larva migrans, seen especially in children, and in the idiopathic 
hypereosinophilic syndrome, seen in adults. In disorders generally associated with moderate 
eosinophilia (parasites, Hodgkin's disease, periarteritis nodosa, drug hypersensitivity) the 
eosinophilic response may occasionally be exaggerated.
B. Total eosinophil count. Although the number of eosinophils per cubic millimeter o f blood 
can be estimated from the differential and total leukocyte counts, more accurate counts can be 
obtained by the use of special diluting fluids that hemolyze the erythrocytes and stain the 
eosinophils. The eosinophils can then be counted directly in a counting chamber. Normal values for 
absolute eosinophil counts are 0 to 450 cells/cu mm for adults, 50 to 700 cells/cu mm for young 
children, and 20 to 850 cells/cu mm for newborns.
C. Smears for eosinophils. The nasal secretions, conjunctival secretions, and sputum of 
atopic patients usually reveal eosinophils. During symptomatic periods, eosinophils predominate in 
these secretions. Intercurrent infection may produce a prominent neutrophil response. Repeat 
smears after treatment o f the infection reveal the characteristic eosinophilic nature of the cells. 
Conjunctival secretions are obtained by a cotton swab. Nasal secretions are secured by having the 
patient blow the nose in a piece of wax or nonabsorbent paper. In younger children, nasal secretions 
may also be obtained with a bulb-suction apparatus, a syringe with feeding tube, or cotton-tipped 
applicator. Sputum is obtained by inducing a deep cough. Eosinophils are best demonstrated by 
Hansel's stain; alternatively, Wright's stain may be used. If clinically indicated, these secretions may 
be stained and cultured for bacteria and fungi.
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D. Total serum IgE levels. An elevated total serum IgE level supports the diagnosis o f atopic 
disease. However, there is an overlap of IgE values between atopic and normal persons; a normal 
IgE level does not exclude the diagnosis of an allergic disorder. Newer techniques, such as the 
direct sandwich radioimmunoassay (paper radioimmunosorbent test [PRIST]) are more sensitive, 
especially for low levels (< 50 Units/ml). Accurate interpretation of IgE levels must be based on 
knowledge of the test assay and normal values for each laboratory. Using a PRIST method, 
approximately 63% of adults with asthma, or hay fever, or both will have an IgE value above the 2 
S.D. limit for healthy adults. In children with high serum IgE levels, 96% are found to have 
significant allergy. Patients with atopic dermatitis and respiratory symptoms often have a markedly 
elevated IgE level (> 1000 Units/ml).
1. The following are the current clinical indications for IgE determinations (laboratory kits for 
IgE determinations are commercially available):
a. Differentiation of atopic and nonatopic asthma and rhinitis (especially in young children)
b. Differentiation of atopic and nonatopic eczema (especially in children)
c. Prediction of allergy among children with bronchiolitis
d. Initial laboratory screening for allergic bronchopulmonary aspergillosis
e. Evaluation of immunodeficiency
f. Evaluation of drug reactions
g. Paraprotein evaluation in patients with multiple myeloma
2. Parasitic infections, a common cause of marked IgE elevations, must be excluded.
Diseases with known elevations of IgE are listed in Table 3-2.
Table 3-2. Disorders associated with elevated serum IgE levels
Common disorders
Atopic diseases 
Parasitic infections 
Laennec's cirrhosis 
Mononucleosis
Less common disorders
Selective IgA deficiency 
Gluten-sensitive enteropathy 
Pulmonary hemosiderosis 
Drug-induced interstitial nephritis 
Minimal change nephritis 
Bullous pemphigoid 
Acral dermatitis
Mucocutaneous lymph node syndrome (Kawasaki disease)
Wegener's granulomatosis 
Polyarteritis nodosa
Rare disorders
IgE myeloma
Т-Cell deficiency (DiGeorge syndrome, Wiskott-Aldrich syndrome, Nezelof
syndrome)
Job-Buckley syndrome
Bone marrow transplantation (immediate post-transplantation period)
E. Skin tests for immediate hypersensitivity
Skin testing is the tool used most widely to diagnose clinical allergies. As the antigen 
combines with immunoglobulin (Ig) E antibody fixed to mast cells, mediator substances, 
particularly histamine, are released from the mast cells. The mediators cause local vasodilation and 
increased capillary permeability. Wheal-and-flare reactions appear within 15 to 20 minutes. A
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typical scoring system is listed in Table 3-3. If the negative control comes up positive, or if the 
histamine control produces no reaction, the tests are impossible to interpret.
Test results greater than the 'positive' negative control might be considered positive: this is 
risky, and confirmatory blood tests should be undertaken.
Table 3-3. Commonly used scoring system for grading the response to hypersensitivity 
skin testing
Grade Wheal Erythema
O(-) < 3mm 0-5 mm
1+ 3-5 mm 0-10 mm
2+ 5-10 mm 5-10 mm
3+ 10-15 mm >10 mm >20 mm
4+ > 15 mm or with pseudopods
The immediate wheai-and-flare reactions are often followed by late-phase reactions. There is 
evidence that if high enough concentrations of antigens are presented, 100% of immediate reactions 
will go on to late phases. These late-phase reactions in the skin are also manifested in the nasal 
mucosa and bronchi.
There are two types o f skin tests - the epicutaneous, also referred to as scratch, puncture 
(SPT), and prick technique, and the intracutaneous, or intradermal test (IDT).
Indications for testing
• SPT is the gold standard for allergy diagnosis and should be considered as the first choice 
for testing.
• Testing should be driven by clinical symptoms: the use of routine panels of allergens on 
every patient is wasteful and can be misleading (irrelevant positives).
• Where no commercial antigens are available, direct SPT (prick to prick) with allergens such 
as foods may be desirable. This is the test of choice for fruit and vegetable allergens that are labile.
• IDT is used to follow-up SPT, particularly for drug allergy investigations.
Limitations
• If patients cannot stop their antihistamines, then blood tests may be the only way of 
diagnosis.
• It is advisable to avoid any form of skin testing in patients known to have had a severe 
systemic reaction to any of the proposed test agents. The small amount of allergen introduced 
during SPT may be enough to trigger a reaction in a susceptible individual.
Precautions. Several precautions should be observed during skin testing procedures.
a. Testing should be deferred during periods of symptomatic bronchospasm to prevent 
worsening of the clinical status.
b. Epicutaneous tests (scratch or prick tests) are done initially. This type of testing can 
detect the sensitive patient with minimal risk of systemic reaction.
c. Emergency treatment materials - syringes, and needles should be readily available to 
treat systemic reactions.
d. A trained technician or nurse may perform skin tests, but a physician must be 
immediately available.
e. The back is preferable for prick or scratch testing because its flat surface permits the 
performance of many tests.
Methods of skin testing
EPICUTANEOUS SKIN TESTS
Prick skin tests
1. Procedure. Cleanse the skin with isopropyl or 70% ethyl alcohol and allow it to dry by 
evaporation. Using a pen or inked stamp, mark future test sites 2 cm apart to prevent coalescence of 
positive test reactions. Every fifth site should be coded to recheck the test order. Then place a drop
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of allergic solution at each mark, and insert a sterile 26-gauge needle, a sterile sewing needle, or a 
blood lancet through the drop into the superficial skin and withdraw with a slight lifting of the skin. 
Do not draw blood. Because blood lancets and sewing needles are not hollow, they can be simply 
wiped with sterile gauze after testing at each site. Alternatively, a fresh disposable needle can be 
used for each test site. After 15 to 30 minutes, observe the test sites for erythema and wheal 
formation. The average (greatest and smallest) or largest diameter of the wheal in millimeters 
should be noted and compared with controls. If a large wheal (> 15 mm) appears in less than 15 
minutes, wipe the allergen solution from the test site.
2. Because stored allergen solutions lose potency within weeks to months, extracts, 
especially diluted preparations, must be regularly renewed. Most suppliers place a 2- to 3-year 
expiration date on concentrated allergen solutions. The half-life of an allergen solution decreases 
with increasing dilution and increasing temperature. Properly stored allergen solutions (2 to 8°C) at 
1:100 dilution or stronger may maintain antigenicity up to 1 year, but more dilute (1:1000 or 
weaker) solutions may lose antigenicity in 2 to 6 months (less in very weak solutions).
3. A test using diluent solution alone (a negative control) should be included to assess skin 
reactivity to mechanical trauma. (This diluent is usually a phosphate-buffered physiologic saline at 
pH 7.4 with 0.4% phenol added to inhibit bacterial growth.)
4. If patients with dermatographia are detected, reactions greater than those in the control 
site may be considered positive.
5. A 0.1% histamine solution (histamine phosphate) can serve as a positive control. This 
histamine control aids in interpreting skin tests (a "standard" 3+ reaction) and demonstrates 
diminished or absent skin reactivity, which is commonly found in very young or very old patients or 
in patients taking medications such as antihistamines.
Scratch tests employ the same principles as prick tests but are less sensitive and more time 
consuming. There are, however, minor technical differences.
1. After the skin is cleansed and marked, a 2-mm skin scratch without bleeding is made with 
small scalpel, needle, or punch scarifier.
2. The test controls and allergen solutions are aseptically dropped onto and gently rubbed into 
the scratch areas, using a clean toothpick for each allergen.
3. Allergen solutions are wiped off and reactions read after 15 to 30 minutes.
The epicutaneous method has many advantages. It is easy and safe to perform and causes little 
discomfort. It is inexpensive, and test solutions are stable because they are suspended in 50% 
glycerine. Positive epicutaneous tests correlate well with clinical symptoms (Table 3-4).
Table 3-4. Advantages of epicutaneous versus intracutaneous
Epicutaneous Intracutaneous
Easy to perform More reproducible
Safe More sensitive
Little discomfort
Inexpensive
Stable test solutions
Correlates well with symptoms
One possible disadvantage to this method is that it can result in false-negative reactions due to
a lack of sensitivity (Table 3-5).
_____ Table 3-5. Disadvantages of epicutaneous versus intracutaneous
Epicutaneous Intracutaneous
Less sensitive More time consuming
More difficult to perform
More discomfort
Increased risk of systemic reaction
More false-positive result
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INTRACUTANEOUS SKIN TESTS
Following scratch or prick testing, intradermal skin testing is done to allergens that did not 
elicit clearly positive reactions. Because intradermal skin testing employs a larger antigen challenge 
than does scratch or prick testing (between 100-fold and 1000-fold, depending on the concentration 
of antigens), marked local or systemic reactions can occur if intradermal testing is performed with 
the same antigens that produced positive prick or scratch reactions. In patients with five or less 
positive epicutaneous skin tests, intradermal tests can be done immediately following the reading of 
scratch or prick tests. If the number of positive epicutaneous tests is large, intradermal tests should 
be deferred to another day. In sensitive patients it is best to divide cross-reactive groups (especially 
grasses) into separate testing sessions since many strongly positive reactions may yield systemic 
symptoms. Careful antigen selection correlated with the geographic area and history will minimize 
the number of tests.
Intracutaneous skin tests are more reproducible than epicutaneous tests and are 100 to 1000 
times more sensitive. Thus, they are associated with fewer false-negative reactions. The drawbacks 
to intradermal tests are that they are time consuming and tedious to perform and are often associated 
with discomfort and an increased risk of systemic reactions. Even more important, they are more 
likely to produce false-positive results because of their increased sensitivity. Mildly positive 
intradermal reactions are not considered clinically relevant.
The sequential steps in intradermal testing are as follows:
Use a 1:500 or 1:1000 (weight to volume) dilution of allergen, a 0.01% histamine base 
solution (histamine phosphate) as a positive control (3+ reaction), and a buffered saline 
diluent as a negative control.
The upper half of the volar surface of the forearm and the lateral aspect of the upper 
arm are choice test sites. The skin o f the back may be used. This site precludes the use of a 
tourniquet in case of systemic reactions. Intradermal skin testing in young children (2-5 
years of age) is easier on the back because tests can be applied with better control than on a 
moving arm.
With the patient comfortably positioned, cleanse the skin and mark test sites 
approximately 2.5 cm apart.
Fill sterile plastic disposable 1-ml tuberculin syringes with approximately 0.1 ml of 
test solution. To avoid misleading "splash" reactions from injected air, expel all air 
bubbles.
Stretch the skin taut and introduce the needle into the skin at a 45-degree angle with 
the bevel facing downward. Advance the needle until the entire bevel of the needle is into 
the skin.
Inject the smallest amount of allergen solution that will raise a 1- to 3-mm wheal 
(approximately 0.02 ml of solution). If no wheal forms immediately after injection (either 
the needle is too deep, with subcutaneous fluid injection or too superficial, with a fluid leak), 
withdraw the needle and repeat the injection at a different site.
Read the skin test reactions after 15 to 30 minutes. Measure the size of the erythema 
and the size of the wheal with a millimeter ruler. As in scratch or prick tests, this may be 
done by measuring the greatest and smallest diameter of each reaction and taking the 
average. Alternatively, only the greatest diameter can be used. Pseudopods (protrusions 
from the wheal) should be noted. A helpful method of measuring wheal size is to stretch the 
skin taut between the fingers. The wheal will appear as a definite blanched central area that 
can be easily measured.
TEST RESULTS
The value of skin tests, like that o f any diagnostic procedure, depends on the knowledge of 
their interpreter. To be informative, the tests must be related to the clinical context of the patient's 
history and physical examination. The selection of antigens and the administration of tests require
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experience and knowledge. The physician must be aware o f the many reasons for false-positive and 
false-negative reactions to properly interpret test results.
False-Negative Results
Several circumstances may account for negative skin test results in a patient who truly has an 
IgE-mediated allergic disease (Box 3-1).
Box 3-1. Reasons for false-negative skin test results
Improper storage of antigen
Improper administration
Inherent host factors
• Age
•  Skin area
•  Time of day
•  Skin temperature
Refractory period
Inhibiting drugs
The antigen in solution - a protein - if  improperly stored may lose potency with time or 
exposure to heat, thereby causing a false-negative result. Antigen solutions must be refrigerated and 
replaced at appropriate intervals.
A false-negative result may also occur due to the improper administration of a test. Too 
superficial a scratch or prick of the skin or too deep an intracutaneous injection will prevent the 
allergen solution to reach the skin area in which mast cells are located.
The patient's age must also be considered when a skin test result is negative. In general, the 
skin of infants and elderly persons is less reactive than that o f other age groups. In the same 
individual, the skin on the forearm is less reactive than the skin on the back, and responsiveness is 
lower in the early morning than later in the day.
The refractory period of a test may also contribute to a false-negative result. Soon after a 
systemic reaction to an allergen, such as insect venom, penicillin, or food, the patient enters a 
refractory period during which a skin test reaction to that substance may be negative. The reason is 
that specific IgE is consumed by the severe allergic reaction, so a 3- to 4-week period is needed for 
the allergic antibody to build back up to its prereaction levels. Therefore, if a patient has a systemic 
reaction to an allergen, it is best to wait a full 4 weeks before performing skin tests.
As sensitization is dependent on circulating IgE reaching the mast cells at the test site, it is 
possible, where the allergic reaction is highly localized, to get negative results, as insufficient IgE is 
present in the circulation.
Finally, a number of drugs, particularly antihistamines, may inhibit skin reactivity and 
therefore should be discontinued at least 72 hours before skin testing. Whenever a skin test is 
performed, histamine should be included as a positive control. If the histamine skin test is negative, 
further testing should be deferred. A more complete list o f drugs that can inhibit immediate skin 
reactivity is provided in Box 3-2.
Box 3-2. Drugs that may inhibit immediate skin test reactivity
•  All Hl-blocking antihistamines
• Ranitidine
• Amitriptyline
•  Desipramine
• Nortriptyline
• Imipramine
• Protriptyline
• Trimipramine
• Triavil
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Corticosteroids, theophylline, cromolyn, leukotriene modifiers, beta agonists, and 
decongestants are not presently known to be inhibitory.
False-Positive Results
When a skin test is positive in the face of a negative clinical picture, several explanations may 
be offered (Box 3-3).
Box 3-3. Reasons for false-positive skin test results
•  Improper preparation and administration of allergen solution
•  Nonspecific histamine release
• Dermographism
• Remnant of past sensitivity
• Harbinger of future sensitivity
• Disparity with clinical sensitivity
Many factors contribute to the production of nonspeciftcally irritating skin test solutions. 
Deviation from a physiologic pH or from the correct osmolarity may cause a false-positive skin test 
result. Extracts may contain low-molecular-weight irritants, and it is necessary to dialyze these 
materials before utilizing them as skin testing agents. Glycerine, commonly used as a preservative 
in allergy extracts, causes nonspecific irritation at a concentration of 6% if injected intradermally. 
Injecting too large a volume of extract intradermally may also cause false-positive reactions. The 
optimal injection volume is 0,02 ml.
Allergen solutions to a wide range of allergens are available commercially from several 
manufacturers. They should be checked regularly to see that they are still within date. False-positive 
tests may often be found to food allergens, although the rate is lower with SPT than IDT. Where 
commercial food allergens give an unexpected false-negative, use of the fresh food may be possible. 
Where no commercial antigens are available, direct SPT (prick to prick) with allergens such as 
foods may be desirable. This is the test of choice for fruit and vegetable allergens that are labile.
Materials that are urticariogenic may cause a wheal and erythema skin test response in all 
subjects on a non-IgE-mediated basis. Examples are morphine and codeine. Some food extracts, 
particularly those from cheese, have a high histamine content and I may cause false-positive 
reactions.
Dermographism also may be responsible for a false-positive test result. It is present in 5% to 
20% of the population, depending on the degree of pressure applied. Skin testing should also 
include a negative saline control to ensure that the patient is not demographic. A positive response 
to saline obviously makes other positive skin test reactions suspect.
Positive skin test reactivity may persist in an individual whose clinical sensitivity has 
disappeared either spontaneously or through the use of immunotherapy. Additionally, false-positive 
results are often harbingers of future sensitivity. The risk of developing an allergic condition is 
considerably greater for individuals with positive skin test results.
Perhaps the most important reason for the false-positive skin test reaction is the physician's 
failure to recognize that a positive skin test is not necessarily an indicator of clinical sensitivity.
PRINCIPLES OF PA TCH TESTING
The purpose of patch testing is to identify type IV hypersensitivity, usually in the context of 
contact hypersensitivity to environmental agents.
• As for skin-prick testing, an area of normal skin is required: the upper and mid zone of the 
back is usually appropriate.
• Allergens are made up in petrolatum jelly or in aqueous solution on a filter paper and 
applied under occlusion in a small metal chamber (Firm chamber), which is secured firmly to the 
back with hypoallergenic tape.
• Chambers are left in place for 48 hours and the patients are told not to wash the area.
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• When the chambers are removed, the application areas are inspected for erythema, 
vesiculation, and evidence of cellular infiltrate.
There may be false-positives at this stage due to reactions of types I and III.
The sites should be re-read at 72-96 hours.
False-positive reactions at 48 hours will have disappeared on the later reading.
• It is usual for a standard panel to be used in the initial screen, unless there are clear 
indications of the most likely allergens (e g. through the occupation and exposure history, site of 
eczema, etc ). Standard panel will include metals (nickel, chromium), preservatives, fragrances, 
rubber mix, lanolin, formaldehyde, balsam of Peru, and colophony.
• Where there are positive reactions to one of the mixed reagents (rubber mix, fragrances) 
there are usually supplementary panels of the individual ingredients.
• If the patient is exposed to an unusual substance, then it or its contents may be made into 
extemporaneous patch tests, provided that appropriate safety data can be obtained from the 
manufacturers.
• Some allergens only cause reactions when there is concomitant exposure to sunlight. This 
can be reproduced in the clinic using a photopatch test.
Here duplicates of each allergen are applied and, after 14-48 hours, one of the pair is 
taken off and the back exposed to UV-A light (10 joules).
The other one of the pair is then taken off and the sites read as for an ordinary patch
test.
The unexposed member of the pair serves as the control.
Indications fo r  testing
Contact eczema or dermatitis.
Tests are only appropriate for delayed hypersensitivity (type IV).
Patch testing for drugs may be valuable where reactions are atypical and delayed.
Interpretation
•Results can be roughly graded as:
0, no response;
1+, erythema and oedema;
2+, erythema, papules, and small vesicles;
3+, marked erythema, induration, and large blisters;
•Grades 2+ and 3+ are positive.
•Antihislamines have no effect on the responses, but topical steroids applied to the sites of 
application or systemic steroids will significantly reduce or abolish the responses.
F. PROVOCATIVE CHALLENGE TESTING
The skin test and measurement o f total serum IgE and specific IgE antibody levels in the 
serum are indirect assays o f an allergic state. Direct challenge, either by inhaling or ingesting 
antigens may be of greater diagnostic use. It is wise to avoid challenging someone who has had a 
severe systemic reaction, or who has pre-existent severe asthma, with allergens. Challenge tests are 
potentially dangerous and should be carried out by experienced staff prepared to deal with any 
adverse reactions that may arise. Informed consent should always be sought from the patient prior 
to the test.
In addition to the antigen challenge, the general hyperresponsive state of the airway associated 
with asthma may be evaluated by exercise or by inhalation o f chemical substances to which 
asthmatic individuals are more sensitive than are nonasthmatics.
NONSPECIFIC TESTS
Exercise
Physical exercise is a major precipitant o f bronchial asthma. The diagnosis of asthma can 
usually be made after 6 to 8 minutes o f exercise and pre- and postpulmonary function testing (Fig. 
3-1).
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Figure 3-1. A classic response in exercise-induced asthma.
Initially, the patient exhibits a bronchodilation effect, along with an increase in the forced 
expiratory volume in one second (FEVi). In the patient with exercise-induced bronchoconstriction, 
6 to 8 minutes o f exercise is generally followed by a 20% or greater fall in FEV|.
Bronchial Challenges
Asthma is characterized by enhanced bronchial hyperreactivity. This hyperreactivity can be 
manifested clinically by the asthmatic's adverse response to cold air, cigarette smoke, fumes, 
weather changes, and other stimuli that have little or no effect on a non-asthmatic patient. In the 
doctor's office setting, hyperreactivity can be demonstrated by the patient's response to a bronchial 
challenge, such as the inhalation of methacholine or histamine (Fig. 3-2).
Mo«fcy ite r*  and derived item  6  2008 by U saty. Inc.
Figure 3-2. The effect o f methacholine inhalation on an asthmatic patient. The asthmatic subject 
shows a greater than 20% fall in FEV, after inhalation of methacholine 5 mg/mL. Saline inhalation 
results in no change in FEV|. A control patient inhales methacholine through a concentration of 25 
mg/mL and shows no change in FEV],
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A greater than 20% fall in FEVi after the inhalation of a methacholine solution at a 
concentration of less than 25 mg/mL is indicative of a positive response.
SPECIFIC TESTS
Bronchial Challenges
Specific airway reactivity can be assessed by measuring the patient’s bronchial response to the 
inhalation of certain allergen solutions. There is evidence that skin test results generally correlate 
well with bronchial-provocation test results. Therefore, bronchial-challenge testing with specific 
allergens is generally not necessary in everyday practice. There may be special instances, however, 
such as with occupational asthma, or in investigative work when specific bronchial-challenge 
testing is indicated. Several bronchial responses have been documented after the inhalation of 
antigen solutions. Figure 3-3 illustrates the immediate, dual, and late-phase responses that are seen.
challenge
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Figure 3-3. The different patterns of bronchial response after a bronchial challenge.
The ''classic11 asthmatic response to inhaled allergens had been thought to be immediate, 
occurring in all cases within minutes, but it is now estimated that approximately 50% of allergic 
asthmatics demonstrate a dual immediate and late-phase response (may occur 6-8 hours after the 
challenge): the patient must be kept under observation for this period. An isolated late-phase 
bronchial response is seen largely in instances of occupational asthma.
Pretreatment with different medications may alter the bronchial responses to antigen 
inhalation. Bela agonists block the late reaction but have no effect on the immediate response, and 
pretreatment with cromolyn inhibits both bronchial responses.
Enthusiasts may carry out endobronchial challenge through a bronchoscope, which allows 
them to observe the changes in the bronchial mucosa and also to carry out bronchoalveolar lavage 
to look at the release of mediators and the cellular response. This is important in research but not for 
routine diagnosis.
Nasal Challenges
Inhaled antigen solutions can also be used to challenge the nasal mucosa, to diagnose allergic 
rhinitis. Usually performed by spraying a diluted solution (1:1000 of SPT solution) of the test 
allergen into one nostril, while spraying a similarly diluted solution of the buffer only into the other 
nostril.
Patient's symptoms are recorded (running nose, sneezing, itching eyes, etc.) and the nasal 
mucosa inspected for signs of inflammation and oedema. Each nostril is inspected.
The response can be gauged by the measurement of nasal airway resistance through anterior 
or posterior rhinomanometry or by changes in the cellular or mediator content of the nasal mucus. 
The nasal challenge technique is useful in studying the pathophysiology of the nose, the action of 
drugs, and instances of occupational rhinitis.
Oral Challenges
In instances when a suspected allergen is ingested, an oral challenge can be performed. The 
challenge can be open, in which case both the physician and the patient know the content of the 
substance ingested; single blind, with only the doctor knowing the content; or double blind, with 
neither the patient nor the physician knowing the content of the challenge. The food or drug can be 
administered either whole or in a lyophilized preparation contained in an opaque capsule.
Oral challenges serve several purposes. First, double-blind, placebo-controlled food 
challenges (DBPC) have proven useful in discerning IgE-mediated food sensitivities. Second, oral 
challenges can also help diagnose sensitivity to ingested substances, such as aspirin or sulfites, in 
which the sensitivity is not on an IgE basis. In such instances, skin testing or measurement of serum 
specific IgE levels would be of no use.
For open incremental food challenge, incremental doses of food are given at 15 minute 
intervals, with monitoring of BP, PEFR, and symptoms before each increment. Steps are: food on 
lip (may be omitted), 1%, 4%, 10%, 20%, 20%, 20%, 25% of a normal portion (this may be 
variable!). Over the course o f the challenge, 100% of the normal portion size is administered.
Where multiple foods are suspected, an oligoallergenic (elimination) diet may be instituted for 
a period to see whether symptoms remit. If symptoms persist, food allergy/intolerance is not the 
cause.
If symptoms improve, foods may then be reintroduced as open challenges one at a time and 
the patient's symptom response noted. This should ideally be followed by a DBPC challenge where 
the patient, on an oligoallergenic diet is challenged with the suspect food concealed in opaque 
gelatin capsules, interspersed with identical capsules containing an innocuous substance, in a 
random sequence, determined by the dietician but unknown to the patient and doctor.
This is time-consuming, as some food allergic symptoms may require exposure for several 
days before they appear and, equally, may take several days to disappear when the food is 
withdrawn. There needs to be a wash-out period between the placebo and the active capsules.
Injections
A naturally occurring injection in the form of a Hymenoptera family insect sting has been 
carried out at some medical centers. This has been performed to determine whether a preceding 
course of immunotherapy with venom of that particular insect had been successful. At present, this 
is an experimental technique that should only be performed under the most carefully controlled 
conditions.
Drug allergy testing
• Type I reactions are investigated by skin prick and intradermal testing.
Some drugs are irritant and provoke non-specific reactions on intradermal testing.
Some drugs (opiates, radiocontrast media) cause direct histamine release from mast cells.
• There is only a limited range of tests available for in vitro testing for IgE to drugs; many oi 
the drug allergens are unvalidated in clinical practice.
• Flow cytometric assays of basophil degranulation/activation are available, but appear tc 
correlate poorly with SPT/1DT testing.
• Type IV reactions are investigated by patch testing.
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• Reactions o f types II and III are more difficult to investigate.
• Open and blinded challenge tests may be appropriate for atypical reactions.
IPatients with Stevens-Johnson reactions must not be tested— reactions may be severe.
• Testing is time-consuming.
• The table 3-6 shows starting concentrations and usable dilutions for SPT and DDT. 
Table 3-6. Starting concentrations and usable dilutions for SPT and IDT
Drug SPT at dilution IDT at dilution Comment
1/10 mg/ml Neat
mg/ml
/1000
ig/m
1/100
pg/ml
1/10 pg/ml
Quaternary ammonium compounds
Succinylcholine
(suxamethonium)
5 mg/ml 50 mg/ml 0 pg/ml Irritant IDT 
>1/1000
Benzylisoquinoloncs
Atracurium 1 mg/ml 10 mg/ml 10 pg/ml — — Irritant IDT 
>1/1000
Cisatracurium 0.2 mg/ml 2 mg/ml 2 pg/ml 20 pg/ml 200 pg/ml
Mivacurium 0.2 mg/ml 2 mg/ml 2 pg/ml — — Irritant EDT 
>1/1000
Galtamine 4 mg/ml 40 mg/ml 40 pg/ml 400 pg/ml —
Doxacurium*
Aminosteroids
Pancuronium 0.2 mg/ml 2 mg/ml 2 pg/ml 20 pg/ml 200 pg/ml
Vercuronium 0.4 mg/ml 4 mg/ml 4 pg/ml 40 pg/ml 400 pg/ml
Rocuronium* 1 mg/ml 10 mg/ml 10 pg/ml 100 pg/ml —
Rapacuronium
Local anaesthetics
Arti caine 1 mg/ml 10 mg/ml 10 pg/ml 100 pg/ml 1000 pg/ml
Bupivacaine 0.25 mg/ml 2.5 mg/ml 2.5 pg/ml 25 pg/ml 250 pg/ml
Citanest with 
Octapressin
3 mg/ml 30 mg/ml 30 pg/ml 300 pg/ml 3000 pg/ml
Lignocaine 1 mg/ml 10 mg/ml 10 pg/ml 100 pg/ml 1000 pg/ml
Pritocaine 0.5 mg/ml 5 mg/ml 5 pg/ml 50 pg/ml 500 pg/ml
Procaine 1 mg/ml 10 mg/ml 10 pg/ml 100 pg/ml 1000 pg/ml
Induction agents
Etomidate 0.2 mg/ml 2 mg/ml 2 pg/ml 20 pg/ml 200 pg/ml
Propofol 1 mg/ml 10 mg/ml 10 pg/ml 100 pg/ml — Irritant IDT 
>1/100
Thiopental 2.5 mg/ml 25 mg/ml 25 pg/ml 250 pg/ml 2500 pg/ml
Analgesics
Alfentanil 50 pg/ml 500 pg/ml — — — Mast cell 
degranulator
Fentanyl 5 pg/ml 50 pg/ml — — — Mast cell 
degranulator
Morphine 1 mg/ml 10 mg/ml — — — Mast cell 
degranulator
Pethidine 5 mg/ml 50 mg/ml — — — Mast cell 
degranulator
* - Information not available. Based on information collated by Dr. Mansour Karadsheh.
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• Open drug challenge uses incremental doses:
1%, 4%, 10%, 20%, 20%, 20%, 25% of a standard oral dose at 15-minute intervals, with 
observation of BP, PEFR, and symptoms before each incremental step.
Over the period of the challenge, the challenge administers 100% of the normal dose.
Indications for testing
• Suspected drug allergy, where testing will alter clinical management.
• Do not test where there are readily available and safe alternatives (i.e. do not test all 
'penicillin-allergic' patients).
Interpretation
• Interpretation of testing requires the demonstration of wheal and flare. Reactions to drugs 
will usually be much smaller than the typical reactions on SPT/ID to inhalant antigens. 
Photographing the results for the medical records is desirable.
• Knowledge of irritant concentrations is required. This may require testing on non-atopic 
volunteers.
• Clear goals are required for testing:
testing to prove causality,
testing to prove safety of alternative drugs.
• Information must be provided to patient as well as referring doctor (and GP if referred by 
other specialist).
• Advice to patient on the use of medical alert bracelets may be required.
Limitations
• Preparation of drug dilutions is time-consuming: assistance from pharmacy is required. 
Preparation of dilutions in clinical areas is not recommended.
• Where testing is carried out with controlled drugs, appropriate steps must be taken to 
account for receipt and disposal of the drugs, according to local regulations.
G. Passive cutaneous transfer testing
Passive cutaneous transfer testing (Prausnitz-Kustner [P-К] testing), now more of historical 
interest, provided the first demonstration of a substance (reagin) in the serum of allergic persons 
that is capable o f sensitizing the skin of nonallergic persons. In the past, P-К testing was used in 
patients with dermatographia or generalized skin eruptions. Currently, it is impractical even in these 
selected patients because in vitro testing for specific IgE antibodies (radioallergosorbent test 
[RAST]) provides the same information without the risk of transferring serum from one person to 
another. If P-К testing is done, the donor serum must be screened for the presence of hepatitis В 
antigen-antibody and for syphilis. The P-К test involves the following: Inject allergic serum (0.1 
ml) intradermally into a carefully marked site on the forearm of a nonallergic person. After 24 to 48 
hours this site is challenged with intradermal allergen (0.02 ml) and observed for an immediate 
positive wheal-and-flare response not present on the control site.
H. In vitro tests of antigen-specific IgE
In vitro allergy tests do not substitute for clinical history-taking, examination, and direct 
patient testing (SPT, patch tests, challenges).
Allergen-specific IgE 
• Units: 1 IU/ml = 1 kU/1.
• Range:
<0.35 IU/ml
0.35-0.70 IU/ml
0.70-3.50 IU/ml 
3.50-17.5 IU/ml 
17.5-50.0 IU/ml 
50.0-100 IU/ml 
>100 IU/ml
RAST score 0; 
RAST score 1; 
RAST score 2; 
RAST score 3; 
RAST score 4; 
RAST score 5; 
RAST score 6.
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Principles of testing
• Detection of allergen-specific IgE in the blood is by sensitive R1A, EIA, or fluorescent 
assay. There are numerous acronyms for this process, depending on the method (RAST, MAST, 
FAST tests).
• Radioimmunoassay is now little used.
• Principles o f all the tests are identical, with allergen bound on to a solid phase that is then 
incubated with a labelled anti-IgE antibody.
• Pharmacia Unicap/immunocap system is most widely used system in the UK.
• Tests are expensive due to costs o f purification and standardization of allergen.
• CE marking requirements have reduced the number of commercially available allergens.
• EQA and international standards are available.
Indications for testing
• Skin prick testing remains the gold standard.
• In vitro EIA assays may be used on patients with a high risk of anaphylaxis (SPT 
contraindicated), on drugs that interfere with SPT (antihistamines, calcium channel blockers, 
antidepressants), or with extensive skin disease, and on small children.
• Patients with a total IgE <20 kU/1 have a low (but not zero) probability o f having positive 
specific IgE tests.
Interpretation
• The assays are carried out quantitatively and reported in units.
• It is more usual for the results to be graded on a scale o f 0-6, where 0-1 represent no or 
minimal specific IgE and 2-6 represent increasing levels of positivity.
• RAST scores o f 0 and 1 are usually considered to indicate a negative result.
• High total IgE levels (>1000 kU/1) may cause false-positive tests for allergen-specific IgE, 
due to non-specific binding of IgE to the solid phase: this is less common with newer systems, but 
applies particularly to food allergens.
• Units are standardized against an international standard for birch pollen allergen, but this 
cannot validly be applied to reactions with other allergens.
• Attempts are being made to standardize allergens in terms of defined proteins and protein 
nitrogen. With a potentially limitless list of allergens, this is a slow process.
• The important clinical implication is that the detection of a grade 3 response to two different 
allergens does not indicate that the same amount o f IgE is present against both and that equivalent 
clinical reactions might be expected.
• There is no close relationship between the grade and the severity of reactions (either past or 
future).
• The presence of allergen-specific IgE is a marker only of exposure. Positives may be 
detected where there is no evidence of any clinical reaction.
• Levels will fall with time if the offending allergen is avoided over a long period, so 
low or negative results may be obtained even with sensitized patients.
• As with skin-prick tests, if the allergic reaction is highly localized, there may be insufficient 
spill-over o f specific IgE into the circulation to be detected, leading to a false-negative.
• Results must always be interpreted in the light of the clinical history (blood tests are not a 
substitute for proper history-taking!).
Limitations
• Few allergens are available for robustly identifying IgE to drugs.
• Reagents for penicillin contain major but not minor determinants: a negative result does not 
exclude significant allergy, and SPT and IDT are required with a minor determinant mixture.
• Reagents for labile food allergens such as fruits are unreliable: use SPT with the fresh fruit.
• If there is a good history for type I food allergy and an unexpected negative result, consider 
SPT with fresh food.
• 15% of NRL-allergic patients will be negative by specific IgE testing.
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Churg-Strauss syndrome (acute active disease).
• Synovial fluid levels are increased in:
rheumatoid arthritis: 
ankylosing spondylitis.
• Urine levels are increased by carcinoma of the bladder. CSF levels are increased by 
malignant but not benign tumours. Levels correlate with the degree of underlying inflammation. 
Assay requires timed separation of samples, although the assay itself uses very similar methodology 
to that used for detecting allergen-specific IgE.
ECP may be released during the coagulation process.
This significantly limits the usefulness of the test.
Eosinophil count
• Units: cells x 109/L
• Normal range:
Newborn, <0.85x109/1;
Children 1-3 years, <0.70 x 109/l;
Children >3 and adults, <0.44 x 109/1.
Principles of testing Routinely on the newer automated haematology counters, which are 
capable of providing a five-part differential. Where older counters are used, an additional manual 
differential with special stains may be required.
Indications
Allergic disease, including drug reactions;
Lymphoma;
Vascutitis;
Pulmonary infiltrates;
Parasitic infection.
Interpretation
• Raised eosinophil counts are not specific for allergic disease; counts >10 x 109/1 are not due 
to allergy or parasitic disease.
• Moderate elevations are seen in:
parasitic infestations; 
drug reactions;
lymphoma (especially Hodgkin's lymphoma); 
after radiation therapy;
vasculitides (Churg-Strauss vasculitis, polyarteritis nodosa); 
dermatitis herpetiformis;
primary immunodeficiencies (Omenn's syndrome, matemo-fetal engraftment); 
hepatic cirrhosis.
• Exceptionally high eosinophil counts are seen in:
• larva migrans;
• hypereosinophilic syndromes;
• severe vasculitis (CSS, PAN) and occasionally in lymphoma and cirrhosis.
Eosinophil count is reduced by acute infection, stress, fasting for more than 24 hours, and by 
corticosteroids.
Examination of nasal and conjunctival secretions for the presence of eosinophils may provide 
confirmatory evidence for an allergic cause for local symptoms.
Eosinophilia o f nasal secretions may be seen in non-allergic rhinitis (non-allergic rhinitis 
with eosinophils—NARES).
Flow-CAST® and CAST-ELISA®
These commercial assays rely on activation of basophils either directly or via specific IgE in 
the patient's serum.
CAST-ELISA® measures the release of sulphidoteukotrienes by activated basophils by EIA.
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Assay is extremely slow and time-consuming and is impractical for a busy diagnostic 
laboratory.
The Flow-CAST® uses flow cytometry to identify basophils, labelled with anti-IgE-FITC, 
and then anti-CD63-PE, a marker of activated basophils, which identifies basophil degranulation.
Manufacturer provides an array of specific allergens including food additives and drugs.
Both assays work well for normal inhalant allergens, but appear less useful for drugs and 
additives.
Modification of the Flow-CAST® assay using anti-CD203c in place o f anti-CD63 improves 
the characteristics o f the assay.
Results for drug allergens compare poorly with those from IDT.
The assays cannot therefore be recommended as a non-invasive way of testing for drug 
allergy.
Assays are more expensive and labour-intensive than standard E1A for routine inhalant 
allergens.
Histamine-release assays
In vitro release o f histamine by basophils in response to stimulation by cytokines or by 
allergens is a complex test. Measurement of free histamine is required (difficult as it is labile in 
serum/plasma).
Assays are of value in the research setting. In the clinical setting assays have been used for 
investigating the histamine-releasing properties of certain drugs. Like all bioassays, they suffer from
difficulties in standardization.
Immunoglobulin E (total IgE) 
. Units: kU/1.
• Normal ranges:
. age <1 year,
. age <2 years,
. age 2-3 years,
. age 4-5 years,
. age 6-7 years,
. age 8-10 years,
. age 11-12 years,
. age 13-14 years,
. age >14 years,
<11 kU/1;
<29 kU/1;
<42 kU/1;
<52 кШ ;
<56 kU/1;
<63 kU/1;
<45 kU/1;
<70 kU/1;
<100 кШ .
Principles of testing
• Usually the same as for allergen-specific IgE (RIA, EIA).
• Some nephelometers have the capacity to run total IgE.
Indications for testing
• Allergic disease (as screen for atopic tendency).
• Lymphoma.
• Vasculitis (Churg-Strauss vasculitis).
• Primary immunodeficiency.
• Myeloma.
Interpretation
• Measurement o f total IgE may be helpful in diagnosing allergic disease.
• Normal range is very wide and levels correlate poorly with clinical disease.
• High level o f specific IgE to a single allergen may occur with a total IgE within the 'normal'
range.
• In asthmatic patients, a level o f >150 kU/1 is suggestive of an allergic basis, while a level 
<20 kU/1 is very much against it The severity o f asthmatic symptoms correlates very poorly with 
total IgE (but better with eosinophil count).
• In the investigation of dermatitis, a level of >400 kU/1 is usual while a level o f <20 kU/1 is 
against atopic dermatitis.
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• Very high levels of IgE are seen in atopic eczema, allergic bronchopulmonary aspergillosis 
(ABPA), parasitic infections (larva migrans, hookworm, schistosomiasis, and filariasis), lymphoma 
(especially Hodgkin's disease), and liver disease.
• Levels may be elevated in EBV infection, the Churg-Strauss syndrome, systemic sclerosis, 
and bullous pemphigoid, although this is a poor marker of disease activity.
• Some primary immunodeficiencies are associated with raised IgE, such as Wiskott-Aldrich 
syndrome and Omenn's syndrome.
• Highest levels are seen in the hyper-IgE syndrome (Job syndrome, Buckley's syndrome): 
here levels frequently exceed 50 000 kU/1, a level rarely, if ever, seen in atopic disease.
• IgE myeloma is exceedingly rare: diagnosis will have been made on electrophoresis and 
immunofixation.
• Levels are often higher in Asians, although it is not clear whether this is just due to a higher 
risk of parasitic diseases.
Limitations
• Specific IgE testing becomes inaccurate with very high levels of IgE (>1000 Ш/1), due to 
non-specific binding.
• Conversely, where the total IgE is very low, it is not useful to perform tests for specific IgE.
Serial monitoring
• Justified in ABPA (a rise in the level of IgE precedes relapse, and the level falls with 
appropriate therapy).
• Justified in Churg-Strauss syndrome (responds to therapy).
IgE autoantibodies/IgE receptor antibodies
• These have been reported in patients with allergic problems.
• Antibodies to the IgE receptor have been reported as a possible cause of chronic urticaria, 
although the evidence is very weak.
• Routine assays are not available at present and the clinical utility needs to be confirmed in 
further studies.
IgG to food allergens
• IgG antibodies to food allergens are available (UniCAP®ftmmunoCAP®).
• It has been suggested that these may be valuable in the investigation of irritable bowel 
syndrome (IgG to wheat, milk).
• IgG to food allergens occur frequently in healthy individuals, especially against bovine, 
ovine, and porcine proteins.
• Clinical value remains to be determined.
Mast cell tryptase
• Units: pg/1.
• Normal adult range: 2-14 pg/1.
Sample Serum, preferably on several occasions within a 24 hour period after an acute reaction 
(tryptase is stable in serum).
Principles of testing Measured by Pharmacia UniCAP® system (EIA). Indications for 
testing
• Confirmation of mast cell degranulation (is a specific marker of mast cell granules).
• Investigation of atypical 'allergic' reactions.
Interpretation
• Does not distinguish between anaphylactic and anaphylactoid reactions.
• Relatively stable in serum, being catabolized in the liver with a half-life of approximately 3 
hours.
• Levels may be significantly raised for 24 hours after an acute reaction involving mast cell 
degranulation.
• Good correlation between plasma histamine and mast cell tryptase makes mast cell tryptase 
the preferred marker for mast cell activation.
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• Persistently elevated levels may be seen in patients with urticaria pigmentosa and systemic 
mastocytosis.
• Elevated levels may also be detected in nasal and bronchial lavage fluids after allergen 
challenge.
• In order to assess the significance of a result taken during an acute reaction in a given 
patient, it is important to have a sample taken when the patient has fully recovered.
Thromboxanes and prostaglandins
• Assays o f these short-lived mediators are available in the research setting but do not have 
much applicability to the routine management o f allergic problems at the present time.
• Assays are usually by RIA.
Urinary methyl histamine
Histamine release from mast cells is a key feature of acute severe allergic reactions.
It is rapidly cleared destroyed in the circulation: measurement o f free histamine is therefore 
difficult and limited to research settings.
The urinary metabolite, N-methyl histamine, is stable and is therefore useful in determining 
whether mast cell degranulation has taken place in an acute reaction.
The commercial assay and consequently the routine clinical service from the Supra-Regional 
Protein Reference Units has been withdrawn.
Mast cell tryptase is available as an alternative.
Renal function must also be known to evaluate results.
Venom-specific IgE and IgG
Measurement o f specific IgE to bee and wasp venom is an essential investigation in suspected 
insect-sting allergy.
This is carried out as for other allergen-specific IgE tests.
Negative results may occur with the in vitro assays.
SPT with incremental concentrations of venom may be required.
Incremental SPT for bee and wasp can be carried out with solutions of 10, 100, and 300 
(ig/ml. IDT with diluted venom may occasionally be required.
10-fold steps from 0.0001 pg/ml to 1 pg/ml.
Measurement o f venom-specific IgG may be helpful in determining the success of 
desensitization.
I. Pulmonary function testing
1. Measurement o f pulmonary function is employed in patients with allergic pulmonary 
disease to aid in the differential diagnosis o f obstructive airway disease, to evaluate bronchial 
challenge objectively, and to determine the clinical severity and monitor the results o f therapy. 
Although complete spirometry before and after the use of bronchodilators is performed initially, a 
simple measurement such as peak expiratory flow rate or forced expiratory volume at 1 second is 
used to follow patients routinely. Arterial blood gases are the best guides to gas exchange 
abnormalities. In severe asthma they should be assessed frequently to predict the onset of 
respiratory failure.
2. Spirometric measurements o f nasal airflow and resistance are technically difficult and are 
not commonly employed in clinical practice.
J. X-ray examinations
1. X-ray examination o f the chest is indicated during the initial evaluation of allergic 
pulmonary disease. The chest x-ray film in asthma is usually normal; accentuation of the 
bronchovascular markings, thickening o f the bronchi on end, or hyperinflation may be noted in 
patients with chronic disease. During acute exacerbations, an x-ray can exclude complications such 
as pneumonia, atelectasis, or pneumothorax.
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2. Tomography and, in selected cases, bronchography are helpful in patients with suspected 
bronchiectasis or other lesions not revealed by routine chest radiography.
3. Sinus x-rays are indicated for suspected acute or chronic sinusitis, a common complication 
of upper respiratory allergy.
K. Miscellaneous studies
1. Urinalyses and serum chemistries are usually normal in atopic patients.
2. Stool specimens should be examined for ova and parasites in cases of unexplained 
urticaria, eosinophilia, or elevated serum IgE. A duodenal or small-bowel aspirate can uncover 
parasitic infestation in a patient with negative stool findings (e.g., giardiasis).
3. The erythrocyte sedimentation rate is normal in uncomplicated atopic disease. An 
elevated rate suggests an alternative or additional diagnosis or infectious complications.
4. Alpha-antitrypsin level and phenotype should be assessed in patients showing irreversible 
obstructive airway disease.
5. Serum quantitative immunoglobulins, especially IgA, can be deficient in patients with 
symptoms suggestive of allergy. In immunodeficiency, however, wheezing is not usually the 
predominant presenting symptom.
6. Quantitative sweat chloride test values are elevated in cystic fibrosis, a disease primarily 
affecting children but occasionally seen in adults. Symptoms of poor growth, chronic pulmonary 
infection, and malabsorption should prompt performance of this test.
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4. Anaphylaxis
The term anaphylaxis has been used to define the allergic adverse reaction characterized by 
systemic clinical manifestations that occur in an individual who had been primarily sensitized to a 
foreign substance on subsequent reexposure by any route, whether inhalation, oral, or injection, of 
the same material. The term anaphylaxis was derived from the Greek words a- (against) and - 
phylaxis (immunity protection). The terms anaphylactic and anaphylactoid refer to similar if not 
identical syndromes but have been utilized in the past by some clinicians as meaning IgE-mediated 
or поп-IgE-mediated systemic reactions, respectively.
Anaphylaxis represents the most severe type of allergic reaction and a medical emergency.
I m m u n o l o g i c a l  f e a t u r e s
•  Sudden massive degranulation of mast cells, releasing histamine.
•  Mast cells are stimulated to produce leukotrienes (cause of late reaction).
•  Degranulation can be mediated by bound IgE-allergen cross-linking on the surface or direct, 
IgE-independent, mast cell degranulation (anaphylactoid reaction) responses. Mechanism is 
calcium-dependent
•  Involvement o f IgE requires prior exposure to sensitize the patient. In childhood sensitization to 
peanut may occur via formula milk, which may contain peanut oil. Following sensitization, only 
tiny amounts may be required to trigger subsequent reactions.
• Reaction is an example of type I hypersensitivity, dependent on the presence of specific IgE. 
Other reactions may mimic the clinical symptoms but without the involvement of IgE.
•  Repeated challenge at short intervals may lead to progressively more severe reactions, but 
otherwise the severity of a reaction does not predict the severity of subsequent reactions.
•  Symptoms occur as a result of mast-cell release of histamine, which is responsible for 
bronchoconstriction, increased airway mucus secretion, stimulation of gut smooth muscle, 
hypotension due to increased vascular permeability, and vasodilatation and 
urticaria/angioedema.
•  Other mediators include mast-cell tryptase and chemotactic factors for eosinophils. Activated 
mast cells also synthesize prostaglandins and leukotrienes, which reinforce the effects on 
smooth muscle. Tosyl-Larginine methyl ester (TAME) has a similar effect. Platelet-activating 
factor (PAF) causes the activation of platelets, leading to the release of histamine and serotonin 
and augmenting the effects on vascular tone and permeability.
•  Mast-cell numbers at sites of allergen exposure are critical. It is speculative that there are 
variations in the output of mast cells from bone marrow that influence the possibility of 
developing reactions.
•  Complement and kinin systems are activated (basophils release kallikrein when activated). 
Bradykinin, СЗа, and C5a all act as smooth muscle constrictors and increase vascular 
permeability.
•  Reactions may recur after 2-6 hours, despite successful initial treatment, due to the continuing 
synthetic activity o f mast cells and the release of leukotrienes.
•  Those with underlying atopic disease are said to be more at risk of developing serious allergic 
responses.
S u b s t a n c e s  c a u s i n g  a n a p h y l a x i s
Any substance may cause anaphylaxis, but the most common causes are:
• venoms: bee and wasp venoms;
• legumes: peanuts (and related legumes, soya, and other beans/peas);
• true nuts (walnut, almond, cashew, hazelnut, etc.);
• shellfish (Crustacea, prawns, shrimps, crab, lobster) and fish;
• latex (and related foods: banana, avocado, kiwi, chestnut, potato, tomato);
• egg, milk;
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• antibiotics: penicillin, cephalosporins, other antibiotics;
• anaesthetic drugs: neuromuscular blocking agents (e g. suxamethonium, vercuronium);
• peptide hormones (ACTH, insulin);
• heterologous antisera (antivenins, antilymphocyte globulins, monoclonal antibodies).
In some cases a cofactor is required for the reaction, such as concomitant aspirin ingestion 
with the food, or exercise. It is probable that these cofactors alter the amount of allergen entering 
the circulation.
PATHOGENESIS
IMMUNE MECHANISMS 
IgE-Mediated Reactions
A wide variety o f agents are potentially responsible for IgE-mediated anaphylaxis (Table 4-1). 
Table 4-1. Examples of Agents Causing Anaphylaxis via Immune Mechanisms
IgE Mediated
Antimicrobial 
agents (haptens)
Penicillin, cephalosporin, tetracydine, aminogfycoside, 
streptomycin, amphotericin-B, nitrofurantoin, sulfamethoxazole
Hormones Insulin, thyroid-stimulating hormone, corticotrophin, progesterone, 
adrenocorticotropic hormone
Enzymes Streptokinase, penicillinase, chymotrypsin, trypsin
Antiserum Tetanus, diphtheria, antitoxins, antithymocyte, antilymphocyte globulin
Venoms (and 
saliva)
Hymenoptera (bee, vespid and wasp, fire ant), Chrysops (deer fly), triaroma 
(kissing bug)
Vaccines Tetanus, egg-containing vaccines (influenza), allergen vaccines
Foods Milk, egg, wheat, fish and shellfish, legumes (peanuts), nuts (tree); exercise 
with foods
Miscellaneous Latex, seminal fluid; animal or human proteins; polysaccharides
Complement
Mediated
Transfusion reaction associated with IgA deficiency
Cytotoxic (cell-fixed antigen, transfusion reactions to cellular elements, IgG, 
IgM
Aggregate (intravenous immunoglobulins)
Antibiotics, such as the penicillins and cephalosporins, cause anaphylactic reactions through a 
hapten-protein-initiated IgE antibody-mediated mechanism. Proteins - including insulin, 
chymotrypsin, and venoms - as well as therapeutic agents - such as allergy vaccines and various 
other vaccines - can also be responsible. Foods are a significant source of IgE-mediated 
anaphylaxis, reactions most commonly occurring with eggs, shellfish, and nuts.
Non-IgE-Mediated Mechanisms
Anaphylaxis may occur during the administration of blood and blood products through a non-IgE 
immune complex (probably IgG) mechanism. These reactions are provoked by the development of 
antibodies to the red blood cell antigen or plasma protein (such as immunoglobulin), are presumed 
to be mediated by activation of complement, and can also induce anaphylaxis via fixation of 
complement. However, administration of blood products containing IgA to selective IgA-deficient 
patients may induce the development o f IgE antibodies to IgA, which could mediate an 
anaphylactic reaction.
NON IMMUNE MECHANISMS
Table 4-2 lists agents that cause anaphylaxis via nonimmune mechanisms.
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Table 4-2. Examples of Nonimmune Mechanisms: or Conditions Causing Anaphylaxis 
(Immunoglobulin E Independent)
Direct histamine-releasing agents Muscle relaxants, ciproflaxin, vancomycin, pentamidine, 
radiocontrast media, angiotensin-converting enzyme 
inhibitor, opioids, plasma expander polysaccharides 
(Dextran)
Arachidonate mediated Aspirin and nonsteroidal anti-inflammatory drugs
Physical Exercise, temperature (cold, heat)
Idiopathic
Undifferentiated somatoform 
idiopathic anaphylaxis
Nonorganic symptoms mimicking anaphylaxis
Direct mast cell degranulating agents, such as opiates, curare muscle relaxants, plasma 
expander polysaccharides (dextran), certain antibiotics, and iodinated radiocontrast media, have 
been noted to release histamine from basophils and mast cells. Aspirin is also known to cause 
anaphylaxis through uncertain mechanisms. Aspirin-sensitive patients may also show intolerance to 
other nonsteroidal anti-inflammatory agents, including ibuprofen, indomethacin, and tolmetin. The 
role o f tartrazine and other dyes in producing anaphylaxis is a matter o f controversy. Patients with 
systemic mastocytosis can also manifest reactions resembling anaphylaxis due to release of 
histamine and other mediators from the abundant and excessive mast cells without an overt immune 
mechanism.
IDIOPA THIC ANAPHYLAXIS
A number of patients are also recognized as having idiopathic anaphylaxis, during which 
symptoms occur in the absence of any identifiable inciting agent. It is thought that this type of 
reaction may represent the most severe form of a spectrum of immediate-type reactions due to 
abnormal and inappropriate mast cell or basophil activation. Exercise-induced anaphylaxis may be 
included in this category. These individuals have been described as developing anaphylaxis more 
readily after eating certain foods, such as celery, just prior to exercise. Another subgroup of patients 
with idiopathic anaphylaxis has been classified as having an undifferentiated somatoform disorder, 
because the patient history mimics idiopathic anaphylaxis but lacks correlating objective physical 
findings and has no response to appropriate therapy.
PATHOLOGY
The principle anatomic and microscopic findings in fatal anaphylaxis include pulmonary 
emphysema, laryngeal edema, visceral congestion, pulmonary edema, intraalveolar hemorrhage, 
urticaria, and angioedema. These findings result from hypoxia and hypovolemia. Autopsy findings 
may be complicated by therapeutic measures (iatrogenic procedures).
Microscopic evidence that suggests myocardial infarction, pulmonary hemorrhage, edema, 
increased bronchial secretions, peribronchial vascular congestion, and eosinophilic infiltration of 
the bronchial walls can be found. There is accumulation of thin noninflammatory fluid in the lamina 
propria o f the hypopharynx, epiglottis, and larynx in as many as two thirds of fatal cases. Other 
less-specific findings associated with systemic anaphylaxis include liver, spleen, and other 
abdominal visceral congestion, with an increased number of eosinophils in the red pulp of the 
spleen. Hemorrhagic gastritis also may be seen.
CLINICAL PRESENTATION
Usual features are:
•  generalized giant urticaria;
• angioedema, often involving face, lips, tongue, and larynx, causing stridor;
•  bronchospasm;
•  hypotension with loss o f consciousness;
• gastrointestinal symptoms (nausea, vomiting, abdominal cramps, diarrhoea).
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Not all symptoms will be present during an attack and only 50% of patients will have a rash. 
Onset is rapid after exposure, usually within minutes, although some agents (foods and latex) may 
lead to a slower onset. Agents that are injected (drugs, venoms) give the fastest reactions.
Reaction should be graded:
•  Mild: a feeling of generalized warmth, with sensation of fullness in throat, some localized 
angioedema and urticaria, but no significant impairment of breathing or features of 
hypotension.
•  Moderate: as for mild, but with more widespread angioedema and urticaria, some 
bronchospasm, and mild gastrointestinal symptoms.
• Severe: intense bronchospasm, laryngeal oedema, with severe shortness o f breath, 
cyanosis, respiratory arrest, hypotension, cardiac arrhythmias, shock, and gross 
gastrointestinal symptoms.
DIAGNOSIS
The diagnosis of systemic anaphylaxis has been based on recognition of the clinical features.
History is all-important, particularly the timing of reaction in relation to the suspected trigger. 
If the trigger is not clear, a detailed review of all exposures over the preceding 24 hours is required.
Confirmation of the nature of the reaction may be obtained by taking blood for mast-cell 
tryptase (levels will be elevated for up to 12 hours and it is stable). This is valuable where there is 
doubt about the nature of the reaction; urinary methylhistamine is an alternative, but is not now 
routinely available.
Evidence should also be sought for activation of the complement system (measurement o f C3, 
C4, and C3 breakdown products). Measurement of C3a and C5a is possible but requires a special 
tube, which is unlikely to be available in time.
Total IgE measurements are of no value.
Tests for specific IgE (RAST, etc.) may give negative results in the immediate phase, even 
when it is quite clear what has caused the reaction, due to consumption of the IgE. Repeating tests 
3-4 weeks later may be helpful.
A complete blood count may show an elevated hematocrit secondary to hemoconcentration, 
but usually there is no acute abnormality.
Blood chemistries. If myocardial damage has occurred, elevations of serum glutamic- 
oxaloacetic transaminase (SGOT), creatine phosphokinase (CPK), and lactic dehydrogenase (LDH) 
enzymes are present.
Skin-prick testing may be sufficient to trigger a further systemic reaction and should be 
undertaken with great caution and only in a situation in which full facilities for cardiopulmonary 
resuscitation are immediately available.
Chest x-ray. With bronchial involvement, the chest x-ray shows hyperinflation with or without 
areas of atelectasis. In some cases, pulmonary edema is evident.
Electrocardiogram. Unless myocardial infarction has occurred, ECG changes are usually 
transient and can include S-T wave depression, bundle branch block, atrial fibrillation, and various 
ventricular arrhythmias.
D i f f e r e n t i a l  d i a g n o s i s
Attention must be paid to other conditions that may appear similar clinically: 
pulmonary embolus;
myocardial infarction (but this may follow anaphylaxis in those with pre-existing ischaemic 
heart disease); 
hyperventilation; 
hypoglycaemia; 
vasovagal reactions; 
phaeochromocytoma;. carcinoid; 
systemic mastocytosis;
rarely the symptoms may be factitious (typically occur in those who also have true anaphylaxis).
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Table 4-3 presents characteristic features of the most common conditions confused with 
anaphylaxis.
Table 4-3. Differential Diagnosis of Anaphylaxis by Clinical Features
Condition Anaphylaxis Anaphylactoid Insulin Myocardial Vasovagal
Reaction Reaction Infarction Reaction
Pallor + + + + +
Diaphoresis + + + + +
Altered + + + ± +
consciousness
Urticaria,
angiocdema
+ + - -
Dyspnea + + - + +
Wheezing + + + -
Hyperinflation + + - - -
Stridor + + - -
Hoarseness + + - ’ -
Tachycardia + + + + -
Hypotension + + + + +
Arrhythmias + + + + -
ECG and enzyme 
abnormality
+ ± ” +
Hypoglycemia - - + - -
+ = usually present: ± = may be present; - = usually absent.
Vasovagal reactions and syncopal attacks often occur with injections. The pulse is slow, and 
cyanosis usually does not occur. Although the blood pressure is low, it is usually easily detectable 
and generally higher than in anaphylaxis. Pallor and diaphoresis are common features.
Myocardial infarction. The predominant symptom in myocardial infarction is chest pain, with 
or without radiation. Respiratory difficulty, developing more slowly, results from a restrictive 
abnormality without air trapping or other evidence of bronchial obstruction. There is no upper 
airway edema or obstruction.
Insulin reactions are characterized by weakness, pallor, diaphoresis, and unconsciousness. 
Airway obstruction and respiratory distress do not occur; the blood pressure is usually only 
moderately depressed.
In hysterical reactions, there is usually no objective evidence of respiratory distress, 
hypotension, or cyanosis. Paresthesias are more common than pruritus. Syncope can occur, but 
unconsciousness is momentary. Rapid assessment of vital signs and neurologic status will 
differentiate this condition from anaphylaxis.
TREATMENT OF ANAPHYLAXIS
The treatment of anaphylaxis can be life saving. Prompt recognition is essential, as death may 
occur within minutes. Box 4-1.
Box 4-1. Physician-Supervised Management of Anapnylaxis
1. Assess rapidly (airway, breathing, circulation, and adequacy of mentation).
2. Place in recumbent position and elevate lower extremities.
3. Discontinue inciting agent or allergen.
4. Inject epinephrine 1:1000, 0.01 ml/kg (max 0.3-0.5 ml) intramuscularly, preferably
into the anterolateral thigh or arm (deltoid). Repeat every 5 min as necessary to control symptoms
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and blood pressure. Epinephrine 1:10,000 dilution may be utilized intravenously in moribund 
subjects.
The initial treatment of anaphylaxis with epinephrine is crucial in:
• Supporting blood pressure
• Decreasing bronchospasm, which helps maintain an effective airway
• Decreasing laryngeal edema, especially when given as a racemic epinephrine 
aerosol
• Slowing the absorption of injected agents if promptly used to infiltrate the site of 
injection
A tourniquet can also be applied above the injection site, because this can reduce and 
compress venous return at the site of an injection and decrease systemic absorption of antigen. It 
should be released for 1 o f every 3 minutes.
Never give IV bolus adrenaline to a conscious patient with anaphylaxis under any 
circumstances.
5. Establish and maintain airway. May need racemic epinephrine by nebulizer into a tracheal
tube.
6. Provide supplement oxygen if  needed (6-8 L/min)
7. Establish IV to maintain blood pressure with IV fluids (saline or volume expanders), 
pressors (dopamine hydrochloride 2-10 pg/kg/min or norepinephrine 
bitartrate 2-4 gg/mln). Support blood pressure with IV fluids (colloid or crystalloid): persisting 
hypotension may require further vasopressor agents.
8. Give diphenhydramine 1.25 mg/kg (max. 50 mg) IV over 3-5 min. Antihistamine should be 
given intravenously (chlorphenamine 10 mg).
9. Ranitidine, 50 mg (1 mg/kg in children), may be diluted in 5% dextrose to a total o f 20 ml 
and injected intravenously over 3-5 min. Inhaled p-agonists (albuterol or levalbuterol) or 
amlnophyfline 5 mg/kg over 30 min (may be helpful for severe bronchospasm 0.3-1 mg/kg/hr)
10. Provide hydrocortisone 5 mg/kg (max. 100 mg) IV q 6 hr or methylprednlsolone 1-2 
mg/kg per 24 hr. A bolus of hydrocortisone (100-200 mg) should be given. The latter has no effect 
on the immediate reaction but reduces the possibility of a late reaction. Use hydrocortisone sodium 
succinate; do not use hydrocortisone phosphate as this is frequently associated with severe burning 
genital pain which makes a sick patient feel much worse.
11. Tracheotomy may be required if there is major laryngeal oedema. Admission for 
observation is required (risk of late reactions); a period of 8 hours is usually adequate.
It is essential to move the patient as soon as possible to an emergency room or intensive care 
hospital facility that can manage major complications, such as cardiac arrhythmias, cardio­
respiratory arrest, seizures, myocardial infarction, hypovolemia, and obstruction of the airway. 
Antihistamines (Hi and H2 blockers) are suggested and may decrease the potential for cardiac 
arrhythmias and peripheral vasodilation, as well as possibly urticaria/angioedema and 
gastrointestinal symptoms. Corticosteroids, although requiring several hours to exert beneficial 
effects, are indicated and may prevent late-phase reactions. Recurrent or biphasic anaphylaxis 
occurs 8 to 12 hours after the initial attack in as many as 20% of subjects who experience 
anaphylaxis.
If a patient who is on therapy with a beta-adrenergic-blocking agent, such as propranolol for 
hypertension, vascular headaches, mitral valve prolapse, or cardiac arrhythmias, develops 
anaphylaxis, the management may be compromised by the propranolol. Treatment may require 
massive infusing of fluid (saline or colloid solutions) to support the circulation compromised by the 
decreased peripheral resistance. In addition, judicious administration of epinephrine for alpha- 
adrenergic activity and isoproterenol to attempt to overcome the beta blockade may be indicated, 
Glucagon 1 to 5 mg (20-30 gg/kg [maximum, 1 mg] in children) administered intravenously over 5 
minutes, followed by an infusion of 5 to 15 gg/minute may be used when beta-blocker therapy 
complicates treatment.
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Cardiopulmonary arrest occurring during anaphylaxis may require a high dose of epinephrine 
administered intravenously (1:10,000 dilution). Rapid volume expansion is also mandatory, as is the 
use of atropine and transcutaneous pacing.
Indications for prescription of adrenaline for self-injection 
(Epipen.Anapen®)
Adrenaline for self injection should be given when:
• patient has had a severe allergic reaction;
•  there is a risk of re-exposure or the allergen cannot easily be avoided;
•  patient has had a moderate reaction, but access to rapid medical assistance is impossible;
•  patient has asthma - reactions are likely to be more severe;
• pregnancy is not a contraindication, as the risk to the fetus from hypoxia due to anaphylaxis 
is greater than the risk of adrenaline.
Adrenaline should not be given when:
•  reaction is mild (urticaria or urticaria with minimal angioedema not involving throat);
•  allergen is avoidable;
• patient is unable to use injection device;
•  patient has or is at risk of ischaemic heart disease; this may include the elderly;
• patient is on beta-blockers, this is a relative contraindication and there is some evidence that 
the effect is not significant, however, it is recommended that the dose of adrenaline be 
halved in patients on beta-blockers, to avoid paradoxical hypertension due to unopposed 
alpha-adrenergic activity;
•  patients are on tricyclic antidepressants or abuse cocaine (increased risk of cardiac 
arrhythmias).
Problems with adrenaline self-injection devices:
Confusingly, Anapen® and Epipen are fired differently; they should not be interchanged 
because of this.
Epipen is triggered by pressure on the needle-containing black tip, once the safety cap has been 
removed from the other end. The white plastic under the safety cap looks like a button but 
isn't!
Anapen is fired by pressing the button under the safety cap.
Accidental injection into fingers occurs: there is a risk of ischaemia and patients should be 
advised to go to casualty.
ANAPHYLACTOID REACTIONS
These may be every bit as severe as IgE-mediated reactions. In most cases they are due to 
activation o f mast cells directly or via other mechanisms that will indirectly activate mast cells. 
Causes. The most common causes are:
• direct mast-cell stimulation: drugs (opiates, thiamine, vancomycin, radiocontrast media, 
some anaesthetic agents, especially those dissolved in cremophor, tubocurarine), foods 
(strawberries), physical stimuli (exercise, cold, trauma), venoms;
• immune complex reactions (types II and III), with release of anaphylotoxins СЗа, C5a: 
reactions to IVIg, other blood products, heterologous antisera;
• cyclo-oxygenase inhibitors: nonsteroidal anti-inflammatory drugs (may also stimulate mast 
cells directly);
• massive histamine ingestion; eating mackerel and other related oily fish (scombrotoxin due . 
to breakdown of muscle histidine to histamine).
Immunological diagnosis
• History usually gives the clue. No tests are entirely specific. Challenge is very risky.
• Tryptase wilt be elevated.
• Specific IgE will not be detectable.
Management
• Acute management is the same as for anaphylaxis.
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• For patients who require IV radiocontrast media and are known or suspected to react, then 
pretreatment with oral corticosteroids (50 mg prednisolone, 13, 7, and 1 hour prior to 
examination), together with an antihistamine (cetirizine 10-20 mg or fexofenadine 120-180 
mg orally 1 hour before) and an H2-blocker (cimetidine, 400 mg orally 1 hour before) 
should be used. Low-osmolality dyes should be used as these have a lower incidence of 
reactions.
PREVENTION OF ANAPHYLAXIS
Prevention is the most important aspect of the management of anaphylaxis. Steps should be 
taken to limit exposure to agents known to precipitate and aggravate anaphylaxis (Box 4-2).
Box 4-2. Prevention of Anaphylaxis
1. Avoid exposure to agents known to cause anaphylaxis.
2. A careful history of previous reactions to suspected antigens is mandatory before 
administering any medication (especially parenterally). Attempts to identify specific 
allergens should utilize immediate type hypersensitivity skin tests or radioallergosorbent 
testing when available.
3. Use oral rather than parenteral medication.
4. Have patients wait in office 30 minutes after drug administration.
5. Have patients carry information on person concerning anaphylactic sensitivity.
6. Skin testing or conjunctival testing with various vaccines and antivenoms derived from 
animal serum is mandatory before administration of therapeutic doses.
7. Predisposed patients should be taught self-injection of epinephrine.
8. When antiserum is essential, use human serum preparations.
9. Avoid beta-adrenergic-blocking agents in anaphylaxis-prone patients.
10. Pretreat with steroids and antihistamines of patient requires procedure (radiocontrast 
media) or most have medications.
11. Great care must be taken with latex-allergic patients, as hospital staff with latex gloves and 
resuscitation with latex-containing equipment (masks, catheters, etc.) may make the 
reaction paradoxically worse during resuscitation.
12. Patients who have had severe reactions should be trained to self-administer adrenaline 
using a self-injection aid and should carry a Medic-Alert bracelet or equivalent. See below 
for indications.
13. Regular annual follow-up by a practice nurse should be undertaken to ensure that patients 
remain competent in using the adrenaline injector.
14. Latex-allergic patients need to be warned about possible reactions to foods (banana, 
avocado, kiwi fruit, chestnut, potato, and tomato) and be given advice on avoidance. It is 
important that they tell doctors and dentists as reactions may be triggered during 
operations by surgical gloves or anaesthetic equipment and by investigations such as 
barium enema (rubber cuff on tubing) and dental treatment.
15. Canying a supply of antihistamines may also be helpful (used prophylactically if  entering 
a situation of unknown risk, e g. eating out).
16. Patients deemed to be at risk of further anaphylaxis should not receive treatment with p- 
blockers, as these agents will interfere with the action of adrenaline if required.
17. Patients should receive detailed counselling on how to avoid the triggering allergen; if a 
food is involved this should be undertaken by a dietician experienced in dealing with food 
allergy. Many foods may be 'hidden', so that the consumer is unaware o f the contents. This 
applies particularly to pre-prepared foods and restaurant meals.
18. For bee/wasp anaphylaxis, patients should be warned to avoid wearing brightly coloured 
clothes and perfumes as these attract the insects. They should also stay away from fallen 
fruit and dustbins. Desensitization is possible. This is a process that requires considerable 
dedication on the part o f the patient (and the hospital staff!). It should be reserved for 
those who have had a systemic reaction and where the risk of further stings is considered 
to be high.
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5. ASTHMA
Asthma is one of the atopic diseases. Asthma, a lower airways disease characterized by 
enhanced responsiveness to a variety o f stimuli and manifested by airways obstruction that changes 
spontaneously or therapeutically, is a common illness in both the pediatric and adult populations. 
The most widely accepted definition of asthma includes the following characteristics:
• Lower airway obstruction that is partially or fully reversible, either spontaneously or with 
bronchodilator or antiinflammatory treatments.
• The presence o f chronic airway inflammation.
• Increased lower airway responsiveness to several stimuli, such as cold air or exercise in the 
natural environment and inhaled methacholine or histamine in a laboratory environment, with 
recurrent episodes o f wheezing, coughing, and shortness o f breath.
The cause is multifactorial, with a complex interaction of genetic background with 
environmental factors. There is also a complex interaction at the local level between changes in the 
airway (reactive airways disease), neurogenic components (particularly involving vasoactive 
intestinal polypeptide (VIP) and substance P), and the innate and specific immune system.
EPIDEMIOLOGY
The burden of asthma has been increasing worldwide, with regard to prevalence, cost, 
morbidity, and mortality. Approximately 26 million individuals in the United States have received a 
diagnosis o f asthma sometime during their lifetime, 8.6 million of which were younger than 18 
years. The onset of asthma in children is before the age of 2 years in 50% and before the age of 5 
years in 80%. Asthma is now the most common chronic illness o f childhood and is a leading cause 
o f school absenteeism.
Asthma is considered a component o f the atopic march, whereby genetically predisposed 
infants typically develop eczema (often with food allergies) shortly after birth, which often subsides 
as they develop inhalant allergen sensitivities and allergic rhinitis during the 2nd to 4th years of life 
and, very often, symptoms of asthma
Viral infections that are clinically detectable only in the upper respiratory tract can be 
associated with bronchial hyperreactivity and small airway dysfunction. Viral infections account for 
as many as 80% of wheezing episodes in young children during the fall and winter seasons. 
Typically, respiratory syncytial virus predomintes in children younger than 2 years, whereas 
rhinovirus predominates in those older than 2 years. Respiratory syncytial virus is the main cause of 
infantile bronchiolitis, which generally manifests as wheezing in small babies and, at times, must be 
differentiated from asthma Mycoplasma pneumoniae may cause more than 50% of wheezing 
episodes in adolescents.
As many as 50% of children with asthma, especially those with milder levels of severity, have 
a clinical remission and become asymptomatic during the 10- to 20-year follow-up period. 
However, in these people, airway biopsy studies have documented ongoing airway inflammation 
and remodeling, and many experience a recrudescence o f symptoms during years of follow-up.
PATHOPHYSIOLOGY
GENERAL PA THOPHYSIOLOGY
Although the underlying pathology in asthma is airway inflammation, clinical manifestations 
of asthma are related to the periodic development of airway obstruction (Fig. 5-1).
When evaluated, patients with mild intermittent or persistent asthma may have no detectable 
evidence of airflow obstruction on routine pulmonary function testing. However, those with 
moderate and severe persistent asthma may have abnormalities detectable both on physical 
examination and in pulmonary function testing (office-based spirometry or home-based peak 
expiratory flow measurements).
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Normal
N o rm a l a irw a y  
w aft th ic k n e s s
C h ro n ic  a s th m a  w ith  A ir w a y  R e m o d e lin g
The history usually reveals that asthma patients develop clinical symptoms (and thus, airflow 
limitation) after exposure to allergens, environmental irritants, viral infections, exercise, and cold 
air (Table 5-2).
Table 5-2. Asthma triggers
Infections Viral
Bacterial sinusitis
Allergens Pollens
Animal products
Molds
Dusts
Cockroaches
Airway factors Cold air
Hyperventilation (e.g., crying, laughing) 
Exercise
Irritants Noxious gases, odors
Cigarette smoke
Pharmacologic Aspirin
Psychosocial Emotions
This propensity to develop airway obstruction in response to normally innocuous 
environmental agents is known is airway hyperreactivity. Its presence can be documented in the 
clinical pulmonary function laboratory using bronchoprovocation testing, in which pulmonary 
function is monitored while patients inhale increased concentrations of methacholine or histamine
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to establish the provocative concentration that causes a 20% fall in forced expiratory volume in 1 
second (FEVi).
Other stimuli that can be used to measure the degree of airway hyperreactivity include 
nonpharmacologic agents such as hyperventilation with cold, dry air, and with exercise. Indeed, the 
clinical severity o f asthma - and thus, medication requirements - tends to parallel the degree of 
airway hyperreactivity.
One of the signs of airway hyperreactivity in patients with asthma is an exaggerated 
fluctuation in morning and evening peak expiratory flow rates. This assessment has been 
incorporated into the asthma guidelines in the classification of asthma severity. The normal diurnal 
variability in airflow in nonasthmatics is approximately 10% or less, but the variability may 
increase dramatically in patients with high degrees of airway hyperreactivity and severe asthma.
Postulated mechanisms for the development o f airway hyperreactivity include airway 
inflammation, abnormalities in bronchial epithelial integrity, changes in intrinsic bronchial smooth 
muscle function, changes in autonomic neural control of airways (decreased beta-adrenergic and 
enhanced alpha-adrenergic and cholinergic responses), and the degree of baseline airflow 
obstruction.
One of the primary mechanisms responsible for the development o f airway hyperreactivity is 
airway inflammation, which has now been documented directly using mucosal biopsies. The airway 
inflammation is complex and variable but is present in all persistent asthma severity levels and very 
early in the course o f disease in adults and children. Th-2 lymphocytes, mast cells, and eosinophils 
appear to be the main orchestrators of the inflammatory process, but neutrophils may be involved in 
more severe cases. Eosinophils, whose tissue migration and activation may be directed by the 
secretory products o f pulmonary mast cells, macrophages, and epithelial cells, have been linked to 
alterations in epithelial integrity, abnormalities in autonomic neural control of airway tone, and 
increased airway smooth muscle responsiveness. Another cell with a likely role in these events is 
the T-lymphocyte. Indeed, this cell, once activated by antigen, may orchestrate the development and 
maintenance of airway inflammation through the secretion of proinflammatory, soluble cytokines 
such as interleukin (IL)-4 and IL-5, which have the ability to influence the activation state o f a 
variety of inflammatory cells in both autocrine and paracrine fashions.
Smoldering inflammation is also accompanied by a remodeling process, which includes 
epithelial disruption, edema, hypertrophied and hyperplastic smooth muscle bundles, increased 
vascularity, increased mucous secretion, and a remarkable thickening of the reticular basement 
membrane due to collagen deposition (see earlier figures). This remodeling may relate to the long­
term decline in lung function and loss o f reversibility observed in asthmatic patients.
Inflammatory mediators also play a major role in the pathogenesis o f selected features of 
asthma, including the inflammation and remodeling processes (Fig. 5-2). These include the 
cysteinyl leukotrienes (Fig. 5-3).
Some o f the cells that release these potent mediators, including eosinophils, basophils, and 
mast cells, have an inherent enhanced degree of mediator releasability in asthma, thus providing a 
possible explanation for the observed elevations of plasma mediator levels during laboratory- 
provoked and naturally acquired acute asthma.
Genetics and environment both participate in the pathogenesis o f asthma. Family history very 
often reveals affected siblings, parents, or other first-degree relatives. No specific asthma gene has 
yet been identified, but recent advances in molecular biology promise to better define the genetic 
basis for asthma. Certain environmental factors may be prerequisite for its clinical presentation. For 
example, a propensity to develop airway hyperreactivity may be inherited, but appropriate exposure 
to certain allergens, respiratory viruses, chemicals, or psychosocial stimuli are associated as triggers 
for its clinical expression as asthma.
51
Pathogenesis ot Asthma
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Figure 5-2. C e l ls  a n d  m e d i a t o r s  i n t e r a c t in g  t o  r e s u l t  in  a s t h m a  p a t h o p h y s i o l o g y .  E C P ,  e o s in o p h i l  
c a t io n ic  p r o t e i n ;  G M - C S F ,  g r a n u l o c y t e - m a c r o p h a g e  c o l o n y -s t i m u l a t i n g  f a c t o r ;  I L ,  i n t e r l e u k i n ;  L T ,  
l e u k o t r ie n e ;  N O ,  n it r ic  o x id e ;  O 2- ,  s u p e r o x id e ;  P A F ,  p l a t e l e t -a c t i v a t in g  f a c t o r ;  P G s ,  p r o s t a g l a n d i n s ;  T H, 
h e l p e r  T  c e l l ;  T N F ,  t u m o r  n e c r o s is  f a c t o r .
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Leukotriene Biosynthesis and Blockade
Receptor
МыЬу ite m  and derived it e m  © 2006 by Uotfcy. Inc.
Figure 5-3. L e u k o t r i e n e  b io s y n t h e t i c  p a t h w a y s  a n d  b lo c k a d e .  N o t e  t h e  in t e r a c t io n  o f  t h e  c y s t e i n y l  
le u k o t r ie n e s  w i t h  t h e  C y s L T ,  ( l e u k o t r i e n e )  r e c e p t o r  a n d  t h e  r o le  o f  r e c e p t o r  a n t a g o n i s t s .  S u c h  a  r e c e p t o r  
is  p r e s e n t  o n  t h e  s u r f a c e  o f  c e l l s  s u c h  a s  a i r w a y  s m o o t h  m u s c l e  c e l ls  a n d  e o s in o p h i l s .  H p E T E ,  
h y d r o p e r o x y  e ic o s a t e t r a e n o i c  a c i d ;  P G ,  p r o s t a g l a n d i n ;  R x ,  t r e a t m e n t ;  T X ,  t h r o m b o x a n e .
Laboratory experiments have demonstrated that inhalation of a relevant allergen by an allergic 
asthmatic patient results in the development o f an acute decrease in FEV| and the onset of asthma 
symptoms within 30 minutes o f exposure (Fig. 5-4).
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Figure 5-4. A, E a r l y  a n d  la t e  a s t h m a t i c  r e s p o n s e s  in  F E V i  ( f o r c e d  e x p i r a t o r y  v o l u m e  in  1 s e c o n d )  
t o  i n h a l e d  a l l e r g e n  c h a l l e n g e .  8 ,  A l l e r g e n - i n d u c e d  e a r l y -  a n d  l a t e -p h a s e  a i r w a y  t is s u e  r e s p o n s e s .  N o t a b l y ,  
a i r w a y  h y p e r r e a c t i v i t y  in c r e a s e s  a f t e r  l a t e -p h a s e  a s t h m a t i c  r e s p o n s e s .  E C P ,  e o s in o p h i l  c a t io n ic  p r o t e i n ;  
F c c R I ,  F e e  r e c e p t o r  I ;  G M - C S F ,  g r a n u l o c y t e - m a c r o p h a g e  c o l o n y -s t i m u l a t i n g  f a c t o r ;  I g ,  i m m u n o g l o b u l i n ;  
I L ,  i n t e r l e u k i n ;  L T ,  l e u k o t r ie n e ;  M B P , m a j o r  b a s ic  p r o t e i n ;  P A F ,  p l a t e l e t -a c t i v a t in g  f a c t o r ;  P G ,  
p r o s t a g l a n d i n ;  T G F ,  t r a n s f o r m i n g  g r o w t h  f a c t o r ;  T N F ,  t u m o r  n e c r o s is  f a c t o r .
Such a trigger may cause bronchial mast cells, macrophages, and epithelial cells to release 
inflammatory mediators, which then trigger the bronchospasm. Over the ensuing hours, airway 
function returns to baseline in most patients. If their progress is monitored, approximately 50% of 
these patients then experience a second decline in FEV i approximately 4 to 8 hours after exposure, 
termed a late-phase allergic reaction (see Fig. 5-4). Importantly, the degree of bronchial 
hyperreactivity to nonspecific stimuli is increased in patients experiencing late-phase allergic 
reaction. This is believed to be related to the intense airway inflammation that develops in these 
patients, manifested by increased numbers of eosinophils in the airways, along with other cells. The 
migration o f eosinophils into the airways and their activation may be directed by inflammatory 
mediators released earlier during the immediate allergic reaction. Indeed, patients who experience 
sequential late-phase bronchial reactions could thus experience progressively heightened levels of 
airway hyperreactivity, as seen in asthma.
Viral respiratory infections also play a role in the pathophysiology of asthma with the 
development o f increased levels of airway hyperreactivity and an increased frequency of late-phase 
asthmatic reactions to allergen during acute infections. Indeed, the increases in airway 
hyperreactivity that follow a respiratory viral infection may persist for weeks beyond the infection. 
Possible contributors to these phenomena include direct epithelial damage, the production of virus- 
specific IgE antibodies, enhancement of the production of IgE antibodies specific for other antigens, 
upregulation of neurogenic inflammatory pathways, and increases in the level o f mediator release 
from inflammatory cells.
In addition to viruses and allergens, other environmental agents, including inhaled ozone, can 
induce airway inflammation and hyperreactivity. Once airway hyperreactivity is present, airway 
obstruction - and thus, the common asthma symptoms of wheezing and dyspnea - can be triggered
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by subthreshold levels o f exposure to nonspecific environmental irritants, such as cigarette smoke 
and sulfur dioxide.
PA THOPHYSIOLOG Y OF A CUTE EXACERBA TIONS OF ASTHMA
The development of the typical symptoms of acute asthma (progressive worsening o f cough, 
breathlessness, wheezing, and chest tightness) is accompanied by decreases in expiratory airflow 
rates. Bronchial smooth-muscle contraction is one of the primary factors contributing to the airway 
obstruction. Other contributory factors include inflammation changes, such as mucosal edema and 
mucous plugging, which results in air trapping and hyperinflation. Physiologic changes that 
progress as the acute process worsens include both clinical and laboratory alterations. Clinically, 
patients with progressive airway obstruction use accessory muscles o f respiration 
(sternocleidomastoid muscles) to maintain the state o f hyperinflation. This, in turn, enables patients 
to maintain airway patency and thus, adequate gas exchange. Indeed, the use of accessory muscles 
to breathe correlates very well with the severity o f an episode of acute asthma and is superior to 
dyspnea and wheezing as a sign of a severe episode.
The severity of acute asthma, however, is best assessed by pulmonary function testing. During 
acute asthma, progressive changes are noted in functional residual capacity (increased), FEVi 
(decreased), peak expiratory flow rate (decreased), and forced vital capacity (decreased or normal). 
The latter change correlates with the degree of hyperinflation. Blood gas assessment may reveal 
hypoxemia because of mismatching of ventilation and perfusion. Hypocapnia (reduced arterial 
carbon dioxide levels) and respiratory alkalosis (increased pH) are the usual manifestations o f early 
acute asthma, because alveolar ventilation is maintained at this stage. However, with more severe 
obstruction, ventilation is compromised and arterial carbon dioxide levels rise (hypercapnia) with 
decreased pH and respiratory acidosis. The latter finding signals the development o f acute 
respiratory insufficiency and the presence of an FEV i that is less than 25% of the predicted value.
Other physiologic changes that occur in acute asthma include increased pulmonary vascular 
resistance and an increased after-load on the left ventricle due to the high negative pleural pressures 
that result from lung hyperinflation. The clinical manifestation of these changes is the development 
of pulsus paradoxus, which is an exaggerated fall in systolic pressure during inspiration. Its 
presence correlates with an FEV [ less than 50% of the predicted value for that patient.
CLINICAL PRESENTATION AND DIFFERENTIAL DIAGNOSIS
The diagnosis o f asthma requires the documentation o f episodic airway obstruction and the 
reversibility o f that obstruction, preferably using spirometry in children older than 5 years and 
repeated clinical examinations in younger children, as well as the exclusion of alternative 
diagnoses. These alternative diagnoses can include disorders such as vocal cord dysfunction in the 
older patient and vascular ring in the younger child (Tables 5-3 and 5-4). The presence of recurrent 
cough or wheezing triggered at nighttime or by exercise or cold air exposures, especially in the 
context o f a positive family history, is a particularly helpful clue in establishing the diagnosis of 
asthma.
Some patients present with cough as the sole manifestation of asthma. These patients typically 
have normal pulmonary function tests, with some improvement with the bronchodilator, and 
manifest airway hyperreactivity to provocative stimuli, such as methacholine, exercise, or cold air.
During the history and physical examination, particular attention should be focused on the 
growth pattern o f children. Severe asthma can suppress the growth of young children, but poor 
growth is a predominant feature of many of the masqueraders o f asthma, such as cystic fibrosis. 
Also, the presence o f upper respiratory findings compatible with allergic rhinitis (pale, boggy nasal 
turbinates, suborbital venous congestion -"shiners" - nasal crease, Denie's lines, and skin 
manifestations o f atopic dermatitis should be noted. The examination should focus on the 
appearance of a hyperexpanded chest, presence of cyanosis, degree o f respiratory distress, use of 
accessory muscles, wheezing, decreased inspiratory-to-expiratory ratio, rhonchi, and other findings 
on auscultation that might indicate pneumonia or atelectasis. The cardiac examination should be
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geared toward the identification of congenital heart disease in young children and congestive heart 
failure in adults.
Acute asthma symptoms usually consist of progressively increasing shortness of breath 
(dyspnea), cough and difficulty breathing with or without rhinorrhea, low-grade fever, and other 
manifestations of an upper respiratory infection. On auscultation, expiratory wheezing or a 
prolonged expiratory phase may be the only manifestation of mild asthma. However, as the 
obstructive process progresses, the expiratory phase becomes longer and the musical high-pitched 
rhonchi grow louder.
Tables 5-3. Differential diagnosis of wheezing (causes other than asthma)
Diagnostic Clues Possible Cause
Sudden onset o f wheezing, choking, or coughing; recurrent 
wheezing, persistent cough, or recurrent pneumonia
Foreign-body aspiration
Chronic wheezing that is not responsive to bronchodilators or 
corticosteroids; wheezing may increase with feeding, crying, 
positional changes, or flexion of the neck
Vascular rings
Persistent stridor and wheezing that have been present since 
birth
Laryngeal webs
Noisy breathing, especially on inspiration; noisy breathing and 
wheezing are intermittent and increase when the infant is 
supine; stridor present since birth; history of feeding difficulties
Laryngotracheobronchomalacia
Symptoms of upper respiratory tract infection (cough, fever, 
rhinitis); tachypnea, retractions, cyanosis
Branchiolitis
Failure to thrive, fever, diarrhea, recurrent pneumonia Cystic fibrosis
History of prematurity and intubation; increased airway 
hyperreactivity, severe respiratory distress
Bronchopulmonary dysplasia
Frequent emesis; irritability during feedings; recurrent 
wheezing
Gastroesophageal reflux
Recurrent wheezing and pneumonia; episodes of cough or 
cyanosis associated with feeding
Tracheoesophageal fistula
Recurrent sinusitis, otitis media, and pneumonia Primary immunodeficiency
Tables 5-4. Selected diagnostic tests for the evaluation of wheezing
Suspected Diagnosis Selected Diagnostic Tests
Foreign body Inspiratory arid expiratory chest x-ray*, bronchoscopy
Vascular rings Barium esophagraphy
Laryngeal web Direct laryngoscopy
Laryngotracheobronchomalacia Direct laryngoscopy, airway fluoroscopy
Enlarged lymph nodes/tumors Chest x-ray, CT scan*, biopsy
Bronchiolitis Nasal washing for presence of RSV*
Cystic fibrosis Sweat test, genetic tests
Gastroesophageal reflux pH probe, endoscopy
Tracheoesophageal fistula Barium esophagraphy and fluoroscopy
Primary immunodeficiency CBC with differential, quantitative Ig levels
Asthma Trial of bronchodilators and corticosteroids
Congenital Heart Disease CXR, EKG, ECHO*
* - CBC, complete blood count; CT, computed tomography; CXR, chest x-ray; ECHO,
echocardiogram; EKG, electrocardiogram; 
RSV, respiratory syncytial virus.
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Without appropriate treatment and reversal, signs of hyperinflation (air trapping) develop, 
with depressed diaphragms, decreased excursions of the chest wall with respiration, and 
hyperresonance to percussion. Subjectively, the patient experiences chest tightness and anxiety and 
works harder to breath. Accessory muscle use (visible contractions of the scalene and/or 
sternocleidomastoid muscles) and retractions (visible depressions in the chest wall during 
inspiration) develop with or without a marked degree of wheezing on auscultation. The patient 
usually assumes an upright posture to maximize air exchange. As respiratory muscles tire, the 
patient becomes lethargic and cyanotic, even with supplemental oxygen.
Maximal effort to breathe produces feeble air exchange, manifested by decreased intensity and 
duration or lack of inspiratory breath sounds as air exchange decreases. Consequentiy, a patient 
with severe obstruction and impending respiratory failure may not have audible wheezing because 
too little air is being ventilated to create the sound. With extreme fatigue, respiratory muscles fail, 
retractions decrease, and respiratory failure is imminent unless appropriate therapy is promptly 
initiated. Following the initial examination, serial assessment of the degree of respiratory distress, 
using a standardized clinical scoring system (Table 5-5), facilitates determination of response to 
therapy and ensures early detection of impending respiratory failure or other complications.
Table 5-5. Estimation of Severity of Acute Exacerbations of Asthma in Children*
Sign/Svmptom Mild Moderate Severe
PEFR** 70%-90% predicted 
or personal best
50%-70% predicted or 
personal best
<50% predicted or 
personal best
Respiratory rate, 
resting or sleeping
Normal to 30% 
increase above the 
mean
30%-50% increase above 
the mean
Increase over 50% 
above the mean
Alertness Norma! Normal May be decreased
Dyspnea*** Absent or mild; 
speaks in complete 
sentences
Moderate; speaks in 
phrases or partial 
sentences; infant's cry 
softer and shorter; infant 
has difficulty suckling 
and feeding
Severe; speaks only in 
single words or short 
phrases; infant's cry 
softer and shorter; infant 
stops suckling and 
feeding
Pulsus
paradoxicus****
<10 mm Hg 10-20 mm Hg 20-40 mm Hg
Accessory muscle 
use
No intercostal to 
mild retractions
Moderate intercostal 
retraction with 
tracheostemal 
retractions; use of 
sternocleidomastoid 
muscles; chest 
hyperinflation
Severe intercostal 
retractions, 
tracheostemal 
retractions with nasal 
flaring during 
inspiration; chest 
hyperinflation
Color Good Pale Possibly cyanotic
Auscultation End expiratory 
wheeze only
Wheeze during entire 
expiration and inspiration
Breath sounds becoming 
inaudible
Oxygen saturation >95% 90%-95% <90%
PC02 <35 <40 >40
* - Within each category, the presence of several parameters, but not necessarily all, indicate the 
general classification of the exacerbation. ** - For children 5 yr or older. *** - Parents' or 
physicians' impression of degree of child's breath less ness. **** - Pulsus paradoxus does not 
correlate with phase of respiration in small children. PEFR, peak expiratory flow rate.
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Between episodes of acute asthma, the physical findings vary with the chronicity of the 
disease process. In mild asthmatics, the examination is usually entirely normal, but wheezing may 
be elicited in children by gentle manual chest wall compression, which restricts chest expansion and 
increases the work of breathing. In contrast, severe asthmatics with a long history of airway 
obstruction that has not received appropriate therapy may have signs of chronic lung disease. These 
include a paucity of subcutaneous fatty tissue and a barrel-chest configuration. Adults with chronic 
asthma may produce copious amounts of sputum. Rales, wheezing, rhonchi, and decreased intensity 
and duration of the inspiratory phase of respiration are commonly found on auscultation. Chest 
radiography may show areas of atelectasis.
Asthma should be considered as part of the differential diagnosis in any patient with recurrent 
or chronic lower respiratory symptoms or signs of lower airway obstruction. Patients or their 
parents must be instructed that physician assessment is essential during suspected episodes of 
asthma so that wheezing or other signs of lower airway obstruction and reversibility, if present, can 
be documented.
Asthma is the most common cause of recurrent episodes of cough and wheezing in both adults 
and children. However, asthma is frequently misdiagnosed and underdiagnosed, especially in young 
children who wheeze only during respiratory infections and who are labeled as having bronchitis, 
bronchiolitis, or pneumonia.
Any patient with acute asthma who develops symptoms of pleuritic chest pain, severe 
dyspnea, cyanosis, and tachypnea, as well as physical findings of unilaterally decreased or absent 
breath sounds, should be evaluated radiographically for pneumothorax. With tension pneumothorax, 
the trachea, mediastinum, and cardiac landmarks may be shifted to the opposite side. 
Pneumomediastinum and subcutaneous emphysema, usually involving the neck and supraclavicular 
areas, are more common than pneumothorax. When mild, they may be asymptomatic and detected 
incidentally by radiography. With more extensive air dissection, the patient may complain of neck 
and chest pain, and the subcutaneous emphysema may be visibly evident as a soft tissue swelling of 
the neck and chest, which is crepitant (has a crunching sound) on palpation.
Cardiovascular manifestations can also be detected during acute asthma. Heart rate and blood 
pressure are frequently elevated. Pulsus paradoxus, an exaggerated decrease in systolic blood 
pressure during inspiration, can serve as an indicator of severity and a guide to therapy. Pulsus 
paradoxus and the patient's exaggerated use of accessory muscles both correlate highly with tire 
degree of airway obstruction.
In patients who present with respiratory distress or wheezing for the first time, a complete 
differential diagnosis o f all causes o f upper and lower airway obstructive processes must be under­
taken. In the older child or adult with mild, infrequent episodes of wheezing that respond to 
bronchodilator therapy, asthma is usually readily diagnosed. However, with daily wheezing, 
frequent exacerbations, lack of response to bronchodilators, or poor growth, other diagnoses must 
be considered. These include chronic obstructive pulmonary disease, cystic fibrosis, a r antitrypsin 
deficiency, carcinoid syndrome, and an associated immunologic deficiency.
Chronic obstructive pulmonary diseases, which include chronic bronchitis, emphysema, 
bronchiectasis, and bronchopulmonary dysplasia, are distinguished by their lack of significant 
reversibility with bronchodilator therapy. Cystic fibrosis, a multisystem disease, may present with 
chronic cough, wheezing, and recurrent infections, especially sinusitis. Additionally, malabsorption 
with bulky, foul-smelling stools, failure to thrive, and clubbing of the nail beds are common. 
Indeed, clubbing is a very rare sign of chronic asthma and, if present in a wheezing patient, suggests 
another chronic pulmonary disease, ai-antitrypsin deficiency, an inherited autosomal-recessive 
disorder, is characterized by the onset o f progressive emphysema in adults, especially those who 
smoke cigarettes, but may also manifest as hepatic disease in the neonate and young child.
In wheezing infants, the differential diagnosis includes disorders that are unique to that age 
group (see earlier tables), especially bronchiolitis. In many infants, bronchiolitis is the initial 
manifestation of asthma, and differentiation between the two is occasionally difficult. Even though
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these two diseases share common clinical manifestations, sequelae, and possible pathogeneses, the 
distinction between them remains clinically useful for the following reasons:
1. Many children with bronchiolitis do not develop asthma and may be inappropriately 
labeled as having asthma.
2. Children younger than 2 years frequently do not respond to inhaled or injected 
bronchodilators.
Status asthmaticus, a complication of asthma, is diagnosed by failure to improve significantly 
after appropriate bronchodilator therapy and indicates a need for hospitalization. This is manifested 
by post-therapy wheezing, elevations in respiratory rate, and abnormalities in the inspiratory-to- 
expiratory ratio. Progressive deterioration of respiratory function in the context of maximal medical 
therapy for status asthmaticus indicates impending respiratory failure, which progresses to 
respiratory failure if  untreated. The diagnosis o f impending respiratory failure is based on arterial 
blood gas findings o f Pao2 o f less than 70 in 40% Fi02, and Paco2 greater than 45 (or an increasing 
Расог on serial blood gases) in the appropriate clinical setting.
In children older than 5 years, specific laboratory studies should be performed to document 
asthma or rule out disorders that mimic it.
An algorithm for diagnosing asthma is shown in (Fig. 5-5).
Pulmonary function tests in asthma show airway obstruction at baseline or after methacholine 
challenge and, further, document reversibility of airway obstruction after administration of an 
aerosolized bronchodilator. In children younger than 5 years or people such as the elderly in whom 
testing is unreliable, the diagnosis must be made solely on the basis o f historical and physical 
findings, in conjunction with clinical response to bronchodilators. Lack of a prompt response to 
broncho-dilators does not, however, eliminate asthma as a diagnostic consideration.
Patients who present with a history of isolated chronic cough or exercise-induced wheezing 
can be diagnosed by the reversibility o f symptoms with a bronchodilator. When necessary, this 
impression can be confirmed by a positive pulmonary function or methacholine bronchoprovocation 
test. In patients who have sudden onset of wheezing and respiratory distress, the differential 
diagnosis for lower airway disorders includes respiratory infections, left ventricular failure, and 
foreign-body aspiration. Lower respiratory infections (pneumonia) generally produce fever and 
more localized findings of rales, decrease and change in quality o f breath sounds, and egophony. A 
history of cardiac disease and auscultatory findings of diffuse crackles, basilar rales, and a third 
heart sound help to distinguish left ventricular failure with pulmonary edema from asthma.
In children, especially toddlers, aspiration of a foreign body that becomes lodged in a 
mainstem bronchus may produce wheezing that at times is partially responsive to bronchodilator 
therapy. The history of a choking episode and physical findings of unilateral wheezing and 
hyperresonance aid in distinguishing aspiration from asthma but do not confirm the diagnosis. 
Airway compression by anomalous vessels or mass lesions is often distinguishable from 
bronchiolitis by virtue o f absence of signs of infection and from asthma by failure to respond to 
bronchodilators. Radiographic studies, such as barium swallow with fluoroscopy can be very 
helpful in distinguishing between these entities. Gastroesophageal reflux can be associated with 
asthma and is diagnosed by pH-probe testing or radiography. Cough secondary to drugs (e g., 
angiotensin-converting enzyme [ACE] inhibitors) should be considered in patients presenting with 
cough as the primary manifestation. Patients in whom the diagnosis is unclear should be referred to 
an asthma care specialist.
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Pulmonary function tests are important in confirming suspected asthma. Between episodes of 
acute asthma, the findings depend on the chronicity and severity of the disease. Pulmonary function 
may be entirely normal in mild asthmatics, but acute airway obstruction can be induced by 
provocative methacholine inhalation. In contrast, marked reductions in expiratory flow rates may be 
present in severe asthmatics at baseline and are characteristically observed to a greater degree 
during acute asthma. However, a decreased expiratory flow rate due to asthma, an obstructive lung 
disease, must be differentiated from that due to restrictive lung diseases, such as cystic fibrosis.
Airway obstruction, when present, may or may not reverse with bronchodilators. If 
obstruction is detected, reversibility with bronchodilators should be determined and used to guide 
the formulation of a therapeutic regimen. Bronchodilator effectiveness may relate to the relative 
contribution of smooth muscle contraction versus inflammation as the cause of airway obstruction.
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The clinician conducting an outpatient laboratory evaluation for asthma should always 
consider an immunologic cause and include the appropriate allergy testing so that potential inciting 
agents can be avoided. The most economic and reliable method is allergy skin testing, with serum- 
specific IgE antibody tests serving as an alternative method when skin testing is contraindicated. 
IgE levels may be a useful adjunct in suggesting an allergic cause. Additionally, sinus radiographs 
may be indicated in selected patients, because chronic sinusitis can exacerbate asthma.
Peripheral blood and sputum eosinophilia are usually present during recurrent and chronic 
asthma. Some clinicians, particularly those caring for adults, use the eosinophil count in sputum or 
blood as a guide to therapy, as decreased counts generally accompany clinical improvement. The 
radiographic features o f uncomplicated acute asthma include hyperinflation, peribronchial cuffing, 
and atelectasis. Arterial blood (Table 5-6) usually shows hypoxemia, hypocarbia, and respiratory 
alkalosis, due to hyperventilation during the early stages of acute asthma. However, as the degree of 
airway obstruction increases or respiratory muscles tire, hypoxemia persists and carbon dioxide 
retention (hypercarbia) is detectable, resulting in a respiratory acidosis. This indicates impending 
respiratory failure.
Table 5-6. Arterial blood gas changes during acute asthma
Severity P02 PC02 pH Base excess
Mild i 1 t Respiratory alkalosis
Moderate a Normal Normal Normal
Severe Ш T i Metabolic/respiratory acidosis
*- i, Low; t, high.
Identification of a viral cause using fluorescent antibody tests or enzyme-linked 
immunosorbent assays (ELISA) has little impact on acute therapy due to the paucity of available 
antiviral medications and should be limited to severely ill patients or the onset of an epidemic to 
document epidemiology.
Conclusions
• The diagnosis is dependent on history and examination. There is frequently an atopic 
background and a family history of atopic diseases. Wheeze is less common in children who tend to 
cough instead.
• Serial peak flow measurements may show the typical asthmatic pattern. Chronic disease may 
show loss of reversibility and be difficult to distinguish from chronic obstructive pulmonary disease 
(COPD). Reactive airways may be demonstrated with challenge tests.
• A high total IgE makes asthma more likely but does not correlate well with symptoms. A 
low IgE only excludes IgE-mediated bronchospasm. Skin-prick tests to common aeroallergens may 
pick up positives, but the history will indicate whether these are relevant clinically.
• There may be an eosinophilia on full blood count, although this is rarely marked and is only 
present in about 50% of asthmatics; sputum eosinophilia is much more common.
• Other serum markers have been proposed for assessing the severity o f disease and adequacy 
of therapy. These include soluble CD23 (a cytokine involved in IgE production) and eosinophil 
cationic protein (ECP), which is said to correlate well with the underlying chronic eosinophilic 
inflammation. These tests are expensive and their role in monitoring remains to be determined.
TREATMENT
OUTPA TIENT MANAGEMENT OF CHRONIC ASTHMA
The goals o f effective outpatient asthma management are shown in (Box 5-1).
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Box 5-1. Goals of Asthma Care?
• No chronic symptoms
• Normal or near-normal lung function
•  Normal activity levels
•  No recurrent exacerbations
• No missed school or work due to asthma
• No sleep disruption
• No (or minimal) need for emergency department visits
or hospital izations
• Optimal therapy with minimal adverse effects
• Fulfillment of patient and family expectations and
satisfaction
From NAEPP. Guidelines for the Diagnosis and Management o f Asthma. NIH publication 97- 
4051 A, May, 1997, National Heart, Lung, and Blood Institute: Global Initiative for Asthma. 
November, 1998, NIH publication 96-3659B. American Academy of Allergy, Asthma, and 
Immunology: Pediatric Asthma: Promoting Best Practice: Guide for Managing Asthma in Children. 
Rochester, NY, Academic Services Consortium.
Recent guidelines have focused on four major components of outpatient asthma management: 
1) assessment and monitoring; 2) control of factors contributing to asthma severity, 3) patient 
education for a partnership; and 4) pharmacologic therapy. Asthma is considered a very "care- 
responsive" disease.
Assessment and Monitoring
The two main objective measures of lung function are officered spirometry and home-based 
peak expiratory flow-rate measurements. Office-based spirometry should be conducted in the initial 
evaluation of all patients with suspected asthma and during subsequent evaluations on a periodic 
basis.
To assess the response to therapy in the office, emergency department, or hospital, either 
spirometry or peak expiratory flow-rate measurement can be used. Measurement of peak expiratory 
flow rate (PEFR) with a peak flow meter should be used to monitor the course of persistent 
moderate to severe asthma at home and the response to therapy in patients 6 years of age or older. 
These values can provide valuable information to the managing clinician about asthma severity and 
the need to add or delete medications.
It is essential to provide teaching to patients for whom peak flow meters are prescribed, both 
on the proper use o f the instrument and on the interpretation of values. For the latter, published 
predicted normal values for a given individual can be used. However, because the values for many 
patients are consistently higher or lower than predicted norms, establishing a "personal best" PEFR 
value is an acceptable alternative. The patient and clinician then use this value as a standard in 
evaluating subsequent measurements. Personal best PEFR values can be established by the 
performance of twice-daily PEFR measurements during a "well" period or during a period of 
maximal therapy. This value should be reestablished on a yearly basis. PEFR values should be 
recorded in the moming and evening, both before and after use of any inhaled medications. Highly 
stable asthmatics may not need to continuously monitor PEFR, although the ability to detect the 
early onset o f obstruction may be compromised when not done daily during asymptomatic periods.
Through the use of predicted norm or personal best values, PEFR zones should be developed. 
Green zones (80% to 100% of predicted or personal best) indicate normal values. Yellow zones 
(50% to 80%) signal caution and a possible need for a temporary increase in medication. 
Alternatively, an increase in prophylactic therapy may be indicated. Finally, red zones (under 50%) 
indicate a medical emergency, whereby an inhaled bronchodilator should be used immediately and
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the clinician should be notified if the values do not increase into the yellow or green zones (Fig.5-
6).
Transport to an emergency facility may be indicated if  the response is inadequate. This also 
signals the need for a temporary increase in medication (such as systemic corticosteroids).
Janie Doe Height 49" Predicted norm 300 Patient personal best 260
Instructions
Green zone 
(60-100%)
Yellow zone 
(50-100%)
Red zone 
( < 50%)
Date Jan 18 Jan 19 Jan 20 Jan 21 Jan 22 Jan 23 Jan 24
Drugs
7am 7pm 7 am 7pm 7am 7pm 7am 7pm 7am 7pm 7am 7pm 7am 7pm
Time
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Figure 5-6. T y p i c a l  p e a k  f l o w  m e t e r  d i a r y .  T h i s  p a t i e n t  d ip p e d  in t o  t h e  y e l l o w  z o n e  o n  J a n u a r y  
1 9 t h  a n d  r e c o v e r e d  a f t e r  u s e  o f  a  s h o r t - a c t i n g  b e t a - 2  a g o n is t .  T h e  p a t i e n t  e n t e r e d  t h e  r e d  z o n e  o n  
J a n u a r y  2 2 n d  a n d  g r a d u a l l y  i m p r o v e d  a f t e r  b e g i n n in g  t h e r a p y  w i t h  s y s t e m i c  c o r t i c o s t e r o i d s .  ( N a t i o n a l  
A s t h m a  E d u c a t io n  a n d  P r e v e n t i o n  P r o g r a m :  P r a c t ic a l  G u i d e  f o r  t h e  d i a g n o s i s  a n d  m a n a g e m e n t  o f  a s t h m a .  
B e t h e s d a ,  M D ,  N a t i o n a l  H e a r t ,  L u n g ,  a n d  B l o o d  I n s t i t u t e ;  N a t i o n a l  I n s t i t u t e s  o f  H e a l t h ,  1 9 9 7 . )
Control o f  Factors Contributing to Asthma Severity
After identification of the offending allergens, thorough environmental control measures 
should be implemented in the patient's living and working environments. This may include:
■ measures to control outdoor allergen exposure, such as staying indoors with windows 
closed in an air-conditioned environment (especially during midday and afternoon, when pollen 
and mold counts may be high), and reduction of indoor allergen exposure to molds, dust mites, 
cockroaches, and pets. Indoor humidity levels should be maintained at 35% to 50%. Several 
other control measures may be particularly helpful, including air conditioning and the use of 
central indoor air-cleaning devices, such as mechanical filters (high-efficiency particulate air, or 
HEPA, filters) and electrical fitters (electrostatic precipitator). Vacuum sweepers have a 
tendency to mobilize fine respirable allergens and provoke symptoms when used by dust-
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allergic people, who should use a facemask, a central vacuum cleaner system with the collecting 
bag outside the home, or a cleaner fitted with a high-efficiency particulate air filter.
■ additionally, nonallergen, indoor irritants, such as tobacco smoke, smoke from wood- 
burning heating stoves, strong odors and sprays, and chemical air pollutants, especially ozone 
and sulphur dioxide, may contribute to asthma exacerbations. Exposure to these irritants should 
also be reduced.
• attempts should be made to reduce house dust-mite exposure by reducing ambient 
temperature and avoiding high humidity (fewer house plants).
■ avoid thick-pile carpets, heavy curtains, and other dust traps.
■ mattress covers are desirable and all bedclothes should be washable (at high 
temperatures).
■ de-miting mattresses is difficult: liquid nitrogen is effective but needs specialist 
services Acaricides such as benzylbenzoate may also be effective but may be irritant.
■ if animal danders are a problem, the animal should go, although this news is rarely 
popular with patients! This is controversial as there is evidence that early exposure of children 
to pets in atopic families may reduce the chance of developing allergies.
■ if allergen avoidance is not possible and the appropriate medications fail to control 
symptoms of allergic asthma, allergy immunotherapy may be considered. Allergy 
immunotherapy has been shown to reduce the symptoms of asthma associated with a variety of 
allergens, including house dust, cat dander, grass pollen, and altemaria. More recent studies 
have documented that children with monosensitization are less likely to develop new allergen 
sensitivities and that children with allergic rhinitis alone are less likely to develop new asthma 
when treated with allergen immunotherapy. Adverse reactions following allergen 
immunotherapy are higher in patients with asthma, so appropriate and additional vigilance and 
precautions are necessary to avoid asthma exacerbation.
■ parents should also be queried about daycare attendance in infants and toddlers, since 
it may result in repeated exposure to respiratory viruses, which are a major trigger of wheezing 
in this age group. Reduction in the frequency of upper respiratory infections caused by such 
viruses may result in a significant clinical improvement.
Patient Education fo r  a Partnership
Asthma education and the formulation of a partnership between the patient, family, and 
physician are of paramount importance in managing asthma. Educational topics should include a 
definition of asthma, asthma triggers and how to avoid or control them, key points about signs and 
symptoms of asthma, characteristic changes in the airways o f patients with asthma, the role o f the 
different types of medications (anti-inflammatory, bronchodilator), treatment, and patient fears 
about medications. This should also include education on the correct use of inhalers, criteria for pre­
medicating to prevent symptoms, the optimal use of home PEFR monitoring, and the provision of 
written plans on recommended treatments for daily therapy (maintenance plan) and episodic acute 
asthma exacerbations (action plan). Specific, individualized guidelines for seeking advice from the 
clinician or emergency department care should also be provided. Such asthma education has been 
shown to reduce the morbidity associated with asthma and to improve asthma control.
Pharmacologic Therapy
General approach
Starting Initial Therapy—Reliever/Rescue Therapy Every palient with asthma of any severity 
requires uninterrupted access to the as-needed use o f a short-acting bronchodilator. As 
indicated in the "Rules o f Two™" (Box 5-2), refill o f such a "quick-relief inhaler" more than 
two times a year can serve as a useful indicator of patients whose disease is poorly controlled. Also, 
use o f more than one canister in 1 month indicates inadequate control and the need for more 
anti-inflammatory therapy. Regularly scheduled, daily use of short-acting beta-2 agonists is 
generally not recommended, as these agents have no long-term anti-inflammatory activity. Albuterol 
is generally the drug of choice for relief of bronchospasm, even though it is composed of a 50/50
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racemic mixture of two stereoisomers o f albuterol. Levalbulerol, the stereoisomer that provides the 
therapeutic benefit, is available for use when the albuterol response is poor or includes; side effects.
Box 5-2. Take control of your asthma "Rules of Two™ Can Help"*
•  Do you take your quick-relief inhaler more than TWO TIMES A WEEK?
•  Do you awaken at night with asthma more than TWO TIMES A MONTH?
• Do you refill your quick-relief inhaler more than TWO TIMES A YEAR?
• If you can answer yes to any of these questions, ask your doctor or pharmacist about 
a long-term controller antiinflammatory medication.
• A long-term controller medication can help to improve breathing and prevent asthma 
emergencies!
‘ Rules o f Two™ is a registered trademark o f Baylor Health System, Houston, TX.
Starting Initial Therapy— Controller Therapy
Define Severity Level: After diagnosing asthma but before beginning therapy the severity of 
a patient’s asthma should be defined (Table 5-7).
Table 5-7.Clinical features of asthma— classification of severity
Classification For Children >5 yr Who Can Use a Spirometer or Peak Flow Meter
Days with 
Symptoms
Nights with 
Symptoms
FEV, or PEF PEF
Severe persistent Continual Frequent <60% >30%
Moderate
persistent
Daily >5/mo >60%-<80% >30%
Mild persistent. >2/week 3-4/mo >80% 20%-30%
Mild intermittent <2/week <2/mo >80% <20%
Because pulmonary function testing is difficult in children younger than 6 years, only 
symptoms can be used to define severity in preschool asthma. Recently updated guidelines have 
made recommendations on the timing of initiation of controller therapy in preschool children with 
asthma (Box 5-3).
Box 5-3. When to Initiate Daily Asthma Therapy for Infants and Children Younger 
Than 5 y r
•  Three or more episodes/yr o f wheezing lasting more than 1 day affecting 
sleep in a child with Atopic dermatitis and/or parental asthma
Or two of the following - physician diagnosis of allergic rhinitis, peripheral 
eosinophils, wheezing apart from colds
•  Symptomatic treatment more than two times a wk
• Two or more severe exacerbations less than 6 wk apart
Guidelines; for Diagnosis and Management o f Asthma—Update on Selected Topics 2002. 
Bethesda, MD, National Institutes o f Health, National Heart, Lung, and Blood Institute. June 2002, 
Publication No. 02-5075.
The general approach to therapy emphasizes early and aggressive use of controller 
medications with anti-inflammatory activity for persistent asthma. The severity level should decline 
after initiation of appropriate therapy. The patient's asthma can be reclassified after optimal therapy 
is attained according to the level of treatment required to maintain the control. These are as follows:
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(1) no daily controller needed for mild, intermittent; (2) one daily controller needed for mild, 
persistent; (3) inhaled corticosteroids (ICSs) with or without additional long-term control 
medications needed for moderate persistent; and (4) multiple, long-term control medications, in­
cluding high-dose ICSs and possibly oral corticosteroids such as prednisone needed for severe 
persistent asthma.
There are several pitfalls to consider in assigning severity levels in patients with asthma. First, 
the severity of disease can change over time in either direction. Also, patients whose asthma is 
classified as "mild" - and indeed any patient with asthma - can have a severe exacerbation 
potentially resulting in death at any time. Finally, patients, particularly children, with viral-induced 
wheezing can have severe episodes with complete absence of symptoms for months in between the 
episodes.
Tailor Therapy to Severity: After assignment o f a severity level, j therapeutic options can be 
selected based on the severity classification (Fig. 5-7).
Controller Therapy for Persistent Asthma in Children > 5 Years of Age
Mild Moderate Severe  j
Preferred: 
Low-dose ICS
Alternative: 
cromolyn, LTRA, 
nedocromil, or 
SR theophylline
Preferred:
Low- to medium-dose 
ICS + LABA
Alternative: 
flCS to med-dose 
or
low-to med-dose 
ICS + either LTRA 
or theophylline
Preferred: 
High-dose 
ICS + LABA 
and
if needed systemic 
corticosteroids
W ----------- — V . 4 . 4
ICS = inhaled corticosteroid; LABA = long-acting p2-agonist; 
LTRA=Leukotriene Receptor Antagonist; SR = sustained release
<Fnm ЕмоЛЬ» Seavm y attm  НАЕЯР Реи* ««port: Ш М ч ю  tor9м riugMMit and m enage»* of «в», ra — update m  М к М  «орк* 2002
taeente Ira itjM  of HM>«; NeianaJ Нмп, Lung, and Blood tostteda ftełieeda, MO, (*u«ca4ori No 02-9075, А ла 2002 >
Figure 5-7. C o n t r o l l e r  t h e r a p y  f o r  p e r s i s t e n t  a s t h m a  in  c h i l d r e n  o l d e r  t h a n  5  y e a r s .  I C S ,  in h a le d  
c o r t i c o s t e r o i d ;  L A B A ,  l o n g -a c t i n g  b e t a - 2  a g o n i s t ;  L T R A ,  l e u k o t r ie n e  r e c e p t o r  a n t a g o n i s t .  ( F r o m  E x e c u t i v e  
S u m m a r y  o f  t h e  N A E P P  E x p e r t  P a n e l  R e p o r t :  G u i d e l i n e s  f o r  t h e  d ia g n o s is  a n d  m a n a g e m e n t  o f  a s t h m a -  
u p d a t e  o n  s e le c t e d  t o p i c s  2 0 0 2 .  N a t i o n a l  I n s t i t u t e s  o f  H e a l t h ;  N a t io n a l  H e a r t ,  L u n g ,  a n d  B l o o d  I n s t i t u t e .  
B e t h e s d a ,  M D ,  P u b lic a t io n  N o .  0 2 - 5 0 7 5 ,  J u n e  2 0 0 2 . )
For first-line therapy, the guidelines recommend no daily controller for intermittent asthma; 
daily inhaled corticosteroids (Table 5-8) for mild (low dose), moderate (medium dose), and severe 
(high dose) persistent asthma; and consideration of several non-ICS alternatives, including 
leukotriene receptor antagonists, in children with mild persistent asthma.
There are two general approaches to therapy: step-up (start low and intensify if needed) and 
step-down (start high and taper). Starting therapy with a non-ICS alternative and then stepping up to 
an ICS if needed in a patient with mild persistent asthma is one example of the step-up approach. 
Another example is starting ICS therapy using a low dose and then stepping up to a medium dose if 
needed in a patient with moderate persistent asthma. In general, a step-down approach using 
corticosteroids and designed to gain the quickest control of inflammation is recommended. An 
example of this approach is starting the patient with moderate persistent asthma on one of the 
following regimens and then tapering to the lowest possible dose: a high-dose ICS or medium-dose
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ICS plus a short course o f prednisone. Patient-specific factors such as age, ability to use inhalers, 
steroid phobia, and disease perception, as well as caregiver-specific factors, such as time available 
at the visit, should be considered. Proper inhaler use and airway delivery o f the ICS depends on 
selection of the proper age-dependent delivery device and time spent educating the patient or 
parent.
Table 5-8. Estimate comparative daily dosages for inhaled corticosteroids
Drug Low Daily Dose 
ftg
Medium Daily Dose 
M-g
High Daily Dose 
Mg
Adult Child Adult Child Adult Child
Beclomethasone CFC 
42 or 84 pg/puff
168-504 84-336 504-840 336-672 >840 >672
Beclomethasone FIFA 
40 or 80 ug/puff
80-240 80-160 240-480 160-320 >480 >320
Budesonide 
DPI 200 pg/inhalation 
Inhalation suspension 
for nebulization (child 
dose)
200-600 200-400 
0.5 mg
600-1200 400-800 
1.0 mg
>1200 >800 
2.0 mg
Flunisolide 
250 pg/puff
500-1000 500-750 500-750 1000-2000 >2000 >1250
Fluticasone
MDI: 44, 110, or 220
pg/putt
88-264 88-176 264-660 176-440 >660 >440
DPI: 50, 100, or 
250 pg/inhalation
100-300 100-200 300-600 200-400 >600 >400
Triamcinolone acetonide 
100 pg/puff
400-1000 400-800 1000-2000 800-1200 >2000 >1200
DPI, dry powder inhaler; MDl, metered-dose inhaler.
National Heart Lung and Blood Institute: The NAEPP Expert Panel Report: Guidelines for the
Diagnosis and Management of Asthma—Update on Selected Topic; 2002.
Education should be provided to empower the patient or parent with sufficient knowledge to 
commit to and understand the needs as follows:
1. For the use o f daily therapy (even if symptoms are minimal).
2. To continue using the drug even after symptoms improve.
3. To not expect immediate benefit from a controller drug (in contrast to their reliever drug). 
Although there is marked individual variability in responses, the onset o f action o f ICSs generally 
occurs over 7 to 10 days.
4. To maximize airway delivery o f drug (if an inhaler or a nebulizer is chosen).
5. To understand possible medication side effects, expected benefits, and alternatives to 
treatment.
Reassessment After Starting Initial Therapy: Reassessment should generally occur within 
3 months of the initial visit, at which time disease control should be assessed as evidenced by 
minimal or no nighttime awakening and cough, exertional symptoms, rescue beta-agonist use, and 
normal pulmonary function testing or peak flow meter values.
If this assessment reveals adequate disease control and the initial therapy was an ICS, then a 
25% to 50% dose reduction is recommended if tolerated. If  the first-line controller provided 
incomplete or no control, additional considerations are warranted.
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Alternative diagnoses should be considered and eliminated either clinically or in the 
laboratory. These include cystic fibrosis, immune deficiency, and congenital airway anomalies. 
Likewise, concomitant conditions that increase asthma severity, such as sinusitis and 
gastroesophageal reflux disease, should be considered and treated if  present. Adherence and 
administration technique should also be evaluated. It is possible that patients who report adherence 
may not truly be adherent, which could be revealed during an examination of pharmacy prescription 
refills. Also, an excellent drug may be providing no benefit because of inadequate airway delivery 
secondary to poor technique or an improper delivery device. Environmental exposures to allergen or 
smoke could be driving disease severity, such that no medication or combination of medications 
will be able to provide complete disease control. If these considerations provide no cause for the 
lack of drug response, then a referral to an asthma specialist (allergist or pulmonologist) should be 
considered and drug therapy adjusted. Possibilities include a doubling of the dose of the ICS, or the 
addition o f a second controller (such as an LTRA or a long-acting beta-2 agonist if the initial choice 
was an ICS), or replacement of the initial controller with a new controller (such as replacement of 
an LTRA with an ICS).
Ongoing Reassessment: After disease control is established, regularly scheduled office visits 
should occur roughly every 12 months for mild intermittent, every 6 months for mild persistent, 
every 3 months for moderate persistent, and every month for severe persistent asthma. Drug doses 
and the number of drugs should be adjusted, with the goal of using the minimum effective dose and 
minimal number of drugs. However, even subtle signs o f poor disease control, such as occasional 
exertional symptoms, should be viewed as evidence against a reduction or elimination of therapy.
Criteria for Possible Discontinuation of Controller Therapy:
Patients, especially children, who are on a low dose of a single drug, have been asymptomatic 
for at least 12 months (through all four major seasons of the year), and have a normal PEFR or FEV 
are the best candidates for discontinuation. Children in whom controller therapy is discontinued 
should be monitored carefully for evidence of recrudescence o f disease activity, which has been 
reported within several months of discontinuation of long-term anti-inflammatory controller 
therapy.
Exercise-Induced Bronchoconstriction: Virtually every patient with typical, chronic asthma 
has exercise-induced bronchoconstriction (EIB) in varying degrees, but sometimes EIB can occur in 
isolation in the absence of any other evidence of chronic asthma. The treatment approach for the 
former type was summarized previously and includes daily controller therapy. However, even 
patients with well-controlled asthma may still have EIB. In general, most patients can prevent 
symptoms by use of a short-acting beta-2 agonist 15 minutes prior to exercise. However, albuterol 
is not always effective, and alternative medications should be considered. Inhaled cromolyn can 
prevent EIB and is free of the potential side effects of beta-2 agonists, such as tremor. For patients 
regularly active over an extended period, such as over 2 or more hours, a long-acting beta-2 agonist 
or LTRA can be considered because each has demonstrated a longer duration of effect and could be 
given at home. Finally, ICSs have been shown to reduce the severity o f EIB and could be used daily 
to reduce the impact o f EIB.
Individual Drug Considerations
Inhaled Corticosteroids
Inhaled corticosteroids are the gold standard for the long-term management o f asthma in 
adults and children because they have been shown to reduce asthma symptoms, rescue medication 
use, the markers of airway inflammation, and, uniquely, the risk of asthma mortality. Early 
intervention with ICSs may preserve pulmonary function and prevent irreversible airway 
obstruction, remodeling, and hyperresponsiveness. The benefits o f early intervention with ICSs in 
milder cases with recent onset were recently documented. These tremendous benefits must and can
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be balanced against small, well-defined, and manageable risks of potential systemic adverse effects, 
including growth suppression in children. Local airway effects, such as thrush and dysphonia, are 
rare when spacing devices and mouth-rinsing are utilized.
Sources and Determinants of Systemic Bioavailability of Inhaled Corticosteroids: Even 
though ICSs were developed to replace more highly bioavailable oral corticosteroids, they can 
nonetheless be absorbed into the systemic circulation. Ordinarily, approximately 20% of the dose of 
an ICS enters the airways, and the remainder (about 80%) is swallowed (Fig. 5-8). ICSs can be 
absorbed from both the gastrointestinal system and the airway mucosa, but, especially for the newer 
ICSs, the majority o f bioavailable drug originates from the airways. Thus, factors that increase the 
degree of airway delivery, while expected to enhance a drug's benefit, also generally increase the 
systemic bioavailability o f a drug. Highly sensitive measurement techniques are required to detect 
the small effect that systemically bioavailable drugs can have on childhood growth.
The Fale oł Inhaled CorBcoetetoids
Figure 5-8. T h e  f a t e  o f  i n h a l e d  c o r t i c o s t e r o i d s .  N o t e  t h a t  t h e  m a j o r  s o u r c e  o f  e f f ic a c y  ( l u n g  
d e l i v e r y )  is  a ls o  t h e  m a j o r  s o u r c e  o f  s y s t e m i c  b io a v a i la b i l i t y  a n d  a n y  s a f e t y  c o n c e r n s .  G I ,  g a s t r o in t e s t in a l .
Inhaled Corticosteroids and T heir Delivery Devices: The swallowed fraction of the ICS
dose is absorbed and metabolized "first-pass" in the liver. Fluticasone and mometasone are almost 
completely (approximately 99%) inactivated in the liver, and budesonide and triamcinolone, about 
90% and about 80% to 90%, respectively, are also inactivated. Beclomethasone diproprionate, 
however, is largely metabolized to active metabolites and thus has the highest degree of 
gastrointestinal bioavailability. This difference likely provides the newer ICSs with a better safety 
profile compared with beclomethasone diproprionate.
Most o f the drug in the blood, however, originates from the lower airways, where there is no 
local metabolism following absorption. Therefore, minimizing gastrointestinal bioavailability via 
the selection of newer ICSs or use o f a spacing device will not necessarily eliminate the possibility 
of systemic bioavailability. Furthermore, factors that increase airway dose and delivery (i.e., 
increasing the microgram dose, use of spacers, formulation changes that result in smaller particle 
sizes [hydrofluroa!kane-134a (HFA) versus chlorofluorocarbon (CFC) propellants], improved 
inhalation technique) may provide better benefit but may also increase the systemic bioavailability 
of the drug.
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Disease Severity Considerations: In patients with mild asthma, airways are more patent than 
in those with more severe asthma. As a result, drug deposition and absorption, and thus systemic 
side effect risk, may be higher. Several studies and indirect lines o f evidence support that 
possibility, and the growth effects of ICS generally have been greatest in those with the mildest 
severity (see later). ICS-induced adrenal axis suppression was directly related to airway function in 
one study of asthmatic individuals. Nonetheless, the results argue for the approach most often taken: 
using low-dose ICS for the mildest cases or considering nonsteroid alternatives.
Growth Suppression: Prior to examining the potential effects of ICS on growth, it is 
important to recognize that poorly controlled asthma and systemic corticosteroid bursts can 
adversely affect growth. The Food and Drug Administration recently issued new guidelines for the 
class labeling of all corticosteroids, both inhaled and nasal, to reflect the possibility of a small 
degree of growth suppression. Many factors likely influence this risk, including total dose, drug 
delivery device and technique, genetic predisposition, age, adherence, and asthma severity.
Influence of Asthma Severity on Inhaled Corticosteroid-Induced Growth Suppression 
(Intermediate Term): Three 1-year trials compared the growth of children from 6 months to 8 
years of age treated with budesonide nebulizing suspension or conventional asthma therapy. In 
these trials, the group of children with the mildest severity manifested a small degree of growth 
suppression, while the two groups with higher severity levels showed no such evidence. Most of the 
earlier studies examining the growth effects of ICSs also enrolled children with milder degrees of 
disease severity because poorly controlled asthma and frequent prednisone bursts (in the more 
severe patients) can also have an adverse impact on growth.
Long-Term Inhaled Corticosteroid Use: Linear growth was examined in children with 
asthma in the Childhood Asthma Management Program (CAMP). Compared with children re­
ceiving placebo or nedocromil sodium, the budesonide treatment group had a small reduction in 
growth velocity during the last year that was not sustained for the remainder of the 4- to 5-year 
study. This study was reassuring and suggested that the effect of ICSs on growth was transient and 
restricted to the 1st year of a 4- to 5-year course of continuous therapy. A second study, with a 
different design, produced similarly reassuring results. In that study, children treated with 
budesonide for an average of 9.2 years reached their calculated target adult height, based on 
parental height, compared with 18 control, ICS-naive asthmatic patients and 51 healthy siblings. 
This study showed that, even if the ICSs do suppress growth during the 1st year o f therapy, "catch­
up" growth likely occurs later.
Risk Management: Strategies for Balancing Safety and Efficacy of Inhaled 
Corticosteroids: The most obvious method is the step-down approach to ICS therapy, whereby the 
patient is started on a high dose to achieve quick control o f airway inflammation and then gradually 
tapered to the minimum effective dose that would be continued to maintain long-term control and 
less likely to have any impact on susceptible processes such as growth. Determining and 
maintaining a "low" minimum effective dose could depend on attention to other aspects of asthma 
care, including rigorous smoke and allergen environmental controls, vaccination for influenza virus, 
the diagnosis and treatment of concomitant conditions that could worsen asthma (i.e., rhinitis, 
sinusitis, gastroesophageal reflux disease), and the appropriate use of add-on therapy.
The safety o f ICSs can be further managed and optimized through attention to several other 
aspects o f care. The time of day of ICS administration - morning or evening for those who are 
stable on once-daily dosing - may modify the risk for growth suppression. A 4-week study of 
chiidren with asthma examined the growth-suppressing effects of budesonide (800 gg) administered 
under two different dosing strategies. During one period, it was given as a single dose in the 
morning; during the other period, it was given as two divided doses - 400 gg in the morning and
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400 pg in the evening. Lower leg growth rates were significantly lower in children receiving an 
evening dose than in children receiving only a morning dose. The results of this study suggest that 
for patients who are stable on once-daily dosing, the morning is the safest time for administration. 
Because that administration time may not maximize adherence or efficacy, other factors must be 
considered in designing an individualized therapeutic strategy.
When the ICS fails to provide sufficient control, options include doubling the ICS dose or 
adding on a second nonsteroidal controller medication. The latter possibility was supported by a 
recent study showing that, in children treated with ICS, halving the ICS dose and adding a second 
nonsteroidal drug was associated with faster short-term lower leg growth with no loss o f asthma 
control, versus maintaining the original higher ICS dose alone. This result supports the widely held 
recommendations to use the lowest effective dose and, in poorly controlled patients, to add non-ICS 
therapy rather than double the ICS dose.
Safety management should also incorporate the monitoring of growth every 3 to 6 months and 
interpreting the resultant measurement and changes. The mouth should be rinsed after ICS 
administration to minimize the swallowed portion of drug. Also, careful attention should be given 
to potency differences when dosing ICS, especially when changing from a lower-potency to a 
higher-potency ICS. For example, a clinically equivalent dose of fluticasone and beclomethasone 
diproprionate may differ by twofold - about 400 pg of beclomethasone diproprionate are equivalent 
to about 200 pg of fluticasone.
Leukotriene Receptor Antagonists
Leukotrienes promote smooth muscle constriction and inflammatory events. Not surprisingly, 
leukotriene receptor antagonists (LTRAs) can reduce markers of inflammation and smooth muscle 
contraction. Thus, pediatric asthma guidelines state that LTRAs may be an alternative to low-dose 
ICS therapy in mild persistent asthma and may be an effective add-on to ICS therapy in moderate 
persistent asthma.
Zafirlukast, the first LTRA approved in the United States, was shown to be effective in the 
management o f mild-to-moderate asthma It improved pulmonary function and reduced the clinical 
symptoms of asthma as well as the need for ICSs. Zafirlukast is indicated for twice-daily oral 
treatment for the management of asthma in children as young as 7 years. Because it can inhibit the 
CYP450 isoenzyme CYP3A4, it can increase concentrations of certain concomitant medications 
such as theophylline. Food can also reduce zafirlukast's bioavailability; therefore, according to its 
package insert, it should be taken 1 hour before or 2 hours after a meal.
Controlled clinical trials have shown that montelukast, another approved LTRA, is effective in 
the management o f adult and pediatric asthma. Montelukast is indicated as once-daily therapy for 
the treatment of mild-to-moderate asthma in children as young as 12 months and does not have 
known drug interactions or food restrictions. Efficacy was initially demonstrated in adults and 6- to 
14-year-old children24 and, more recently, in younger children. Interestingly, montelukast provided 
beneficial effects on (3-agonist use that were noted on the first day of use and provided the same 
improvement in pulmonary function, regardless of whether the patients were receiving ICS. A 
granule formulation of montelukast can be used to treat children as young as 1 year. Also, a recent 
controlled study showed that, in ICS-treated children with persistent asthma, the addition of 
montelukast improved pulmonary function and symptoms, with significant reduction in beta-2 
agonist use.
Chromones
Cromolyn sodium has been used for more than 30 years as an inhaled mast cell stabilizer in 
the treatment o f persistent asthma.
Efficacy has been demonstrated in adults and can be achieved in patients as young as 2 years 
using a nebulizer. Although patients taking cromolyn have experienced minor adverse effects such 
as cough, no serious adverse effects have been noted. The safety o f this product has been the major 
driving force o f usage over the years, even in the context o f rather poor effectiveness. Controlled 
clinical trials in young children have shown that cromolyn is safe and efficacious as either 
monotherapy or in combination with beta-2 agonists. However, a randomized trial in more than 200
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children to 4 years of age with moderate asthma showed that cromolyn was not more effective than 
a placebo. Also, cromolyn added little or no benefit to ICS therapy, supporting current pediatric 
guidelines that do not recommend cromolyn as add-on therapy to ICSs. These results, combined 
with a requirement for frequent three- or four-times-a-day dosing and the need for metered dose 
inhaler (MDl)/spacer or nebulizer, have led to an overall decline in cromolyn use and a 
recommendation that cromolyn not be used as first-line preventive therapy.
Inhaled nedocromil sodium appears to have a similar mechanism of action and a similar 
clinical profile to cromolyn, with the major advantage of safety and major disadvantage of minimal 
efficacy. In addition, bitter taste is a frequent complaint of regular nedocromil users. In the CAMP 
study, nedocromil significantly reduced the number of urgent-care visits (P = 0.02) and courses of 
prednisone (P = 0.01) but was similar to placebo in all other endpoints, including airway 
hyperresponsiveness, pre- and post-bronchodilator FEV,, rate of hospitalization, daily symptom 
score, and rescue bronchodilator use. One difference from cromolyn is that, added to ICS therapy, 
nedocromil was modestly beneficial in asthmatic adults. Because this efficacy was not 
demonstrated in children, pediatric asthma guidelines do not recommend the use of nedocromil as 
add-on therapy to ICSs.
Methylxanthines
Theophylline has been used to treat asthma for more than 60 years. Theophylline is a 
phosphodiesterase inhibitor, relaxes airway smooth muscle (bronchodilation) - consequently 
improving airway function - and may have mild anti-inflammatory effects. However, its mechanism 
of action in asthma is not completely clear.
Theophylline was shown to be effective in treating mild-to-moderate asthma in children. 
Steroid-dependent children with asthma also demonstrated added benefit when theophylline was 
added to ICS therapy. These studies support the recommendation that theophylline can be used as 
add-on therapy to ICSs. Practically, it is usually the third drug added on after LTRAs and long- 
acting beta-agonists. Although it can be considered an alternative first-line therapy, it is not 
preferred for persistent asthma.
Theophylline use in children has been linked to changes in behavior and school performance. 
These adverse effects are more common when blood levels exceed the upper limits of the thera­
peutic range (10 pg/L to 20 gg /L in adults, 5 pg /L to 15 pg /L in children) but also can be seen at 
therapeutic concentrations. Adverse effects, such as headache and other effects on the central 
nervous system, tremor, nausea, vomiting, and gastric irritation, also have been reported frequently 
in patients taking theophylline. Theophylline has numerous drug interactions that alter plasma 
levels. As a result of these safety issues, as well as the need for plasma concentration monitoring, 
theophylline use has dramatically decreased recently despite relatively low cost.
Long-Acting Beta-2 Agonists
Salmeterol is a long-acting inhaled beta-2 agonist indicated for long-term use and has been 
available as both an aerosol and a dry-powder inhaler. The latter is approved for children as young 
as 4 years. Salmeterol is not indicated for the treatment of acute j symptoms or exacerbations, due 
to a slow onset of action. Thus, patient education about the role of this medication is essential. 
Salmeterol was more efficacious than short-acting beta-2 agonists and placebo in treating mild-to- 
moderate asthmatic children, with effects (bronchodilation) lasting up to 12 hours. Although long­
term benefits are well established in adults, a recent review article raised questions about whether 
treated children experienced the same degree of benefit and whether they shared the same disease 
processes as adults.
Tolerance can develop with prolonged salmeterol use, which can result in decreased 
bronchoprotection against methacholine challenge and exercise-induced bronchoconstriction. 
Although salmeterol has a protective effect against exercise-induced asthma, the duration o f this 
effect may wane even during regular once-daily salmeterol treatment, despite the reduced frequency 
of dosing and concomitant use of ICSs in children.
Current asthma guidelines recommend that long-acting beta-2 agonists should not replace 
anti-inflammatory therapy but should be considered as possible add-ons. For children with
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moderate-to- severe asthma, combining salmeterol with budesonide improved morning and evening 
PEFR and symptom-free days and reduced the use of rescue medications. Patients should be 
instructed not to stop anti-inflammatory therapy while taking salmeterol even though their 
symptoms may significantly improve. Also, salmeterol was recently reformulated to include 
fluticasone in a single inhaler. As such, the fluticasone/salmeterol dry-power inhaler may be a 
useful option for nonadherent patients or for those who require combination therapy, since it 
reduces the number o f inhalations per day.
A second agent, formoterol, has been approved in the United States for use by adults and 
children older than 12 years. Formoterol has a quicker onset of action than salmeterol. The 
advantages and limitations o f long-term asthma controllers, including long-acting beta-2 agonists, 
are summarized in Table 5-9.
Oral Corticosteroids
Orally administered or injected corticosteroids are indicated for the acute, short-term therapy 
of severe asthma exacerbations. Systemic corticosteroid therapy is indicated in the management of 
acute asthma and is mandatory in the therapy of status asthmaticus. By appropriately timing the 
intervention with corticosteroids, the clinician may benefit the patient and reduce hospitalizations. 
Since the action of corticosteroids is dependent on cellular internalization, therapy should be 
instituted promptly once an indication for use is established.
Typically, patients begin oral prednisone (2 mg/kg/day or max. 60 mg/day) at the onset of an 
acute exacerbation and continue I the treatment for 3 to 10 days. Oral preparations also can be used 
as alternate-day maintenance therapy for severe persistent asthma. Although high-dose, short-term 
corticosteroid therapy is relatively safe in severe life-threatening disorders, chronic systemic 
administration in patients with severe asthma carries a significant risk for adverse effects, including 
growth suppression, adrenal suppression, osteoporosis, fractures, cataracts and glaucoma, weight 
gain, and hypertension. Complications detectable on physical examination include weight gain, 
"moon-type" fades, hirsutism, polycythemia (red, ruddy complexion), and short stature. Such side 
effects of excessive steroid therapy for chronic asthma should be avoidable complications, and oral 
corticosteroid exposure can be reduced by the use of inhaled corticosteroids.
Table 5-9. Advantages and limitations of long-term asthma controllers
Drug Class Advantages Limitations
Inhaled
corticosteroids
Reduce exacerbations 
Improve pulmonary function 
Reduce airway responsiveness 
Reduce airway inflammation
Increased risk of systemic side effects with 
prolonged, high-dose therapy 
Limited information on long-term use in 
children
Limited information on use in young 
children
Leukotriene
antagonists
Reduce symptoms
improve pulmonary function
Reduce exercise-induced
bronchospasm
Prevent allergen-induced
inflammation
Limited information on reduction of airway 
inflammation
No apparent effect on airway 
responsiveness
No information about impact on natural 
history of asthma
Long-acting beta-2 
agonists
Reduce exacerbations 
Improve pulmonary function 
Reduce airway responsiveness 
Attenuate exercise-induced 
bronchospasm
Reduced effect with long-term treatment 
No apparent effect on inflammation 
No information on use in young children
National Heart, Lung, and Blood Institute: The NAEPP Expert Panel Report: Guidelines for 
the Diagnosis and Management o f Asthma—Update on Selected Topics 2002.
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Anticholinergic Agents
In the outpatient setting, anticholinergic agents such as ipratropium bromide can have possible 
additive benefit to inhaled beta-2 agonists for severe exacerbations and can be used as a possible 
alternative bronchodilator for children who do not tolerate inhaled beta-2 agonists.
Anti-Immunoglobulin E Antibody
Efficacy of a humanized monoclonal antibody against human IgE (Omalizumab) was recently 
demonstrated in patients with allergic asthma. "Ibis antibody is administered by subcutaneous 
injection and dramatically reduces serum IgE levels. The drug improved a number of asthma 
outcomes but did not induce remission and also benefited patients with allergic rhinitis. Effects 
disappeared when the drug was discontinued. Likely positioning in the future will be in severe 
asthmatics who are using high-dose ICSs or maintenance oral corticosteroids and possibly in those 
who are nonadherent with daily controller therapy (because anti-IgE is given every several weeks). 
Cost will be an important consideration in its use.
Allergen Immunotherapy
Allergen immunotherapy has demonstrated efficacy in and is widely used to treat allergic 
rhinitis, even in patients with asthma. The role of allergen immunotherapy is less well defined in 
patients with asthma, and some studies have raised doubt about beneficial effects in such cases. 
Safety concerns are also slightly higher in patients with asthma than in those with uncomplicated 
allergic rhinitis. When used properly by an asthma specialist, allergen immunotherapy may be a 
viable option for patients whose asthma is triggered by allergic triggers and whose condition cannot 
be controlled with pharmacologic therapy. The next decades are virtually certain to improve both 
the efficacy and safety of this therapeutic approach.
Other Therapies
Other therapies are available for patients who fail to respond adequately to the medications 
discussed here but will generally be used by asthma specialists due to issues regarding efficacy or 
safety. Most patients who are viable candidates for these therapies already failed therapy with high- 
dose ICSs and maintenance oral corticosteroids. These agents have immunosuppressive or anti­
inflammatory effects and include methotrexate (an antimetabolite), cyclosporin A (an 
immunosuppressive fungal metabofite), gold, troleandomycin (a macrolide antibiotic), and 
cytokine-directed therapies. Annual influenza virus vaccination is recommended for adults and 
children with asthma severe enough to require regular medical follow-up or hospitalization.
Home/Emergency Department Management o f  Asthma Exacerbation
The guidelines for the management of asthma exacerbations at home, in the emergency 
department, and in the hospital are summarized in Figures 5-9 and 5-10. Status asthmaticus (poor 
response to emergency department treatment protocol) is treated with IV corticosteroids, oxygen, 
and a nebulized beta-agonist on a regular, frequent (every 1 to 2 hours), or even continuous basis. 
Patients are weaned from it as they improve. If the patient has been on chronic maintenance 
theophylline therapy as an outpatient, then parenteral theophylline therapy also should be instituted. 
Most pediatric patients improve on this therapeutic regimen and are discharged within 3 days, but 
adults frequently respond less rapidly and require longer periods of hospitalization. In general, beta- 
adrenergic dosing intervals of less than 2 hours require observation and monitoring in an intensive 
care facility. A patient with status asthmaticus must be monitored closely during the first 6 to 12 
hours o f hospitalization for impending respiratory failure so that therapy to prevent progression to 
respiratory failure can be instituted.
Therapy for impending respiratory failure consists of the correction of acid-base imbalances 
in the setting of an intensive care unit, where cardiac and respiratory function can be closely 
monitored. If respiratory failure supervenes despite intense I medical management, artificial 
mechanical ventilation is indicated.
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Management of Asthma Exacerbations: Home Treatment
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Management of Asthma ЕхасейгаСгола: Emergency Department end H-ospitei-Braed Care
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Management o f  Asthma During Pregnancy
It is essential that sufficient lung function and blood oxygenation be maintained during 
pregnancy so that an adequate oxygen supply to the fetus is provided. Increased perinatal mortality, 
increased prematurity, and low birth weight can all result from poorly controlled asthma. For most 
drugs used to treat asthma, there is little evidence to suggest an increased risk to the fetus.
Exceptions include corticosteroids and epinephrine. Therapy with the lowest possible doses of 
the fewest possible medications should be the goal o f treatment of asthma during pregnancy.
Identification o f  Patients at Risk fo r Asthma-Related Death
Care of asthmatic patients should include the identification of patients at risk for asthma- 
related death (Box 5-4).
Box 5-4. Risk Factors for Death from Asthma
History o f  Severe Exacerbations
•  History of sudden severe exacerbations
•  Prior intubation for asthma
•  Prior admission for asthma to an intensive care unit
Asthma Hospitalizations and Emergency Visits
• Two of more hospitalizations in the past year
• Three or more emergency care visits in the past year
• Hospitalization or emergency visit in past month
Beta-2 Agonist and Oral Steroid Usage
•  Use of more than two canisters per month of short- acting inhaled beta-2 agonist
•  Current use of oral steroids or recent withdrawal from oral steroids
Complicating Health Problems
• Comorbidity (e.g., cardiovascular diseases or chronic obstructive pulmonary disease-
COPD)
• Serious psychiatric disease, including depression, or psychosocial problems
• Illicit drug use
Other Factors
• Poor perception o f airflow obstruction or its severity
•  Sensitivity to Attemaria (an outdoor mold)
•  Low socioeconomic status and urban residence
Clues include the presence of previous life-threatening exacerbations of asthma, the lack of 
adequate and ongoing medical care that provides appropriate follow-up and prophylactic therapy, 
and significant depression or psychosocial behavioral problems.
Asthma as a Component o f a Whole-Airway Disease
There is a strong relationship between events in the upper and lower airways, which are linked 
epidemiologically and pathophysiologically. The evolving concept is "one airway, one disease." 
This has led to the development o f a set of guidelines termed ARIA, for Allergic Rhinitis and its 
Impact on Asthma. These guidelines strongly recommend that persistent asthmatics be evaluated for 
nasal disease (allergic rhinitis) and vice versa. Moreover, a combined approach to therapy, 
considering both safety and efficacy, is recommended.
Sulphite sensitivity
Some individuals are unusually sensitive to sulphites. These agents include sulphur dioxide, 
sodium and potassium metabisulphite, and sulphite. These agents are used widely in foods and 
drinks as antioxidants and preservatives.
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Presentation Reactions include severe wheeze accompanied by flushing, tachycardia and, if 
severe, may mimic anaphylaxis. Urticaria and angioedema are not usually features.
Cause Mechanism is unclear but probably involves direct mast-cell stimulation and 
cholinergic stimulation. IgE antibodies have occasionally been detected. There does not appear to 
be any cross-reactivity with other agents.
Diagnosis
• The history is usually diagnostic, with reactions typically to white wine or beer, soft drinks, 
pickles, salami and preserved meats, dried fruits, shrimps/prawns, and prepared salads.
• Certain drugs for injection contain sulphites, particularly adrenaline-containing local 
anaesthetics used by dentists.
• No tests are of particular value except for exclusion followed by re-challenge under 
controlled conditions (with facilities for resuscitation).
Treatment Management is by avoidance and proper dietary advice is required. Care must be 
taken with the prescription of drugs. Severe reactors may need to carry adrenaline (without 
sulphites).
Aspirin sensitivity
Presentation In addition to its propensity to cause angioedema, aspirin is also associated with 
a triad of asthma, nasal polyposis, and hyperplastic sinusitis (Samter's triad). Each feature can occur 
without the others.
Cause
• Effect is due to a sensitivity to cyclo-oxygenase inhibition, and therefore occurs with other 
NSAIDs but not usually with choline or sodium salicylate or paracetamol.
• There is a loss of bronchodilating prostaglandins and a shunting of substrate to the 
lipooxygenase pathway with the production of bronchoconstrictor leukotrienes.
• Some patients with aspirin intolerance also react to tartrazine and related azo-dyes.
Diagnosis
• Specific IgE tests are of uncertain value. Flow-CAST assay may show positives in some 
patients.
• Aspirin challenge is not recommended unless there is doubt about the diagnosis, as reactions 
may be severe.
T reatment
• Exclusion of natural salicylate from the diet may be helpful if asthmatic symptoms and nasal 
polyps are troublesome.
• Obstructing polyps need to be removed surgically; oral or topical corticosteroids will lead to 
shrinkage. Regrowth after surgery may be prevented by diet and drug therapy with topical nasal 
steroids and oral agents.
• Large polyps may need treatment for short periods with betnesol drops, before nasal steroid 
sprays will be effective. Intransal frusemide spray may be an alternative (50 pg/puff).
• The combination of oral antihistamines and monteleukast can be helpful.
• Aspirin desensitization can be undertaken: incremental doses of aspirin are administered 
over 2 days; tolerance persists only while aspirin is administered regularly. Risks of triggering 
severe acute asthma are high, and the treatment should be undertaken with intensive care unit back­
up.
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6. ALLERGIC RHINITIS
Allergic rhinitis is the most common allergic disease. Although not life threatening, this 
frequent illness causes considerable morbidity and results in the expenditure of billions of dollars in 
direct and indirect health care and the loss of millions o f work and school days.
Allergic rhinitis is provoked by exposure to antigenic environmental factors referred to as 
allergens, with resultant sneezing, nasal pruritus, rhinorrhea, nasal mucosal edema, and subsequent 
nasal obstruction induced by an immunoglobulin (Ig) E-mediated response. Symptoms can be 
episodic or perennial; because symptoms recur annually during certain months, the syndrome is 
sometimes called seasonal allergic rhinitis. The predominate allergens causing seasonal allergic 
rhinitis are outdoor pollens, such as tree, grass, or ragweed pollen. Typically, seasonal allergic 
rhinitis does not develop until after the patient has been sensitized by two or more seasons. Seasonal 
allergic rhinitis is frequently referred to as hay fever or summer cold, but these descriptive terms are 
misleading and should be discarded because fever is not a symptom of allergic rhinitis, and the 
common cold virus is not the etiology. Perennial allergic rhinitis can be constant or recurrent and 
occurs year-round. It can also be associated with seasonal exacerbations.
Recent guidelines for the management of allergic rhinitis have redefined the illness as 
intermittent or persistent rather than seasonal and perennial (see Box 6-1). Intermittent rhinitis is 
defined on the basis o f symptoms that are present for less than 4 days per week and for less than 4 
weeks. If symptoms are present for more than 4 days per week or have lasted for more than 4 weeks 
regardless of the number of days per week, the illness is classified as persistent allergic rhinitis. In 
addition, the severity of symptoms should be designated as mild or moderate to severe.
Box 6-1. Clinical classification of allergic rhinitis
1. Duration
a. Intermittent (seasonal): Symptoms present
• Less than 4 days/wk or
• Less than 4-6 wk/yr
b. Persistent (perennial): Symptoms present
• More than 4 days/wk and
• More than 6 wk
2. Severity
a. Mild. Symptoms do not affect lifestyle
b. Moderate-severe: Symptoms affect lifestyle
• Sleep disturbance
• Impair leisure or sport activities
• Impair school or work
CAUSES OF RHINITIS
Allergic.
Vasomotor.
Non-allergic rhinitis with eosinophilia (NARES).
Drug-induced: a-agonist nasal sprays, cocaine abuse (direct); antihypertensives, 
chlormethiazole (indirect).
Irritant: fumes, solvents.
Infectious: viral, bacterial, leprosy, cilial dyskinesia.
Vasculitis: Wegener's granulomatosis.
Mechanical: nasal polyps, septal deviation, foreign bodies, tumours, sarcoidosis.
Pregnancy: last trimester (related to oestrogen levels).
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IMMUNOLOGICAL MECHANISMS
• Mechanisms in allergic rhinitis are very similar to those described above for asthma, 
although histamine release plays a more significant role and the role of neurogenic mechanisms is 
less well established.
• Histamine and leukotrienes are though to be responsible for the itch, sneezing, rhinorrhoea, 
and nasal obstruction, through swelling and hyperaemia.
• There is a predominant eosinophilia in tissue and secretions.
• Perennial rhinitis may be a manifestation of chronic antigen exposure and, like chronic 
asthma, may lead, via type IV mechanisms, to chronic tissue damage with connective tissue 
proliferation.
• Allergens involved are similar to those involved in asthma, i.e. aero-allergens, although 
larger allergens will tend to be trapped preferentially in the nose.
• Nasal polyps may occur as a result o f chronic allergic stimulation.
PATHOPHYSIOLOGY
Allergic rhinitis adversely affects normal nasal function which, besides its role as an airway 
(Fig. 6-1A and includes filtration of particulate matter from inspired air, humidification o f air.
olfaction, and phonation. — и  
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Figure 6-1. A, The inside of the nose, illustrating how the inspired air, after entering the nose, 
circulates over, under, and around the inferior, middle, and superior nasal turbinates. This pattern of 
circulation enables the nasal mucosa to more effectively filter, humidify, and warm the air.
B, Major aspects of the nasal function.
The patient with allergic rhinitis has compromise not only of nasal function but also of other 
portions o f the contiguous respiratory tract, including the eustachian tube, sinuses, and bronchi, 
which can be affected. Allergen-provoked eustachian tube obstruction has been detected not only 
after intranasal provocation but also during seasonal, natural pollen exposure. Allergen, 
methacholine, or histamine bronchial challenge provokes lower airway obstruction (i.e., asthma) in 
30% or patients with allergic rhinitis. That allergic rhinitis contributes to the pathogenesis of 
sinusitis has also been suggested.
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CLINICAL PRESENTATION
Seasonal (intermittent) allergic rhinitis begins with frequent sneezing, nasal pruritus, and clear 
rhinorrhea and then progresses to nasal obstruction (Table 6-1).
Table 6-1. Allergic rhinitis: symptoms, pathophysiology, and effector mediators
Symptoms
Tickling, itchiness, nose rubbing, 
allergic "salute"
Sneezing
Nasal congestion, stuffy nose, mouth 
breathing, snoring
Runny nose, postnasal drip, throat 
clearing
Pathophysiology
Pruritus
Sneezing 
Mucosal edema, 
increased vascular 
permeability 
Rhinorrhea, mucous 
secretion
Effector mediators
Histamine, prostaglandins
Histamine, leukotrienes 
Histamine, leukotrienes, 
bradykinin, platelet­
activating factor 
Histamine leukotrienes
Perennial (persistent) allergic rhinitis tends to manifest more stuffiness. Patients emphasize 
early morning and late evening symptoms, and nasal obstruction may interrupt sleep. They also 
complain o f itching o f the eyes, throat, ears, and nose. To relieve the nasal itch, some children may 
press the palm or arm upward against the nose in an "allergic salute". Constant rubbing of the itchy 
nose may produce a transverse nasal crease, a horizontal groove across the lower third of the nose. 
With nasal obstruction, the patient becomes a mouth breather, so snoring is a nighttime symptom. 
Mouth breathing may contribute to orofacial dental abnormalities that require orthodontic 
procedures, but this has not been established definitely.
Seasonal (intermittent) allergic rhinitis is frequently accompanied by allergic conjunctivitis. 
When symptoms of nasal obstructin are severe, adjacent sinuses may be involved, causing facial 
discomfort or headaches. Patients with eustachian tube dysfunction complain of fullness or popping 
sounds in the ears. Hearing loss in a child with perennial (persistent) allergic rhinitis suggests a 
conductive hearing deficit associated with otitis media with effusion. Loss of sense of smell and 
taste is also described. A few patients may complain of generalized malaise, irritability, and fatigue, 
which may be related to interrupted sleep.
Patients with seasonal (intermittent) pollinosis describe increased symptoms as the season 
progresses, especially on dry, windy days; symptoms may continue well beyond the season. 
Repeated exposure to allergens increases nasal reactivity and "primes" nasal mucosa, so that 
ordinarily innocuous concentrations o f allergens and other environmental factors provoke 
symptoms. The pattern of symptoms helps distinguish seasonal (intermittent) from perennial 
(persistent) allergic rhinitis. In subtropical climates, a seasonal aeroallergen exposure pattern may 
not be obvious, as pollen seasons extend for many months and fungi can be airborne year-round. In 
much of the United States, as well as other temperate climates, trees pollinate in spring, grasses in 
late spring and summer, and weeds during late summer and early fall. Increased pollen concentra­
tions - and thus, frequent complaints of more symptoms - are noted in areas of high plant density. 
Yet, windblown, airborne pollens can spread for miles and cause symptoms. If they have direct 
contact with considerable amounts of pollen, patients can have angioedema, especially o f the eyes 
and throat.
Patients with perennial (persistent) symptoms are more of a diagnostic challenge. Continuous 
exposure to home or occupational factors induces persistent symptoms, because congestion of the 
mucosal tissues does not return to normal during the few hours free of allergen exposure. In these 
patients, nonallergenic aerosolized irritants, such as cigarette smoke, fumes, industrial pollutants, 
and cosmetics, provoke increased symptoms. Additional nonallergenic factors include changes in 
barometric pressure, temperature, and humidity.
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Examination of nasal mucosa requires the use of a nasal speculum with an appropriate light 
source. Although fiberoptic rhinoscopy is not needed for most cases, it can be a valuable adjunct in 
a more thorough inspection of the nose and nasopharynx. With development of nasal allergy, clear 
nasal secretions are evident. The mucosa appear pale, boggy, blue-gray, and edematous without 
much erythema The turbinates become swollen and obstruct the nasal airway. When this occurs, it 
may be necessary to shrink the mucosa and to use a vasoconstrictor to document nasal polyps, 
which occur in 10% to 15% of adult patients. Conjunctival edema and hyperemia, along with 
Dennie’s lines, are frequent findings. Allergic rhinitis patients with considerable nasal obstruction 
and venous congestion, particularly children, demonstrate edema and darkening o f the tissues 
beneath the eyes. These so-called "allergic shiners" are not pathognomonic for allergic rhinitis; they 
can also be seen in patients with recurrent nasal and sinus congestion of any cause.
DIAGNOSIS
• Diagnosis relies heavily on the history and on examination of the nose. Rhinoscopy may be 
necessary to obtain a good view; use of an otoscope is adequate for most purposes.
• Eosinophil count in blood is rarely elevated.
• Elevated total IgE may indicate an allergic basis, but a normal IgE does not exclude allergy.
• Skin-prick tests (SPTs) demonstrate sensitization to aeroallergens, but the clinical relevance 
can be determined only from the history. The most useful allergens in study of allergic rhinitis are 
the inhalants, especially the pollens, the molds (fungi), house dust, and animal product (Box 6-2.)
• Specific IgE (RASTs) should be limited only to confirming equivocal SPTs, or when drugs 
such as antihistamines cannot be discontinued. Both RASTs and SPTs may be negative even in the 
presence of significant local allergy if no specific IgE is free to spill over into the bloodstream.
• Examination of nasal secretions for excess eosinophils may be helpful, although there is a 
condition of non-allergic rhinitis with eosinophilia (NARES). This is often associated with aspirin 
sensitivity and asthma; sinusitis is also common. Peripheral blood eosinophilia is variable and is a 
poor diagnostic marker.
• If the suspect allergen is available, then nasal provocation tests may be possible.
Box 6-2. Selected inhalant allergens useful in evaluation and testing for allergic rhinitis
pollens (vary with geographic area)
Weeds (ragweed, plantain, etc.)
Grasses (timothy, rye, etc.)
Trees (oak, maple, etc.)
Fungi (molds)
•  Seasonal (Alternaria, etc.)
• Storage (Aspergillus, etc.)
Animal products
House dust mites (cuticle, feces)
Dogs, casts (dander, saliva)
Birds (feathers, droppings)
DIFFERENTIAL DIAGNOSIS
Allergic rhinitis needs to be distinguished from non-allergic causes, such as vasomotor 
rhinitis, rhinitis medicamentosa, and infectious cause and other condicions (Box 6-3).
Box 6-3. Differential Diagnosis of Chronic Rhinitis and Nasal Obstruction
Rhinitis
•  Allergic rhinitis: Seasonal or perennial
•  Infectious rhinitis: Chronic or acute (frequent recurrences)
•  Obstructive foreign body
• Rhinitis secondary to topical decongestants, rhinitis medicamentosa
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•  Nonallergic rhinitis with eosinophilia (NARES)
•  Nonallergic vasomotor rhinitis (cholinergic)
•  Hormonal rhinitis: Pregnancy or hypothyroidism
•  Atrophic rhinitis
O ther Causes of Nasal Obstruction
Rhinos inusitis
Anatomical abnormality (e.g., deviated septum, enlarged adenoids)
Nasal polyps
Tumor (e.g., angiofibroma)
Cerebrospinal fluid leakage secondary to perforation of the cribriform plate by fracture 
or tumor Granulomatous disorders (e.g., Wegener's granulomatosis, sarcoidosis)
A comparison of allergic and nonallergic rhinitis (persistent) is made Table 6-2.
Table 6-2. Comparison of allergic and nonallergic rhinitis
Allergic Nonallergic
NARES* Vasomotor
History
Occurrence Seasonal, perennial Perennial Perennial
Age Children, adults Mostly adults Mostly adults
Sex Male, female Male, female Mostly female
Physical examination
Edema Moderate, marked Moderate Moderate
Secretions Watery Watery Mucoid, watery
Laboratory tests
Nasal eosinophils Common Common Coincidental
Allergen tests Positive Coincidental Coincidental
Therapy
Antihistamines Beneficial Rarely help Rarely help
Decongestants Helpful Sometimes help Sometimes help
Steroids Beneficial Helpful Rarely help
Cromoryn Beneficial Not helpful Not helpful
Ipratropium Not helpful Not studied Helpful
Immunotherapy Beneficial Not indicated Not indicated
* - NARES, nonallergic rhinitis with eosinophilia
TREATMENT
• Topical or systemic antihistamines provide relief in mild cases.
• More severe cases may require topical steroids or mast-cell blocking agents such as 
disodium cromoglycate or nedocromil sodium.
• Ipratropium bromide is particularly helpful in vasomotor rhinitis.
• Ensure patient understands optimum head position for use of nasal sprays: head forward 
looking at feet, with nozzle pointed away from the nasal septum. Most therapeutic failures are due 
to incorrect use o f sprays.
• Decongestants should be used with caution (or not at all) because of a rebound increase in 
symptoms.
• Very severe cases may require courses o f oral corticosteroids. Depot injections of long- 
acting steroid have been used in the past in seasonal rhinitis: these are not recommended (risk of 
avascular necrosis o f joints).
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• If drug therapy fails at maximal levels, then immunotherapy may be appropriate if a single 
allergen is responsible and there are no contraindications such as severe asthma, pregnancy, 13- 
blockers, or ischaemic heart disease. This should only be undertaken in hospital. Results for 
seasonal allergens are excellent.
• Surgery may be required for sinus involvement and for polyps, if topical steroid therapy 
fails to reduce them.
• Environmental control may be important as adjunctive measures. Avoidance of allergens 
where possible should be tried. In the grass-pollen season avoid opening windows more than 
necessary during the day (especially in the afternoon and evening when pollen count is high). Air 
filtration systems able to trap pollens are available for cars and for houses, although the latter are 
expensive to install. Masks are likely to be of little value.
• Cold air and spicy foods may exacerbate symptoms in vasomotor rhinitis.
The Algorithm for Management o f Allergic Rhinitis, Formulations and Dosages of Selected 
Hi-Antagonist, Formulations and Dosages Intranasal Corticosteroids are outlined in Table 6-3, 
Table 6-4, Table 6-5.
Studies comparing intranasal steroids versus placebo showed decreased histamine levels in 
nasal lavages of those treated with the steroids, which was associated with significant improvements 
in nasal symptom scores, use o f rescue medications, and number of symptom-free days. These 
agents have been shown to be effective in adults, adolescents, arid children. A 3- to 5-day course of 
a topical decongestant such as oxymetazalone may be used when starting intranasal corticosteroid 
therapy in patients with severe allergic rhinitis to optimize intranasal corticosteroid delivery to the 
nasal mucosa.
Table 6-3. Stepwise algorithm for management of allergic rhinitis
Intermittent (Seasonal) Persistent (Perennial)
Mild Moderate-Severe Mild Moderate-Severe
Environmental control Environmental control Environmental control Environmental control
plus plus plus plus
Antihistamine Antihistamine Antihistamine Antihistamine
± decongestant ± decongestant ± decongestant ± decongestant
or plus or plus
Nasal corticosteroid Nasal corticosteroid Nasal corticosteroid Nasal corticosteroid
or or or or
Nasal cromolyn LT receptor antagonist LT receptor antagonist LT receptor antagonist
or plus consider plus
LT* receptor 
antagonist
Specialist referral 
consider 
Allergen 
immunotherapy
Specialist referral Specialist referral 
consider 
Allergen 
immunotherapy
* - leucotriene
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Table 6-4. Formulations and dosages of selected Hi antagonists
Hl-Receptor antagonist Formulation Recommended dose
First Generation (Selected)
Chlorpheniramine (Chlor- 
Trimeton)
Tablets: 4 mg, 8 mg, 12 mg Syrup: 10 
mg/5 mL Parenteral solution: 10 
mg/mL
Adult: 8-12 mg 2x/day 
Child: 0-0.35 mg/kg/24 hr
Hydroxyzine Atarax Capsules: 25 mg, 50 mg Syrup: 10 
mg/5 mL
Adult: 25-50 mg 2x/day 
Child: 2 mg/kg/24 hr
Diphenhydramine
(Benadryl)
Capsules: 25 mg, 50 mg Elixir: 12.5 
mg/5 mL Syrup: 6.25 mg/5 mL 
Parenteral solution: 50 mg/mL
Adult: 25-50 mg 3x/day 
Child: 5 mg/kg/24 hr
Second Generation
Cetirizine (Zyrtec) Tablet: 10 mg Syrup: 5 mg/5 mL Adult: 10mg/day 
Child 2-6 yr old: 2.5-5 
mg/day
>6 yr old: 5-10 mg/day
Fexofenadine (Allegra) Tablets: 30 mg, 60 mg, 180 mg Adult: 60 mg 2 x/day or 180 
mg/day
Child 6-11 yr old: 30 mg 2 
x/day
>12 yr old: 60 mg 2 x/day or 
180 mg/day
Loratadine (Claritin) Tablets: 10 mg SL Tablets: 10 mg 
Syrup: 1 mg/1 mL
Adult: 10 mg/day
Child >3 yr old, >30 kg: 5
mg/day
>3 yr old, >30 kg: 10 
mg/day
Desloratadine (Clarinex) Tablets: 5 mg Adult: 5 mg/day
Child: >12 yr old: 5 mg/day
Concerns about steroid systemic side effects in children have led to numerous growth studies 
using intranasal steroids. In a year-long study of prepubertal children 6 to 9 years old with perennial 
allergic rhinitis treated with beclomethasone dipropionate 168 mg twice daily, overall growth rate 
was significantly slower, by 1 cm, than in the placebo-treated group. The difference in growth rate 
was evident as early as 1 month into treatment. No significant between-group difference was found 
in the hypothalamic-pituitary-adrenal axis assessment. In a similar 1-year study, prepubertal 
patients between 3 and 9 years of age with perennial allergic rhinitis were treated with mometasone 
furoate agueous nasal spray 100 pg once a day. After 1 year, no suppression of growth was seen in 
subjects treated with mometasone furoate agueous nasal spray, and mean standing heights were 
actually higher in the mometasone furoate agueous nasal spray group than in the placebo group at 
all time points.
Local adverse events associated with Intranasal Corticosteroids include rare nasal-septal 
perforation, usually related to improper administration directed toward the septum instead of to the 
lateral area o f the nasal cavity. More commonly, there is dissatisfaction with smell, taste, and a drip 
sensation.
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Table 6-5. Formulations and dosages of intranasal corticosteroids
Generic name Brand name Formulation Pediatric dose Adult dose
Beclomethasone Beconase AQ Spray 42 pg 6-12 yr old 1 
spray bid
>12 yrold 1-2 sprays 
bid
Dipropionate,
monohydrate
Vancenase AQ 84 pg >6 yr old 1-2 
sprays qd
1 -2 sprays qd
Beclomethasone
Dipropionate
Beconase Inhalation 
Aerosol 42 pg
6-12 yr old 1 
spray bid
>12 yr old 1 spray bid- 
qid
Budesonide Rhinocort AQ Spray 32 pg >6 yr old 1 spray 
qd
1 spray qd
Flunisolide Nasarel Solution
0.025%
6-14 yr old 2 
sprays bid
>14 yrold 2 sprays bid
Fluticasone
Propionate
Flonase Spray 50 pg >4 yr old 1 spray 
qd
1-2 sprays qd
Mometasone
Furoate,
monohydrate
Nasonex Spray 50 pg 3-11 yrold 1 
spray qd
>12 yr old 2 sprays qd
Triamcinolone Nasacort Spray 55 pg 6-12 yrold 1 
spray qd
>12 yrold 2 sprays qd
Acetonide Tri-Nasal 50 pg >12 y ro ld 2 
sprays qd
2 sprays qd
DECONGESTANTS
Decongestants contain sympathomimetic agents that activate alpha-adrenergic receptors and 
cause vasoconstriction, thus reducing nasal congestion. Available oral formulations include 
pseudophedrine and phenylephrine. Based on a recent report regarding the risk of hemorrhage 
stroke in patients receiving phenylpropanolamine, the U.S. Food and Drug Administration has 
removed it from the market. The effective dose for pseudophedrine is 1 mg/kg four times a day in 
children younge than 6 years; 30 mg four times a day in children 6 to 12 years old and 60 mg four 
times a day or 120 mg extended release twice a day in patients older than 12 years. Unfortunately, 
some patients experience side effects with pseudophedrine, including nervousness, irritability, 
tachycardia, palpitations, headache, and insomnia. These drugs should be used with caution, as they 
may cause urinary retention and increased blood pressure in older individual and prostate 
hypertrophy in men. Prolonged use of oral decongestants may lead to withdrawal symptoms of 
headache and fatigue when the drug is discontinued. They have limited action on the other 
symptoms of rhinitis, including rhinorrhea, sneezine and itching. Combinations of antihistamines 
and decongestant provide patient convenience and additional relief o f symptoms of allergic rhinitis. 
Pseudophedrine combined with fexofenadine (Allegra D), ceterizine (Zyrtec D), and lortradine 
(Claritin D) are examples, o f these products.
MAST CELL STABILIZERS
Intranasal cromolyn sodium is a nonsteroid mast cell stabilizer agent that is available without 
a prescription. Although the mechanism of action remains uncertain, it has anti-inflammatory 
properties and clearly blocks the early- and late-phase responses in a laboratory setting. It has been 
shown clinically to relieve sneezing, rhinorrhea, nasal congestion, and pruritis. Yet in head-to-head 
clinical trials, intranasal corticosteroids are more effective than cromolyn. Cromolyn has an 
excellent safety profile, may be used immediately prior to an anticipated exposure to prevent
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symptoms, and is recommended to be administered four times a day. Intranasal cromolyn is 
considered first-line treatment for the pregnant patient with allergic rhinitis.
LEUKOTRIENE RECEPTOR ANTAGONISTS
Several studies have identified clear increments in leukotriene levels in nasal lavage fluid in 
association with the immediate nasal response to allergen. Nasal insufflations provocation studies 
show that both LTC4 and LTD4 induce an increase in nasal airway resistance, as measured by 
rhinometry. The leukotriene receptor antagonist montelukast is currently approved for the therapy 
o f allergic rhinitis. Montelukast selectively blocks the receptor that mediates the function of the 
various leukotrienes. Several clinical trials have documented the efficacy of montelukast in the 
management of allergic rhinitis versus placebo, and its efficacy is comparable to that o f the 
antihistamines.
ORAL CORTICOSTEROIDS
A short burst (3 to 5 days) o f oral steroids may be appropriate for some patients with very 
severe symptoms or to gain control o f symptoms during acute exacerbations. Generally, the 
Prednisone dosage is 1 mg/kg/day for pediatric patients to a maximum of 60 mg/day. Adults may be 
treated with 40 to 60 mg/day in divided doses for 3 to 5 days. Long-term daily treatment with oral 
steroids is contraindicated, and instead, maintenance control o f symptoms with intranasal steroids is 
recommended to gain control of symptoms. The intranasal steroids should be started at the same 
time as the short oral steroid burst.
IMMUNOTHERAPY
When symptomatic drug therapy and avoidance cannot control symptoms, immunotherapy 
(hyposensitization) should be considered. Several double-blind controlled studies have shown 
immunotherapy to be 80% effective in reducing the symptoms of seasonal as well as perennial 
allergic rhinitis. The patient's symptoms should closely correlate with the presence of specific IgE 
antibodies. Positive allergy tests that do not confirm Immunotherapy may be expected to provide 
significant clinical improvement in more than 80% of patients with pollen-induced allergic rhinitis. 
If improvement is not obtained after a 2-year trial, the patient should be reevaluated and 
discontinuation of immunotherapy should be considered. The duration o f immunotherapy injections 
in patients who achieve clinical benefits is dependent on the patient's overall clinical response. In 
response to clinical improvements, the patient should be given the opportunity to stop treatment 
after approximately 3 to 5 years of injections. Many children with allergic rhinitis tend to improve 
with age and time. They are not "growing out" of the allergy, because improvement is related not to 
physical growth but to an as-yet-undeftned age-related phenomenon.
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7. ALLERGIC CONJUNCTIVITIS
Allergic conjunctivitis often accompanies rhinitis (the two areas are connected by the lacrimal 
ducts). The mechanisms are identical.
Presentation
• Typical features include itching and watering of the eye, with redness and swelling.
• More extreme forms include vernal conjunctivitis, in which giant papillae are seen on the 
tarsal surface of the eyelid. In this condition the allergic component is a trigger. This disease is 
difficult to treat but may bum out after 5-10 years.
Diagnosis
• As for rhinitis.
• Specific IgE may be detected in tears but it is rarely of value as a diagnostic test.
• Challenge tests may be helpful in very rare circumstances.
Treatment
•  Topical antihistamines and mast-cell stabilizing agents (disodium cromoglycate and 
nedocromil) may help to relieve symptoms. Lodoxamide is another mast-cell stabilizer 
specifically available for allergic eye problems.
•  Oral antihistamines are valuable for more severe symptoms.
•  Topical steroids may be very valuable but should only be prescribed under 
ophthalmological supervision, as long-term use may lead to glaucoma and cataract.
• Short-course oral steroids may be used for severe symptoms unresponsive to topical 
treatment, and may be used to cover periods of exams, etc.
• Topical cyclosporin and NSAIDs (flurbiprofen and diclofenac) have also been used 
successfully in vernal conjunctivitis.
•  Immunotherapy (either injected or sublingual) is often valuable; vernal conjunctivitis 
however responds less well.
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8. SINUSITIS
Causes
• Allergy, with secondary infection due to allergic swelling closing off the drainage ostia. 
Usually associated with other allergic features.
• Primary infective: due to mechanical drainage problem; secondary to humoral immune 
deficiency.
• Aspirin intolerance.
• Ethmoiditis in children may mimic conjunctivitis.
• Inflammatory disease such as Wegener’s granulomatosis and midline granuloma.
Presentation
• Usually obvious with pain over sinuses.
• Maxillary sinusitis may also present as dental pain in upper molars.
Diagnosis
• Plain radiographs not recommended; CT scanning is most sensitive.
• Nasal smears will demonstrate eosinophilia if there is an allergic cause, but neutrophilia will 
be present in infective cases.
• Measurement o f humoral immune function (immunoglobulins, IgG subclasses, and specific 
antibodies) and antineutrophil cytoplasmic antibodies (ANCA) should be considered in chronic 
sinusitis.
Treatment
• Treat underlying cause
• Obstructed sinuses can be washed out. This can be done by an endoscopic procedure that 
allows the sinuses to be inspected.
• Nasal decongestants and topical steroids assist in reducing oedema and promoting free 
drainage.
• Antibiotics are required for infective problems. Haemophilus influenzae and pneumococcus 
are the most common organisms. Ciprofloxacin, clarithromycin, and azithromycin are appropriate 
as they penetrate well into sinus fluids.
SECRETORY OTITIS MEDIA (GLUE EAR)
It has been suggested that this is related to underlying allergy but there is little evidence for 
this in children, unless there is allergic disease elsewhere in the respiratory tract. Rarely, it may be 
related to specific antibody deficiency or a more widespread antibody deficiency. The history will 
reveal if  there are other infective problems that would suggest such a diagnosis.
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9. FOOD ALLERGY
Food hypersensitivity is a common clinical allergic problem. Adverse reactions to foods are 
classified as either food allergies or food intolerance. The utilization of these terms has allowed 
better communication regarding various reactions to food components. Adverse food reaction is a 
general term that can be applied to a clinically abnormal response to an ingested food or food 
additive. Adverse food reactions may be secondary to food hypersensitivity (allergy) or food  
intolerance.
Food hypersensitivity (allergy) (Box 9-1) is an immunologic reaction resulting from the 
ingestion of a food or food additive. This reaction occurs only in some patients, may occur after 
only a small amount of the substance is ingested, and is unrelated to any physiologic effect o f the 
food or food additive. To most physicians, the term is synonymous with reactions that involve the 
immunoglobulin E (IgE) mechanism, of which anaphylaxis is the classic example.
Box 9-1. Food Hypersensitivity (Allergy): Immunologic Spectrum
IgE m ediated--------------------»Non-IgE mediated
Oral allergy syndrome
Anaphylaxis
Urticaria
Eosinophilic esophagitis 
Eosinophilic gastritis 
Eosinophilic gastroenteritis 
Atopic dermatitis
Protein-induced enterocolitis 
Protein-induced enteropathy 
Eosinophilic proctitis 
Dermatitis herpetiformis
Food intolerance (Box 9-2) is a general term describing an abnormal physiologic response to 
an ingested food or food additive.
Box 9-2. Food Intolerance: Non-Immunologic Adverse Reactions
Toxic/Pharmacologic
о Bacterial food poisoning 
о Heavy metal poisoning 
о Scromboid fish poisoning 
о Tyramine 
о Histamine 
о Caffeine
Nontoxic/Intolerance
о Lactase deficiency 
о Galactosemia 
о Pancreatic insufficiency 
о Gallbladder/liver disease 
о Hiatal hernia 
о Gustatory rhinitis 
о Anorexia nervosa
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This reaction has not been proven to be immunologic in nature and may be caused by many 
factors, including toxic contaminants (e g., histamine in scromboid fish poisoning, toxins secreted 
by Salmonella, Shigella, and Campylobacter spp.), pharmacologic properties o f the food (e g , 
caffeine in coffee, tyramine in aged cheeses), characteristics o f the host such as metabolic disorders 
(e g., lactase deficiency), and idiosyncratic responses.
The term food  intolerance has often been overused and, like the term food allergy, has been 
applied incorrectly to all adverse reactions to foods. IgE-mediated (type I) hypersensitivity accounts 
for the majority o f well-characterized food allergic reactions, although non-IgE -mediated immune 
mechanisms are believed to be responsible for a variety of hypersensitivity disorders. In this 
chapter, we examine adverse food reactions that are IgE mediated, non-IgE mediated, or have 
characteristics o f both.
PREVALENCE
The true prevalence of adverse food reactions is still unknown. As many as 25% of people 
believe that they may be allergic to some food. However, the best available studies suggest that the 
actual prevalence of food allergy is 1.5% to 2% of the adult population. The prevalence of adverse 
food reactions in young children is estimated at between 6% and 8%. Several well-controlled 
studies have revealed that the vast majority o f food allergic reactions present in the 1st year of life.
Causes true food allergy
• True food allergy is very real and may be severe. It is most common in children (up to 0.5% 
may be allergic to cows' milk). Almost any food can cause true allergy mediated via IgE.
• Most allergens involved in food allergy are heat stable (resisting cooking) and acid stable 
(resisting stomach acid). There are exceptions to this, so that a food will be allergenic cooked but 
not raw or vice versa: these foods are typically fruit and vegetables.
• Cows' milk allergy is common, especially in children under 5. The proteins responsible for 
the allergic response include P-lactoglobulin, a-lactalbumin, casein, bovine serum albumin, and 
bovine immunoglobulins. Often the response is against more than one antigen. This allergy usually 
disappears by the age of 5 years. Rarely, gastrointestinal haemorrhage may result (Heiner's 
syndrome is this complex accompanied by iron-deficiency anaemia and pulmonary 
haemosiderosis).
• Egg, milk, and wheat allergy are common in the under-fives, and often disappears with age, 
although anaphylactic responses may occur. The major antigens are ovomucoid and ovalbumin. 
Cross-reaction with chicken meat is unusual.
• Fish allergy may be severe, such that inhalation o f allergens in the vapour from cooking fish 
or second-hand contact (e g. kissing someone who has eaten fish) may be enough to trigger 
reactions. The allergens are species-specific in 50% and cross-reactive with all fish in the 
remainder. Fish allergy is usually permanent. Similar constraints apply to shellfish, both Crustacea 
(prawns, crabs, and lobster) and molluscs (mussels, scallops, and oysters).
• The legumes, peanuts and soya, are major causes of severe allergic reactions. These agents 
cause major problems because they are widely used as food 'fillers' and may not be declared on 
labels. Avoidance may be difficult. Sensitization is often extreme, such that small amounts of 
residual protein in peanut (groundnut) oil may be enough to trigger reactions. Sensitization may 
occur through the use of groundnut oil in formula milks. Arachis oil (groundnut oil) is used as a 
carrier in certain intramuscular injections. True nuts may be equally troublesome. These reactions 
are usually lifelong, although a proportion of children who develop peanut allergy early in life may 
grow out o f it (oral challenge required).
• Cereals may cause direct allergic responses if  ingested or cause symptoms via gluten 
intolerance (coeliac disease). Flour also causes baker's asthma as an occupational disease. Wheat, 
barley, and rye are all closely related. Symptoms are less extreme and this is hypothesized to be due 
to proteolysis reducing the allergenicity, although why this does not apply to other foods is unclear. 
Rice and maize allergies are rare.
• Oral allergy syndromes, where there is allergy to pollens and cross-reactive food allergies 
(usually non-anaphylactic). Allergens tend to be heat-labile.
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• birch pollen allergy with allergy to hazelnut, apple, pear, and carrot;
• birch pollen allergy with stone fruits (plums, peaches, cherries, almonds);
• ragweed allergy with melon, banana;
• grass pollen allergy with tomato, melon;
• mugwort pollen allergy with celery, carrots, spices (includes vermouth!).
• Other described associations include latex with banana, avocado, kiwi fruit, chestnut, lettuce, 
pineapple, and papaya.
• Occasionally trace contaminants may be responsible for allergy, as in the case of antibiotics 
in meat (used by farmers to improve the animals' weight gain), which may lead to reactions to meat 
and to therapeutic drugs.
Causes food intolerance. True food allergy must be distinguished from food intolerance, 
which takes many forms.
• Pharmacological, caffeine and theobromine (tachycardias in heavy tea/coffee drinkers), 
tyramine (headache, hypertension in patients on MAOIs), alcohol (obvious symptoms, plus beer 
drinkers' diarrhoea), NSAIDs (may include natural salicylates), figs (laxatives).
• Toxic: scombrotoxin (histamine from spoiled mackerel), green potatoes, flatoxins (peanuts), 
lectins (PHA in undercooked kidney beans), food poisoning (Bacillus cereus (fried rice), 
staphylococcal toxins), monosodium glutamate (headaches, nausea, and sweating— Chinese 
restaurant syndrome).
• Enzyme deficiencies: lactase deficiency (common in Asians; diarrhoea due to laxative effect 
of lactose), also sucrase and maltase deficiency (excess undigested fructose causes diarrhoea, 
abdominal cramp, and bloating; high levels in onions, peppers, and fruit juices).
• Other bowel disease: Crohn's disease, coeliac disease, infections (Gardia, Yersinia), 
bacterial overgrowth (in association with reduced motility, e g. systemic sclerosis), 'irritable bowel 
syndrome1 (other causes must be excluded).
• Pancreatic insufficiency: cystic fibrosis, Schwachman's syndrome
• Psychogenic: 'smells', somatization disorder.
Immunological mechanisms
For true allergic reactions pre-sensitization is required. The bowel contains a specific 
subset of mast cells, which are capable of being armed by IgE. Activated T cells are also 
present. The pattern of reactions is probably very similar to that in mechanisms involving mast 
cells in other sites, although it is less well studied because of inaccessibility.
Abnormalities of mucosal immunity may contribute to the generation of IgE antibodies to 
foods. IgA deficiency may be a predisposing factor to allergic disease in general and also to 
coeliac disease, although cause-and-effect has not been proven beyond reasonable doubt. 
Exposure of an immature mucosal immune system may also be a factor, hence the lower rates of 
food allergy in babies breastfed and weaned late.
It has been suggested that some of the slower-onset food reactions may involve type III 
(immune complex reactions): this is difficult to prove as IgG anti-food antibodies are not 
uncommon in healthy individuals. Recent publications indicating that irritable bowel disease is 
associated with IgG anti-food antibodies need to be viewed with caution.
Type IV (cell-mediated) hypersensitivity has been discussed in several disorders where the 
clinical symptoms do not appear until several hours after ingestion of the suspected food. This 
type of immune response may contribute to some adverse food reactions, but significant 
supporting evidence of a specific cell-mediated hypersensitivity disorder is lacking.
Clinical manifestation of food hypersensitivity
Symptoms of true food allergy are invariably limited to the gut, the skin, and the respiratory 
tract. Symptoms outside these systems are much less likely to be due to true allergy.
There is no convincing association with arthritis. There is no evidence that food allergy is a 
cause of chronic fatigue syndromes, and thus 'desensitization’ therapies have nothing to offer;
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equally there is no evidence to support Candida overgrowth as a cause of chronic fatigue 
syndromes.
IMMUNOGLOBULIN E MEDIA TED HYPERSENSITIVITY 
Gastrointestinal Food Hypersensitivity Reactions
The signs and symptoms of food-induced IgE-mediated gastrointestinal allergy in human may 
be secondary to a variety of syndromes, including the oral allergy syndrome (Box 9-3), immediate 
gastrointestinal hypersensitivity (Box 9-4), and a small subgroup of allergic eosinophilic 
gastroenterocolitis (Box 9-5).
Box 9-3. Oral Allergy Syndrome (Pollen-Associated Food Allergy)
Oral Manifestations 
Burning 
Swelling 
Itching 
Erythema
Immediate onset of symptoms 
Age o f  Onset
Beyond Infancy 
Typical <5 yr 
Proteins Implicated
Heat-labile fresh fruit and vegetable allergens 
Pollen and latex cross-reactivity 
Pathology
Immunoglobulin E antibodies 
Treatment
Avoidance 
Cooking the food 
Natural History 
Unknown
Box 9-4. Immediate Gastrointestinal Hypersensitivity
Manifestations
Nausea, abdominal pain, and vomiting with 1-2 hr 
Diarrhea within 2-6 hr 
Frequently associated with atopic disease 
Food-specific immunoglobulin antibodies 
Radiographic: Gastric hypotonia and pylorospasm 
Age o f  Onset
Infancy, childhood 
Proteins Implicated
Milk, egg, peanut, soy, cereal, fish 
Pathology
Immunoglobulin E-mediated 
Treatment
Protein elimination 
Natural History
80% of cases resolve after protein elimination diet (except in the case of peanut and fish 
allergy
The diagnosis o f these symptoms is made by a suggestive clinical history, positive prick skin 
tests, complete elimination of the suspected food allergen for up to 2 weeks with resolution of 
symptoms, and oral food challenges. After avoidance of a particular food for 10 to 14 days, it is not
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unusual for symptoms of vomiting to occur during a challenge even when the patient had previously 
ingested that food without vomiting.
Respiratory and Skin Food Hypersensitivity Reactions
Respiratory and ocular symptoms are common concurrent manifestations of IgE-mediated 
reactions to foods. Symptoms may include periocular erythema, pruritus, and tearing; nasal 
congestion, pruritus, sneezing, and rhinorrhea; and coughing, voice changes, and wheezing. Isolated 
naso-ocular symptoms are an uncommon manifestation of food hypersensitivity reactions.
The skin is a frequent target organ in IgE-mediated food hypersensitivity reactions. The 
ingestion of food allergens can either lead to immediate cutaneous symptoms or aggravate more 
chronic symptoms. Acute urticaria and angioedema are probably the most common cutaneous 
manifestation of food hypersensitivity reactions, generally appealing within minutes of ingestion of 
the food allergen. The foods commonly causing these reactions in children include eggs, milk, 
peanuts, and tree nuts. In adults, this list includes fish, shellfish, tree nuts, and peanuts.
Atopic dermatitis is a chronic skin disorder that generally begins in early infancy and is 
characterized by typical distribution, extreme pruritus, chronically relapsing course, and association 
with asthma and allergic rhinitis. As many as one third of children with atopic dermatitis have at 
least one food allergic reaction. Foods to which they typically react include milk, egg, peanut, soy, 
wheat, fish, and tree nuts. Food challenges may be needed to help with the diagnosis of food allergy 
in these children.
MIXED IMMUNOGLOBULIN E MEDIA TED AND NON-IMMUNOGLOBULIN E 
MEDIATED
Allergic eosinophilic gastroenteropathy (Box 9-5) is a disorder characterized by infiltration of 
the gastric or intestinal walls with eosinophils, absence of vasculitis, and, frequently, peripheral 
eosinophils. Patients presenting with this syndrome frequently have postprandial nausea and 
vomiting, abdominal pain, diarrhea, occasional steatorrhea, and failure to thrive (young infants) or 
weight loss (adults). There appears to be a subset of patients with allergic eosinophilic 
gastroenteritis who have symptoms secondary to food. These patients generally have the mucosal 
form of this disease with IgE-staining cells in jejunal tissue, elevated IgE in duodenal fluids, atopic 
disease, elevated serum IgE concentrations, positive prick skin tests to a variety of foods and 
inhalants, peripheral blood eosinophils, iron deficiency anemia, and hypo-albuminemia.
Box 9-5. Allergic Eosinophilic Gastroenterocolitis
Manifestations
Abdominal pain
Anorexia
Early satiety
Failure to thrive
Gastric outlet obstruction
Gastric or colonic bleeding
±70% of cases atopic
Elevated immunoglobulin E
±Food-specific immunoglobulin E
50% of cases with peripheral eosinophilia
Radiographic: Antral obstruction, Menetrier's disease, gastroesophageal reflux, bowel 
wall edema, vomiting, diarrhea, protein-losing enteropathy, decreased albumin
Age at Onset
Neonate to adolescent
Proteins Implicated
Cow's milk, egg, fish, soy, cereals 
<50% skin test specificity
Pathology
Marked eosinophilic infiltration of mucosa and submucosal gastric antrum, esophagus, 
duodenum, and colon
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Treatment
•  50% of patients respond to dietary elimination of documented allergen
•  Excellent response to hydrolyzed protein formula in patients<2 yr
•  Excellent response to L-amino acid formula
•  Responsive to steroids 
Natural History
Disorder is typically prolonged
The diagnosis o f this entity is based on an appropriate history and a gastrointestinal biopsy 
demonstrating a characteristic eosinophilic infiltration. Multiple sites (up to eight) may need to be 
biopsied to effectively exclude eosinophilic gastroenteritis, because the eosinophilic infiltrates may 
be quite patchy. Patients with the mucosal form of the disease may have atopic symptoms, 
including food allergy, elevated serum IgE concentrations, positive skin tests or radioallergosorbent 
tests (RASTs), and peripheral eosinophilia. Other laboratory studies consistent with this disease 
include Charcot-Leyden crystals in the stool, anemia, hypoalbuminemia, and abnormal D-xylose 
tests. An elimination diet for as long as 12 weeks may be necessary before complete resolution of 
symptoms and normalization of intestinal histology.
NON-IMMUNOGLOBULIN E-MEDIATED FOOD HYPERSENSITIVITY 
Dietary protein enterocolitis (also known as protein intolerance) (Box 9-6) is a disorder that 
presents most commonly in children between 1 day and 1 year o f age.
Box 9-6. Dietary Protein Enterocolitis (Protein Intolerance)
Manifestations
Diarrhea with bleeding
Anemia
Emesis
Abdominal distention 
Failure to thrive 
Hypotension 
Fecal leukocytes 
Normal immunoglobulin E
Food challenge: Vomiting in 3-4 hr; diarrhea in 5-8 hr 
Age at Onset
1 day to 1 yr 
Implicated Proteins
•  Cow's milk, soy, rice, poultry, fish 
Pathology
Patchy villous injury and colitis 
Treatment
• 80% or more of cases respond to hydrolyzed casein formula, and symptoms clear in 
3-10 days
•  Up to 20% of cases require L-amino acid formula or temporary intravenous therapy 
Natural History
•  In general: With treatment, 50% of cases resolve by 18 mo; 90% of cases resolve by 
36 mo
• Cow’s milk: With treatment, 50% of cases resolve by 18 mo; 90% of cases resolve by 
36 mo
• Soy: Illness is often more persistent
The typical symptoms are isolated to the gastrointestinal tract and consist of typically 
recurrent vomiting and/or diarrhea. The symptoms can be severe enough to cause dehydration. 
Cow's milk or soy protein (particularly in infant formulas) are most often responsible for this
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syndrome, although egg sensitivity has been reported in older patients. The children will often have 
stools that contain occult blood, polymorphonuclear neutrophils, and eosinophils and are frequently 
positive for reducing substances (indicating malabsorbed sugars). Prick skin tests for the putative 
food protein are characteristically negative. Jejunal biopsies classically reveal flattened villi, edema, 
and increased numbers of lymphocytes, eosinophils, and mast cells. A food challenge with the 
responsible protein generally results in vomiting or diarrhea within minutes to several hours, 
occasionally leading to shock. It is not uncommon to find children who are intolerant to both cow's 
milk and soy protein. This disorder tends to subside by 18 to 24 months of age. Elimination of the 
offending allergen generally results in improvement or resolution of the symptoms within 72 hours, 
although secondary disaccharidase deficiency may persist longer. Oral food challenges, which 
should be done in a medical setting because they can induce severe vomiting, diarrhea, dehydration, 
or hypotension, consist of administering 0.6 g/kg body weight of the suspected food allergen.
Dietary protein proctitis generally presents in the first few months of life and is often 
secondary to cow's milk or soy protein hypersensitivity. Infants with this disorder often do not 
appear ill and have normally formed stools. Generally, this problem is discovered because of the 
presence of blood (gross or occult) in the stools. Gastrointestinal lesions are confined to the small 
bowel and consist o f mucosal edema, with eosinophils in the epithelium and lumina propria. If 
lesions are severe with crypt destruction, polymorphonuclear neutrophils are also prominent. It is 
thought, but without proof from well-controlled studies, that cow's milk and soy protein-induced 
colitis resolves after 6 months to 2 years of allergen avoidance. Elimination of the offending food 
allergen leads to resolution of hematochezia within 72 hours, but the mucosal lesions may take up 
to 1 month to disappear and range from patchy mucosal injection to severe friability with small 
aphthoid ulcerations and bleeding.
Celiac disease is an extensive enteropathy leading to malabsorption. Total villous atrophy and 
an extensive cellular infiltrate are associated with sensitivity to gliadin, the alcohol-soluble portion 
of gluten found in wheat oat, rye, and barley. The general incidence is thought to be 1 in 4000 but 
has been reported as high as 1 in 500 in Ireland. Patient have genetic predisposition to this disease- 
approximately 90% of patients are HLA-B8 positive, and nearly 80% have the HLA-DW3 antigen. 
Patients often have presenting symptoms of diarrhea or frank steatorrhea; abdominal distention and 
flatulence; weight loss; and, occasionally, nausea and vomiting.
Diagnosis
The history may give good clues about particular foods that cause problems.
Skin-prick tests are helpful for foods causing severe reactions (milk, egg, fish, peanuts, true 
nuts), while being less useful for other food groups. There are some minor exceptions to the general 
statement: children younger than 1 year may have IgE-mediated food allergy without a positive skin 
test; and children younger than 2 years may have smaller wheals, possibly due to the lack of skin 
reactivity. Conversely, a positive skin test to a food ingested in isolation that provokes a serious 
systemic anaphylactic reaction may be considered diagnostic. If commercial reagents do not work, 
then the fresh food should be tried (stab lancet into food then into patient). However, SPT may be 
dangerous in those who have had severe anaphylactic reactions. Dose is unstandardized.
An intradermal skin test is a more sensitive tool than the prick skin test but is much less 
specific when compared with a double-blind placebo-controlled food challenge (DBPCFC). 
Intradermal skin testing increases the risk of inducing a systemic reaction compared with prick skin 
testing.
RAST tests are less sensitive. Total IgE is not especially helpful. The newest generation o f in 
vitro studies for specific IgE deludes the CAP-RAST (CAP-FEIA®). For patients with suspected 
food allergy, there are now accepted levels of specific IgE that are more than 95% predictive o f a 
patient being allergic to that food. This test is best used for patients with possible allergic reactions 
to milk, eggs, and peanuts (and possibly wheat, soy, and fish).
The allergy practitioner will need to have a good understanding of the biological families in 
which plants are grouped, as this often helps explain patterns of reactivity: members of the same 
biological family often share common antigens.
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Dietary manipulation plays an important role in diagnosis, but is time-consuming and should 
be undertaken only in collaboration with a dietician. Elimination diets (oligoallergenic diets), with 
gradual reintroduction of foods in an open but controlled manner, may be helpful in identifying 
troublesome foods. Formal confirmation requires a DBPCFC, in which the suspect food is disguised 
in opaque gelatine capsules. A DBPCFC is the best means of controlling for the variability of 
chronic disorders (e g., chronic urticaria, atopic dermatitis), any potential temporal effects, and 
acute exacerbations secondary to reducing or discontinuing medications. Particularly, psychogenic 
factors and observer bias are eliminated. False-negative challenges are rare in a DBPCFC but may 
occur when a patient receives insufficient material during the challenge to provoke the reaction or 
the lyophilization of the food antigen has altered the relevant allergenic epitopes (e g., fish). 
Overall, the DBPCFC has proven to be the most accurate means of diagnosing food allergy at the 
present time.
Open food challenges (or single-blind challenges) may be utilized in many cases to diagnosis 
patients with food allergy. There are many different schemes available for the administration of 
food for an oral challenge.
Differentiation of food intolerance requires careful history-taking. Patients should be 
investigated for evidence of malabsorption (iron, В 12, folate, clotting, calcium, and alkaline 
phosphatase) and for coeliac disease (endomysial or tissue transglutaminase antibodies); if there is 
diarrhoea, do stool microscopy and culture. Acute-phase proteins will indicate likely inflammatory 
bowel disease.
Bacterial overgrowth, lactose intolerance, and pancreatic insufficiency can be diagnosed on 
appropriate radioisotopic tests or by measuring breath hydrogen production.
Radiology of the bowel may be revealing and biopsy should always be considered: enzyme 
levels can be measured and coeliac disease confirmed rapidly. In early coeliac disease, histology 
may show only a lymphocytic infiltrate without complete villous atrophy.
The diagnosis o f food allergy remains a clinical exercise that utilizes a careful history, 
selective prick skin tests or RASTs (if an IgE-mediated), appropriate exclusion diet, and blinded 
provocation (Boxes 9-7, 9-8, 9-9).
Box 9-7. Diagnostic Approach: Non-IgE-Mediated Disease
Includes disease with unknown mechanisms 
Food additive allergy
Elimination diets (may need elemental diet)
Oral challenges
Timing/dose/approach individualized for disorder 
Enterocolitis syndrome can elicit shock
Enteropathy/eosinophilic gastroenteritis-prolonged feedings to develop symptoms 
DBPCFCs preferred
May require ancillary testing (endoscopy/biopsy)
Box 9-8. Diagnostic Approach: IgE-Mediated Food Allergy
Test for specific IgE antibody 
Negative: Reintroduce food*
Positive: Start elimination diet 
Elimination diet
• No resolution: Reintroduce food*
• Resolution
■ Open/single-blind challenges to "screen"
■ DBPCFC for equivocal open challenges
Box 9-9. Food Allergy Prevention
Aimed at "high-risk" newborn
Positive family history: Biparental or parent/sibling
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Breastfeeding generally protective of allergy
Wean/supplement with extensively hydrolyzed hypoallergenic protein hydrolysate
Delay introduction of solid foods >6 mo
Cow milk/dairy: 6-12 mo
Egg: 12-24 mo
Peanut, tree nut, seafood: >24-48 mo
Treatment
•  Distinguish food allergy from intolerance and non-food related symptoms.
•  Education of the patient about their symptoms and the cause. This may be hard if the patient 
already has a well-established preconception that he/she has a 'food allergy. When eating away from 
home, food-sensitive individuals should feel comfortable to request information about the contents 
of prepared foods. Children older than 7 years usually can be taught to inject themselves with 
epinephrine. The physician must be willing to explain and, with the parents, help instruct school 
personnel about these issues. In the home, consider the need to eliminate the incriminated allergen, 
or if this is not practical, place warning stickers on foods with the offending antigens.
• Management of food allergy is mainly avoidance, while maintaining a nutritious diet: 
specialist dietetic support is required. Elimination diets may lead to malnutrition or eating disorders, 
especially if these diets exclude a large number of foods or are utilized for extended periods. 
Studies have shown that symptomatic food sensitivity generally is lost over time, except for 
sensitivity to peanuts, tree nuts, and seafood. Symptomatic food sensitivity is usually very specific, 
so patients rarely react to more than one member of a botanical family or animal species. Certain 
factors place some individuals at increased risk for more severe anaphylactic reactions: (1) history 
of a previous anaphylactic reaction; (2) history of asthma, especially if poorly controlled; (3) allergy 
to peanuts, nuts, fish, and shellfish; (4) the need for beta-blockers or angiotensin-converting enzyme 
(ACE) inhibitors; and (5) possibly being female.
•  Antihistamines (HI and H2) may be of value taken prophylactically when patients with true 
food allergy are eating in unfamiliar surrounding; routine use is unnecessary.
• Patients who have had anaphylaxis need to have adrenaline for self-injection.
• Oral disodium cromoglycate may help occasional patients.
• Short course o f steroids may be necessary for severe disease (eosinophilic gastropathy, 
enteritis).
•  Immunotherapy
• Recent blinded, placebo-controlled studies o f rush immunotherapy for the treatment of 
peanut hypersensitivity demonstrated efficacy in a small number of patients. Birch pollen 
immunotherapy in birch pollen allergic patients with oral allergy syndrome may lead to reduced 
food reactions. Newer types of vaccines for immunotherapy specifically for food-induced 
anaphylaxis are being developed and include humanized anti-IgE monoclonal antibody therapy, 
plasmid-DNA immunotherapy, peptide fragments ("overlapping" peptides), cytokine-modulated 
immunotherapy, immunostimulatory sequence-modulated immunotherapy, bacteria-encapsulated 
allergen immunotherapy, and "engineered" recombinant protein immunotherapy. Additionally, 
recent studies with humanized, monoclonal antibody anti-IgE have been utilized in phase I trials for 
patients with peanut allergy. This type of therapy appears to be a promising option for patients with 
a history of food-induced anaphylaxis or with a food allergy that puts them at risk for a future 
systemic anaphylactic reaction.
• Enzyme-potentiated dcsensitization (EPD) is not of proven value despite claims by some 
practitioners to the contrary.
•  Management of food intolerance depends on the underlying cause.
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10. ATOPIC DERMATITIS
Atopic dermatitis (AD) eczema is the most common manifestation of atopic disease. Among 
the descriptive labels assigned to this itchy, chronic, inflammatory skin condition (including atopic 
eczema, infantile eczema, and neurodeimatitis) is “asthma o f  skin ”, implying its link to the 
pulmonare entity. It is usually worst in childhood, improving with age in 80%. It affects particularly 
the cheeks and flexures and is a risk factor for the development o f contact dermatitis in later life. 
Asthma or rhinitis will develop in 50-75% of patients. It is on the increase. Eye involvement may 
occur, with an atopic keratoconjunctivitis, and in severe cases subcapsular cataract may form. Viral 
infections such as eczema herpeticum, molluscum contagiosum, and warts are common in atopic 
eczema and do not indicate a significant generalized immunodeficiency but are a manifestation of 
disturbed local immunity.
Risk factors that influence the incidence of atopic dermatitis are listed in Box 10-1.
Box 10-1. Risk Factors That Increase the Incidence of Atopic Dermatitis
Parental history of atopy or AD: The strongest risk factor. Maternal atopy»>patemal 
atopy.
Female-to-Male: 1.13:1.
Social class: Upper (35% )» lower (14%).
Family structure: Prevalence o f AD is inversely related to sib-ship size. Strongest 
predictors of AD were lower number of older sibs.
Hygiene hypothesis: The relative freedom from infections caused by viruses, bacteria, 
and helminths during infancy.
Migration: Moving to an urban setting increases the risk of developing atopy.
Maternal smoking: Smoking during pregnancy and lactation increases risk of atopy.
Questionable factors: Prolonged gestational age, increased intake of polyunsaturated fat, 
hard water, and month of birth.
Causes
• There is a genetic basis, as demonstrated by twin studies, although whether the background 
is the same as for asthma (chromosome 11 or 5) has not yet been demonstrated.
• In addition to the immunological factors, there are abnormalities o f the lipids o f the skin and 
evidence for autonomic nervous abnormalities (white dermographism). There is a reduced threshold 
for itch, which leads to a vicious cycle o f itch and scratch, leading to the lichenification of chronic 
eczema.
• Non-specific irritants make the disease worse, such as wool, heat, and stress.
• Staphylococcal infection is common, and may play a role in exacerbating the disease: IgE 
against the bacterium may be detected, although the role is unclear. Staphylococcal superantigens 
have also been suggested to play a role. Cutaneous fungi may also exacerbate the disease.
• Role o f diet is controversial. It has been suggested that maternal diet during pregnancy may 
contribute, as may a  lack of breastfeeding. The contribution of diet to established symptoms is even 
more controversial, although some children are helped by exclusion diets. It is rare that adults are 
helped by dietary manoeuvres.
Immunological features
In atopic individuals, the combination of the genetic predisposition and environmental 
exposures results in the spectrum of immunologic aberrations (Box 10-2).
Box 10-2. Some immunologic aberrations noted in atopic dermatitis
Increased number of (IL-4- and IL-5-secreting) Th2-lymphocytes resulting in increased 
IgE levels with specific IgE antibodies
Eosinophilia with its associated
Increased eosinophilic cationic protein
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Increased eosinophilic major basic protein 
Increased eosinophil-derived neurotoxin levels 
Increased urinary eosinophil protein X 
Decreased number of (IFN-y-secretmg) Thl-lymphocytes 
Increased basophil (and mast cell) spontaneous histamine release 
Increased expression of CD23 on mononuclear cells 
Chronic macrophage activation with
Increased secretion of GM-CSF 
Increased secretion o f PGE2 
Increased secretion of IL-10 
Increased serum sIL-2 receptor levels
T-cell skin homing receptors (cutaneous lymphocyte associated antigen) rather than lung­
homing receptors
Increased number o f high-affmity IgE-bearing Langerhans' cells
• Precise role of type I responses is unclear. IgE levels are often very high, and specific lgE 
may be detected against a variety of aero- and food allergens, although most of the IgE is 'junk', 
with no recognizable specificity.
• Langerhan's cells in the skin do have IgE receptors, although their role in atopic eczema is 
speculative. Keratinocytes release cytokines when damaged, which will excite the immune response 
(TNFo, IL-1, IL-6, IL-8).
• There is more evidence for a type IV reaction with an infiltrate of CD4+ T cells into the 
epidermis and dermis; most of these cells are of the Th2 phenotype which will support IgE 
production. As part of the inflammatory response, eosinophils, mast cells, and basophils are all 
increased in the affected skin, and mechanisms similar to those found in the chronic phase of 
asthma probably predominate.
Diagnosis
The diagnosis of AD can be made by the clinical recognition of three essential criteria: atopy, 
pruritus, eczema. It would indeed be difficult to make the diagnosis of AD without atopy!
Atopy
The simple definition of atopy is a personal or familial history of AD, asthma, or allergic 
rhinitis. The presence of an elevated IgE level or positive skin prick or radioallergosorbent test 
(RAST) adds some objective evidence of atopy. However, these criteria are but epiphenomena of 
what atopy really is.
• Thl/Th2 lymphocyte transient reversal, with its specific, resultant cytokinal profiles, that is 
unique in the patient with AD (Fig. 10-1).
• 80% of cases will have a high IgE, often > 1000 Ш/1. Specific IgE may be detected by SPT 
or RAST, but this rarely helps in management.
• Blood eosinophilia is common.
• Atypical patterns of eczema with other infections should raise the possibility o f the hyper- 
IgE syndrome. Here the IgE is even higher, usually > 50 000 klJ/1, and there may be evidence of 
other humoral abnormalities such as low IgG2, so a full investigation of humoral immunity is 
warranted.
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M A C R O P H A G E C T L  M A C R O PH A G E B -C E L L  EOSINOPHIL
A C TIV A TIO N  S UPPR ESSIO N S TIM U LA TIO N  R ESP O N SES
Figure 10-1. T-helper (Th) cell paradigm. CTL, cytotoxic T-lymphocyte; 1FN, interferon; IL, 
interleukin.
Pruritus
Pruritus could be considered the ‘primary lesion’ o f AD, and the diagnosis o f AD should not 
be made if  there is no history of itching. The pruritus is variable, fluctuating from mild to extremely 
intense.
Box 10-3. The Full Spectrum of "Triggers" of Itch in Atopic Dermatitis
Scratching
Xerosis
Irritants
Lipid solvents (e g., soaps, detergents)
Disinfectants (e.g., bleaches, cleaning chemicals)
Coarse bedding
Occupational and/or hobby irritants
Household fluids (e.g., juices from fresh fruits, vegetables,meats)
Wool
Perfumes
Contact allergens
Furry animals (cat more than dog)
House dust mites 
Pollens (seasonal)
Molds
Human dander ("dandruff")
Microbial agents
Viral (including upper respiratory infections)
Staphyloccocus aureus (as pathogen, or "super-antigen")
Pityrosporon yeast 
Candida (rarely)
Dermatophytes (rarely)
Foods
Vasodilatory (alcohol, sp icey )»  Contactants > allergens
Psyche
Stress
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Anxiety 
Chronic disease 
Sleep deprivation 
Other 
Climate
Especially heat and sweating 
Cold, dry weather
Extremes or sudden changes of temperature and humidity
Hormones
Puberty
Menstrual cycle
ChronicAcute т» Subacute
A  Initial perivascular Infiltration. B. Papillary dermal edema. C. Abnormal scale. 
D. Hyperplasia. E. Hyperkeratosis.
From Murphy G F . D e r m a t o p a t h o lo g y . Philadelphia, Pa: W B  Saunders Com pany; 1995:53.
Eczema
Eczema is a clinical symptom. Histologically, all eczemas are spongiotic dermatitis, but not all 
spongiotic dermatoses are clinically eczematous (Fig. 10-2).
Atopic Dermatitis; Histology i '  , * ' ■ * .  “
‘
Progression of Atopic Dermatitis
Figure 10-2. The histology of eczema.
Spongiosis is the result of T-lymphocyte activation and the proinflammatory mediators 
released from the diverse T cells, and the varied inciting secretagogues produce the spectrum of 
clinical presentations. The bulla and vesiculobullous lesions o f the Thl-driven acute allergic contact 
dermatitis are never seen in the papulovesicular Th2-driven lesions of AD. The eczema of AD is 
almost exclusively isomorphic: It is not an itch that erupts on its own but an itch that erupts when 
scratched (or rubbed).
The characteristic clinical features o f the eczema of AD are as follow:
1. It occurs predominantly at an early age (usually between 2 and 5 months of age). There is 
a correlation between the age of onset of AD and its severity. The earlier the onset, the more severe 
the course.
2. The age-related distribution demonstrates the condition's isomorphic feature (Fig. 10-3).
3. AD is a chronic and relapsing eczema.
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2-9
MONTHS
9-18
MONTHS
18-35
MONTHS
3-4
YEARS
OVER 4 
YEARS
There are other noneczematous finding that are frequency seen in patients with AD. These 
noneczematous finding have been called “’minor”  or nonessential factors for the diagnosis of AD 
(Box 10-4).
Box 10-4. "Minor” or Unessential Features of Atopic Dermatitis
Xerosis ("dry skin")
Keratosis pilaris ("chicken" skin)
Perifollicular accentuation 
Allergic "shiners"
Dennie-Morgan lines
Pityriasis alba
Anterior neck fold
Palmar and/or plantar hyperlinearity
Periocular milia
Anterior capsular cataracts
Keratoconus
Differential Diagnosis of AD are listed in Table 10-1.
Treatment
• Reduce itch by the use of emollients and antihistamines, inflammation by the use of topical 
steroids, and staphylococcal superinfection by the use of appropriate oral antibiotics.
• Ciclosporin is helpful in severe disease as a temporary measure but the disease relapses as 
soon as the drug is withdrawn. Topical agents, tacrolimus and pimecrolimus, may be effective and 
do not have the same adverse effects as steroids.
• PUVA.
• High dose IVIg has also been shown to be beneficial in resistant cases.
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• Theoretically, у-interferon should be helpful, by reducing the Th2 predominance, and this 
has been borne out in several small trials.
• Where babies, by virtue of a strong family history, are at risk of developing atopic eczema, 
avoidance of cows’ milk for the first 6 months of life and late weaning may be helpful.
The addition of y-iinoleic acid and fish oil have been suggested to be helpful; the evidence 
from controlled trials is less supportive.
• Avoidance of egg, milk, or wheat may help some children. In adults if there is concern over 
the contribution of food, then a 2 week trial of an elimination diet will identify whether food is 
contributing.
Table 10-1. Differential Diagnosis of AD
Differential Diagnosis of Pediatric 
Eczemas
Differential Diagnosis of Adult Eczemas
Atopic dermatitis Allergic contact dermatitis
Acrodermatitis enteropathica Cutaneous T-cell lymphoma
Agammaglobulinemia Glucagonoma syndrome
Ataxia-telangiectasia Irritant contact dermatitis
Hartnup's disease Pellagra
Hyper-lgE syndrome Pityriasis rubra pilaris
Netherton's syndrome Psoriasiform eruptions
Phenylketonurea Scabies
Scabies Seborrheic dermatitis
Seborrheic dermatitis
Wiskott-Aldrich syndrome
A recommended algorithm for the management of AD can be found in Figure 10-4.
Mote? iwm» #r>J d«rtv«J * « !  t  woe ty Mcsay Inc
Figure 10-4. An algorithm for the management of atopic dermatitis.
Emollients. The intent o f emollients and moisturizers is to hydrate the skin, which enhances 
medication penetration and the barrier function (see previous section). Vaseline remains the 
standard to accomplish those goals; unfortunately, it is not very acceptable cosmetically. There is 
little evidence that the addition of other ingredients (e g., aloe, vitamins) have any beneficial effect. 
Preparations with fragrances should be avoided. An 8% ceramide-containing cream (e.g. Triceram
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cream) has been shown to repair the damaged barrier function and enhance the water-holding 
function in addition to providing a significant clinical improvement o f xerosis.
TOPICAL CORTICOSTEROIDS
Topical corticosteroids have been the cornerstone of treatment for AD for decades. However, 
monotherapy with topical corticosteroids is not likely to control AD. Adjuvant skin care in 
combination with patient/parent education is also very important. Based on the best evidence-based 
data, once- or twice-daily topical corticosteroids are justified as first-line therapy in all patients with 
AD. The younger the patient, the milder the choice of therapy. Facial, genital, and intertriginous 
areas should be treated with very mild corticosteroids (1% or 2.5% hydrocortisone). Hands and feet 
require higher-potency topical corticosteroids (0.1% triamcinalone ointment). Similarly, lichenified 
plaques warrant higher-potency preparations. Box 10-5 ranks selected topical steroids from 
superpotent (Group I) to less potent (Group IV). Potency o f corticosteroids used to treat the acute 
dermatitis may not be the same as the preparations required for maintenance.
Box 10-5. Ranking of Selected Brand-Name Topical Steroids*
Croup I: Superpotent (anti-inflammatory activity > 1500)
Temovate 0.05%
Diprolene 0.05%
Ultravate 0.05%
Psorocon 0.05%
Group II: High potency (anti-inflammatory activity = 100-500)
• Lidex 0.05%
•  Halog 0.05%
• Cyclocort 0.05%
• Topicort 0.25%
• Diprosone 0.05%
• Elocon 0.1%
• Florone 0.05%
• Maxiflor 0.05%
• Lotrisone 0.05%
Group III: Midpotency (anti-inflammatory activity =  10-100)
• Synalar 0.025%
• Kenalog0.1%
• Aristocort 0.1%
• Cord ran 0.05%
• Locoid 0.1%
• Cutivale 0.05%
• Westcort 0.2%
•  Cloderm 0.1 %
• Valisone0.1%
•  Benisone 0.028%
Group IV: Low potency (anti-inflammatory activity =  1-10)
Hydrocortisone (1 % is OTC; >1 % is prescription)
Tridesilon 0.05%
DesOwen 0.05%
Aclovate 0.05%
Decadron 0.1%
Medrol 1 %
Metiderm 0.5%
Research o f medication compliance in several chronic conditions suggests that between 30% 
and 40% o f medication is not used as prescribed. The successful management o f dermatologic 
conditions is often hindered by intentional or subconscious noncompliance. Aesthetic appeal of a
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product is probably the most important aspect of a topical therapy to a patient. No matter how 
effective a formulation, if patients find it irritating, disagreeable, or difficult to use, the efficacy of 
that product is compromised. In AD, ointments are usually more effective than creams, lotions, or 
gels; however, always take aesthetic appeal into consideration.
Patients who have chronically used topical corticosteroids without success will not be good 
candidates o f their continued use. Many o f these patients will benefit from corticosteroids in 
conjunction with the newer immunomodulators.
TOPICAL IMMUNOMODULATORS
Since the year 2000, topical immunomodulators (caclineuron inhibitors) have been gaining a 
firm footing in the management algorithm of AD and offer an additional treatment option, either as 
monotherapy or in combination with topical corticosteroids. Their safety profile and enhanced 
efficacy; particularly for eczema involving the head and neck, and the fact that they suppress 
inflammation through pathways independent o f those utilized by glucocorticoids is most appealing. 
There is some concern based on animal studies that there may be increased risk of neoplasias with 
prolonged use of these medications.
Tacrolimus (Protopic) ointment in concentrations of 0.03% and 0.1%, Pimecrolimus (Elidel) 
cream 1%. Both are calcineuron inhibitors that have been shown to be efficacious for mild to 
moderately severe AD for both short-term and long-term therapy (up to 3 years of use), with no 
increased infections. The most common adverse effects (with tacrolimus slightly more often than 
with pimecrolimus) were local application site events, included skin burning (up to 23%), pruritus 
(22%), and erythema (8%).
Patients using the immunomodulators experienced fewer flare-ups and reduced the need for 
topical corticosteroids by more than 50%. At present, some clinicians use topical 
immunomodulators initially, and most continue to use topical corticosteroids. However, as soon as 
the case is refractory and requires long-term treatment, the trend is to introduce topical modulators.
ANTIMICROBIALS
The relationship between skin colonization and secondary infection with S. aureus and AD 
activity remains unclear. It is well known that S. aureus is abundant in AD, both in clinically 
involved and uninvolved areas, and the density increases with the severity of the lesion. Few doubt 
the need for antibiotic therapy for the obviously infected lesion, but management o f nonclinically 
infected skin is less certain.
For localized infection, topical mupirocin (Bactroban) usually suffices. Systemic antibiotics 
are necessary for patients with multifocal infections or impetigo. Oral cefuroxime 15 mg/kg twice a 
day for 10 days is the preferred systemic antibiotic. If there is no clinical improvement in patients 
after 2 weeks of antibiotic therapy, a culture for bacterial sensitivities should be taken.
ANTIHISTAMINES
Antihistamines have long been prescribed for AD because it is believed that they will block 
histamine receptor type 1 (Hi)-induced pruritus; however, as noted previously, histamine is but one 
of many mediators that can induce pruritus in AD. Sedating antihistamines may offer some relief by 
their sedative effect; however, this author prefers using more effective sedatives (e.g., chloral 
hydrate, Zolpidem) for more effective sedation for adult patients. Studies comparing sedative and 
nonsedative antihistamines with placebo for the itch of AD do not show a clear benefit for the 
active drugs.
Topical doxepin (Zonalon) has been effective in relieving some of the pruritus o f AD; 
however, it was most effective in those patients who experienced sedation, and there was a 13% 
incidence of allergic contact dermatitis in those using the drug.
SYSTEMIC THERAPEUTIC OPTIONS
For severe AD, especially when other treatments fail, systemic corticosteroids (e g., 
prednisone 0.05 to 1.0 mg/kg/day to a maximum of 60 mg per day; methylprednisolone 0.04 to 0.08 
mg/kg/ day) are recommended for short-term management of disease activity. Long-term 
administration of systemic corticosteroids for AD should be avoided. Cyclosporine (0.3 to 0.5 
mg/kg/day) is an excellent alternative for the short-term treatment of refractory disease, especially if 
repeated courses of prednisone are considered.
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PHOTOTHERAPY
When topical agents fail in the treatment of moderately severe and severe AD, phototherapy 
can be a useful modality. The preferred form of phototherapy is narrowband ultraviolet В (available 
in selected medical centers). Photochemotherapy, which combines methoxsalen with ultraviolet A 
light, has proven efficacious in the treatment o f AD. The administration of phototherapy should be 
restricted to specialists. Remember, the more complex the intervention, the more precarious the 
risk-to-benefit ratio.
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11. CONTACT DERMATITIS (HYPERSENSITIVITY)
Presentation
• Contact dermatitis (CD) is a localized type IV reaction due to contact with a triggering 
allergen. Reaction is eczematous, often with blistering and weeping. The pattern of rash together 
with a careful exposure history usually identifies possible allergens.
• It needs to be distinguished from straightforward irritant dermatitis due to a localized toxic 
effect that does not involve the immune system. Typical irritants are solvents, acids, alkalis, and 
other chemicals. The skin has a limited number of ways in which it can respond, and the appearance 
o f irritant and allergic dermatitis can be clinically similar.
Causes
• Many topically applied compounds can cause delayed-type hypersensitivity reactions.
• nickel allergy often leads to dermatitis affecting the ear lobes, under the back of 
watches, and where jean studs press on the skin. Those regularly handling coins will get 
hand eczema. This is the commonest contact dermatitis.
• aniline dyes in leather cause dermatitis affecting the feet and where leather belts 
come in contact with skin.
• chromium: hand eczema, usually in those handling cement.
• cobalt: used as a stabilizer for the head on beer!
• latex and synthetic rubbers: related to chemical accelerators and hardeners (thiurams, 
mercapto compounds, carbamates); there is no evidence that latex proteins themselves cause 
type IV reactions.
• hair dyes, formaldehyde (perming lotions).
• fragrances and cosmetics (biocides, phenylenediamine, parabens).
• topical antibiotics (gentamicin, neomycin, bacitracin, benzocaines).
•  colophony (rosin) and other resins (adhesives in plasters).
•  ivy, sumac tree, chrysanthemum, feverfew, primula.
•Some allergens require concomitant exposure to sunlight for the effect to develop; rash only 
develops on sun-exposed areas of contact:
plants: limes, lemons, figs, giant hogweed, pine wood;
drugs, including sulphonamides, tetracylines, and phenothiazines; and sunscreens (p- 
aminobenzoic acid, oil of bergamot).
Immunology
Types I and IV hypersensitivity may coexist. In most cases the allergens are low molecular 
weight substances that penetrate the skin readily and lead to neoantigen formation. As with all T- 
lymphocyte-mediated responses, sensitization precedes reactivity. Active lesions show a sparse 
CD4+ T-Iymphocytic infiltrate but few eosinophils.
Diagnosis
The careful history and physical examination give the most important information. This 
should be supplemented by patch testing. SPT and measurement o f total IgE are o f little value.
Standard panel by patch testing will include metals (nickel, chromium), preservatives, 
fragrances, rubber mix, lanolin, formaldehyde, balsam of Peru, and colophony (Table 11-1).
Contact dermatitis should be included in the differencial diagnisis of every eczematous 
eruption (Box 11-1), especially eczematous lesions that do not respond to appropriate therapy or 
any skin lesion that exacerbates following topical therapy.
Unfortunately, the histology (i.e., spongiotic dermatitis) o f all eczemas is the same. Thus, 
whereas a biopsy can confirm spongiosis, it is the history that suggests CD and patch testing that 
confirms allergic CD.
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Table 11-1. Thin-layer rapid-use epicutaneous test panel of standard antigens
Substance Source
Nickel sulfate Metal objects
Wool alcohols (lanolin) Ointments, creams, lotions, soaps
Neomycin sulfate Antibiotic creams, lotions, ointments
Potassium dichromate Cement, industrial chemicals
Caine mix (benzocaine, tetracaine 
hydrochloride, dibucaine hydrochloride)
Topical anesthetic medications
Fragrance mix Toiletries, perfumes, flavorings
Colophony Adhesives, sealants, pine oil cleaners
Paraben mix Cosmetics, skin creams, paste bandages
Negative control
Balsam of Peru Resin used in cosmetics, perfumes, flavoring agent in 
cough syrups, lozenges, chewing gum, and candles
Ethylenediamine dihydrochloride Stabilizer, emulsifier, and preservative in topical 
fungicides, topical antibiotics, eye drops, and nose 
drops
Cobalt dichloride Metal-plated objects and costume jewelry
p-tert-Butylphenol formaldehyde resin Waterproof glues, leather goods
Epoxy resin Adhesives, surface coatings, paints
Carba mix Stabilizer in rubber products, pesticides, glues
Black rubber mix Antioxidant and antiozonate in almost all black 
rubber products (e g , tires, hoses)
C1+ Me-isothiazoiinone Antibacterial preservative in shampoos, creams, 
lotions, and other skin care products
Quatemium-15 Preservative in shampoos, lotions, soaps, and other 
skin care products
Mercaptobenzothiazole Vulcanization accelerator used in most rubber 
products and some adhesives
p-Phenylenediamine Permanent and semipermanent hair dyes
Formaldehyde Building materials and plastics industry
Mercapto mix Accelerators found in rubber products
Thimerosal Mercury-containing preservative in cosmetics, nose 
drops, and eardrops
Thiuram Antimicrobials and antioxidants found in rubber 
products
Box 11-1. Differential Diagnosis of "Eczema"
Contact dermatitis (allergic or irritant)
Seborrheic dermatitis
Atopic dermatitis
Nummular eczema
Stasis dermatitis
Dyshidrotic eczema
Asteatotic eczema
Lichen simplex chronicus
Autosensitization or "id" reaction
Dermatophytosis
Pityriasis rosea
Photoallergy dermatitis 
Photocontact dermatitis 
Polymorphous light eruption 
Drug-induced eczema 
Wiskott-Aldrich disease 
Acrodermatitis enteropathica 
Vitamin deficiencies
Pellagra
Riboflavin deficiency 
Hartnup's disease 
Hyper-IgE syndrome
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Fragrance mix Toiletries, perfumes, flavorings
Colophony Adhesives, sealants, pine oil cleaners
Paraben mix Cosmetics, skin creams, paste bandages
Negative control
Balsam of Peru Resin used in cosmetics, perfumes, flavoring agent in 
cough syrups, lozenges, chewing gum, and candles
Ethylenediamine dihydrochloride Stabilizer, emulsifier, and preservative in topical 
fungicides, topical antibiotics, eye drops, and nose 
drops
Cobalt dichloride Metal-plated objects and costume jewelry
p-tert-Butylphenol formaldehyde resin Waterproof glues, leather goods
Epoxy resin Adhesives, surface coatings, paints
Carba mix Stabilizer in rubber products, pesticides, glues
Black rubber mix Antioxidant and antiozonate in almost all black 
rubber products (e g., tires, hoses)
C1+ Me-isothiazolinone Antibacterial preservative in shampoos, creams, 
lotions, and other skin care products
Quatemium-15 Preservative in shampoos, lotions, soaps, and other 
skin care products
Mercaptobenzothiazole Vulcanization accelerator used in most rubber 
products and some adhesives
p-Phenylenediamine Permanent and semipermanent hair dyes
Formaldehyde Building materials and plastics industry
Mercapto mix Accelerators found in rubber products
Thimerosal Mercury-containing preservative in cosmetics, nose 
drops, and eardrops
Thiuram Antimicrobials and antioxidants found in rubber 
| products
Box 11-1. Differential Diagnosis of "Eczema"
Contact dermatitis (allergic or irritant)
Seborrheic dermatitis
Atopic dermatitis
Nummular eczema
Stasis dermatitis
Dyshidrotic eczema
Asteatotic eczema
Lichen simplex chronicus
Autosensitization or "id" reaction
Dermatophytosis
Pityriasis rosea
Photoallergy dermatitis 
Photocontact dermatitis 
Polymorphous light eruption 
Drug-induced eczema 
Wiskott-Aldrich disease 
Acrodermatitis enteropathica 
Vitamin deficiencies
Pellagra
Riboflavin deficiency 
Hartnup's disease 
Hyper-IgE syndrome
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TREATMENT
The identification of the offending agents is the key to success in managing patients with CD. 
All other measures are directed toward symptom relief with the suppression of the resulting 
inflammatory reaction.
The aggressiveness o f the prescribed treatment should be determined by the limitations on the 
quality o f life caused by the CD. Localized acute CD warrants different treatment than other special 
circumstances, that is, occupational dermatitis, chronic contact dermatitis (Box 11-2).
Box 11-2. Treatment of Contact Dermatitis
1. Avoidance
2. Topical antipruritics
3. Topical anti-inflammatory agents
4. Systemic anti-inflammatory agents
5. Instructions to prevent recurrences
AVOIDANCE
Only after the putative agent is identified can avoidance be instituted. Unless the causative 
agent is removed, all other modalities of treatment are palliative.
TOPICAL ANTIPRURITICS
In the acute phase, when itching, edema, and oozing are features, compresses with cold water 
to which crushed ice has been added are valuable. Cold is usually an effectively antipruritic, 
whereas the addition of calamine, colloidal oatmeal, or other soothing substances is of questionable 
value; topical diphenhydramine (Benadryl) should be strictly avoided because of the risk of 
cutaneous sensitization.
TOPICAL ANTI-INFLAMMATORY AGENTS
Two classes o f effective, topical anti-inflammatory agents are available. Topical 
corticosteroids have a long track record of effectiveness and safety (when used appropriately), and 
the newer calcineuron inhibitors (tacrolimus [Protopic], pimecrolimus [Elidel]), which are at least 
as effective as the low to moderately potent corticosteroids. These topical agents can manage cases 
of CD localized to less than 10% of the patient's body surface area. Low-potency, nonfluorinated 
corticosteroids or calcineuron inhibitors are recommended for the thinner skin (i.e., face, eyelids, 
genital areas), and the higher-potency corticosteroids are indicated for other skin, especially if the 
lesions are lichenified and the condition is "chronic" (see chapter “Atopic dermatitis” Box 10-5).
The amount o f medication to apply remains a most perplexing issue in the management of 
skin disease. A guide for proper application of creams is noted in Figure 11-1.
Another guide is referred to as the "Kleenex test": When a treated site is lightly dabbed with 
tissue paper, it should not reveal any "grease." If there is any on the tissue, too much medication has 
been applied.
SYSTEMIC ANTI-INFLAMMA TORY AGENTS
Systemic anti-inflammatory agents are indicated for those more uncomfortable patients. 
Immunosuppression is usually most appropriate during the acute eruptive stages. Prednisone (0.5 to 
1.0 mg/kg/day) is the treatment o f choice. Generally, this dosage should be tapered (by half, and 
then discontinued) after the acute phase has resolved. The total treatment time is usually 10 to 14 
days. Tapering the treatment too soon often results in a rebound of the initial dermatitis. More 
gradual tapering is not necessary, and steroid side effects, although possible, are very rare with this 
duration of treatment.
Oral cyclosporine at a dose of 3 mg/kg/day should be considered for patients with more 
chronic (6 weeks or longer) allergic CD and for diabetics. Oral antihistamines, while very effective 
for contact urticaria, offer minimal relief from the pruritus o f allergic CD.
I l l
INSTRUCTIONS TO PREVENT RECURRENCES
The patient must be instructed to avoid the cause of the CD once it is identified. Cross­
reacting agents should be included in the list of avoidances.
A PARENT’S GUIDE TO THE USE OF TOPICAL TREATMENT
Use the adult Fingertip Unit(FTU) as your guide
One adult fingertip tfraf(FTU)
The diagram s of the child (below) show how many adult Fingertip 
Units of cream or ointment are required to cover each area of the 
child's body.
( { \ I
Face Aria Leg Trunk Trunk (Back)
&Neck &Hand & Foot (Front) inc. Buttocks
Age Number of FTUs
3-6 mlh 1 1 1 i* 1 11*
1-2 у 1V4 1 V* 2 2 3
3-5 у m 2 3 3 31*
6-10 у 2 2 V* iVi 31* 5
; Reprinted with permission from Long CC, Mills CM, Finlay AY. A practical guide to topical therapy 
in children. 8rJ Dermatol. 1998;138(2):293-296.
i f  rorrt lonjj CC. CM. Firiay AY Apractical (ptdtr to fcprcoi 9 m apy m chtitfcen В» J  OrrrcvYtf 1 9 4 8 , 1 )
Figure 11-1. A parent’s guide to the use of topical treatment. (From Long CC, Millis CM, 
Finlay AY: A practical guide to topical therapy in children. Br J Dermatol 1998;138(2):293—296.)
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12. DRUG ALLERGY
Immunologically mediated adverse drug reaction or drug allergy and/or hypersensitivity 
account for 6% to 10% of adverse drug effect. Table 12-1 provides a general overview of adverse 
drug reaction.
Table 12-1. Classification of Adverse Drug Reactions 
Predictable Adverse Reactions Occurring in Normal Patients 
Reaction Example
Overdosage or toxicity Hepatic failure with acetaminophen
Side effects Urinary retention with anticholinergic medications
Secondary or indirect effects Clostridium difficile colitis with use of ampicillin 
Drug-drug interaction Erythromycin increasing theophylline blood levels
Unpredictable Adverse Reactions
Allergy and hypersensitivity 
reactions (IgE-mediated) 
Pseudoallergic reactions (non- 
IgE-mediated events that mimic 
IgE-mediated events) 
Intolerance
Idiosyncratic reactions
Anaphylaxis from (I-lactam antibiotic 
Anaphylaxis with radiocontrast dye
Tinnitis after a single aspirin
Hemolytic anemia in patients with G6PD deficiency exposed 
to primaquine
There are a number o f specific characteristics that are generally helpful in distinguishing drug 
allergy from other adverse drug reaction.
Chief Characteristics of Drug Allergy and Hypersensitivity:
•  Occurs in only a small fraction of patients after prior sanitization
• Can be reproduced by very small dose of the drug
• Will subside within several days to weeks following discontinuation of the drug
•  Produces manifestations that differ from any known pharmacologic actions of the 
medication
• Can mimic other known allergic reactions, such as serum sickness and/or anaphylaxis
•  Hypersensitivity, which can manifest as pulmonary infiltrates with eosinophilia, drug fever, 
and/or lupus syndrome
• Onset usually prompt (hours or days) but can occur within several months of administration 
of a drug
• Immunologic mechanism that is demonstrable or the putative mechanism
Many drug hypersensitivity reaction can be classified according to the revised Gell and 
Coombs schema. Table 12-2 is a synopsis o f the clinical manifestation and mechanism of each 
reaction type.
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Table 12-2. Examples of Drug Allergy Categorized According to the Revised Gell and 
Coombs Reaction Classification
Reaction Type Clinical 
Presentation
Revised Cell and Coombs 
Reaction Type
Mechanism
Anaphylaxis, bronchospasm, 
urticaria, angioedema
Type I: Anaphylactic Antigen cross-links IgE on cell 
surface, resulting in mediator 
release
Hemolytic anemia due to 
binding of drug to red cells, 
thrombocytopenia, interstitial 
nepliritis
Type 11a: Cytotoxic 
Type Hb: Cell stimulating
Cell-bound antigen reacts with 
IgG or IgM antibody, thus 
activating complement and 
producing cell injury 
IgG cell-stimulating antibody 
interacts with cell surface 
receptors involved in cell 
signaling
Serum sickness, drug fever Type III Immune complex Formation of antigen-antibody 
complexes that activate 
complement, resulting in 
recruitment of macrophages and 
leukocytes that cause tissue 
damage
Contact dermatitis with topical 
application
Type IVal: Cell mediation 
hypersensitivity
Antigen is presented to 
sensitized CD4+ 
T-lymphocytes (Thl cells) that 
release cytokines that attract 
other cells, which cause tissue 
inflammation
Delayed allergic reactions Type IVa2: Cell mediated 
hypersensitivity
Antigen is primarily presented 
to sensitized CD4+ T- 
lymphocytes (Th2 cells); 
sensitized CD8+ T-lymphocytes 
(Th2 cells) also may be involved
Toxic epidermal necrolysis 
(TEN)
Type IVb: Tissue injury by 
cytotoxic T-lymphocytes
Cytotoxic CD8+ T-lymphocytes 
recognize fragments of antigen 
on the surface of target cells
Epidemiolog}'
The frequency of adverse drug reaction is not precisely known. In study of hospitalized 
patients on medical floors, the estimates of prevalence of adverse drug reaction range from 15% to 
30%. Of all adverse reaction, approximately 6% to 10% are believed to represent drug 
hypersensitivity. Drugs that have been implicated frequently in allergic drug reactions are listed in 
Box 12-1.
Box 12-1. Listing of Drug Groups Most Frequently Implicated in Allergic and 
Pseudoallele Drug Reactions
Allopurinol
Anesthetic agents (muscle relaxants, thiopental)
Antiarrythmic agents (quinidine, procainamide)
Anticonvulsants (hydantoin, tegretol)
Antihypertensive agents (hydralazine, methyldopa, angiotensin-converting enzyme 
inhibitors)
П4
Antimalarials
Antipsychotic tranquilizers (phenothiazines, tricyclics)
Antisera and vaccines (antitoxins, monoclonal antibodies)
Antituberculosis drugs (isoniazide, rifampin)
Aspirin and nonsteroidal anti-inflammatory drugs 
Cisplatin
Enzymes (chymopapin, L-asparaginase, streptokinase)
Grisefulvin Heavy metals (gold)
Narcotics (codiene, morphine)
Nitrofurans
Organ extracts (adrenocorticotropic hormone, insulin)
Penicillamine
Penicillins and cephalosporins 
Phenolphthalein 
Radiocontrast media 
Sedative-hypnotics (barbiturates)
Sulfonamides
In recent years, several new classes of drugs have come into wide-spread use special 
consideration. There classes include monoclonal antibodies, cytokines, cyclo-oxygenase-2 (COX- 
2) inhibitors, and angiotensin-converting enzyme inhibitors (ACEs).
Monoclonal antibodies are used to treat many disorders, including lymphoma, breast cancer, 
inflammatory bowel disease, and rheumatoid arthritis. Many monoclonal antibodies are chimerized 
with murine proteins and lead to hypersensitivity reactions. For example, rituximab (Rituxan) is a 
chimeric antibody with a small murine component that binds CD20 on B-lymphocytes and is used 
in the treatment non-Hodgkin's lymphoma. Frequently, there are reactions during infusions, 
including fever, rigors, diaphoresis, flushing hypotension, bronchospasm, dyspnea, and a sensation 
of tongue and throat swelling. These infusion reactions are common with other monoclonal 
antibodies and are easily treated by reducing the infusion rate and, in some patients, pre-treatment 
with antihistamines, acetaminophen, and corticosteroids. There are also rare reports o f allergic 
reactions including anaphylaxis, angioedema, serum sickness, immune-mediated thrombocytopenia, 
and anemia. Cytokine-release syndrome (or cytokine storm) occurs when binding o f the 
monocolonal antibody-target cell complex via the Fc receptor activates macrophages in the liver, 
spleen, or lung. This activation leads to increasing concentrations of tumor necrosis factor alpha and 
interleukin-6 proportional to the number o f malignant lymphocytes.
Treatment with cytokines such as interferon (INF)-p for multiple sclerosis, and INF-a for 
hepatitis C has become widespread in recent years. INF- p for the treatment of multiple sclerosis is 
commonly associated with flulike symptoms and local injection site reactions. There are case 
reports o f capillary leak syndrome, anaphylaxis, and a thrombotic thrombocytopenic purpura-like 
syndrome in patients receiving INF- p. INF- p -neutralizing antibodies can develop and decrease the 
effectiveness o f treatment. Reports o f the prevalence of neutralizing antibodies in patients receiving 
INF-a for the treatment of hepatitis C vary from 1.2% to 20.2%.
Aspirin (ASA) and nonselective NSAIDs are inhibitors of cyclo-oxygenase-1 capable of 
producing nonimmunologic-mediated bronchoconstriction, urticaria, and anaphylaxis. The selective 
cyclo-oxygenase-2 inhibitors celoecoxib (Celebrex) and refecoxib (Vioxx) have been tolerated in 
aspirin-intolerant asthma patients, patients with history o f angioedema with aspirin, and patients 
with adverse respiratory and cutaneous reactions to NSAIDs. There have been reports o f patients 
with NSAID-triggered urticari developing urticaria following COX-2 exposure.
Angiotensin-converting enzyme inhibitors are associated with angioedema in 0,1% to 0,5% of 
patients who use them, and symptoms occur within 1 month of therapy in the majority o f patients. 
Because there appears to be cross-reactivity among ACE inhibitors, the entire class is 
contraindicated in a patient who has developed angioedema. Angiotensin II antagonists (ARB) are 
used as alternatives to ACE inhibitors and are not contraindicated in those with ACE inhibitor-
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induced angioedema. However, there are reports of patients with angioedema secondary to ACE 
inhibitors who subsequently developed angioedema while taking an angiotensin II antagonist. Thus, 
caution must be exercised when giving angiotensin II antagonists to patients with a history of 
angioedema from ACE inhibitors.
IMMUNOGENICITY OF DRUGS
Molecular weight of at least 3 to 5 kDa and multivalency are generally required for a 
compound to be immunogenic. Therefore, with the exception of a few protein drugs, such as insulin 
or streptokinase, very few drugs are complete antigens. The vast majority of drugs are organic 
chemicals with molecular weights less than 1 kDa that function as univalent ligands. Based on the 
classic reports of Landsteiner in the 1920s, it is generally acknowledged that low-molecular-weight 
drugs (haptens) are not immunogenic unless they are bound to a high-molecular-weight (>5 kDa) 
substance, usually a protein (carrier).
P-Lactam antibiotics are reactive with proteins and can directly haptenize carrier proteins. 
Most drugs, however, are not chemically reactive with proteins. It is probable that the haptens from 
most drugs are reactive metabolites of the parent compound that then bind to carrier proteins; 
certainly, this is the case with metabolites of penicillin. Studies of human IgE to sulfonamides have 
demonstrated the N4-sulfonamidoyl determinant to be the major sulfonamide haptenic determinant. 
For most other allergenic drugs, the formation of reactive metabolites and their conjugation with 
carrier proteins is somewhat speculative. In the absence of the relevant drug haptens, immunologic 
assessment is, o f course, impossible.
CLINICAL PRESENTATION
The clinical presentations of drug allergy can take many different forms, and they are 
generally not pathognomonic for drug hypersensitivity. That is, similar clinical presentations can be 
the result of exposure to other allergens, or they can be associated with other nonimmunologic 
diseases. Dermatologic manifestations are the most common manifestation of drug allergy. 
However, many other organ systems can be involved, either alone or in combination, in a patient 
with drug allergy. It should be appreciated that in many reactions that are believed to be drug 
allergy, a definitive immunologic mechanism has not been established. A list of the clinical 
presentations of drug allergy is given in Box 12-2.
Anaphylaxis, a potentially life-threatening condition, can include any or all of the following: 
hypotension, bronchospasm, laryngeal edema, angioedema, and generalized urticaria. If the antigen 
has been ingested, gastrointestinal symptoms, such as nausea, vomiting, diarrhea, or cramping, may 
be prominent. Symptoms ussualy begin within 30 minutes o f drug and generally subside within 24 
hours.
Serum sickness-like reactions occur 1 to 3 weeks after drug exposure. Other multisystemic 
clinical presentations of drug allergy include drug fever, drug-induced lupus erythematosus, and 
vasculitis.
Box 12-2. Listing of Various Single-Organ and Multisystem Manifestations of Drug 
Allergy
Single-organ system involvement
Dermatologic manifestations (see Box 12-3)
Respiratory or pulmonary manifestations 
Asthma
Acute infiltrative reactions (probably allergic)
Hypersensitivity pneumonia 
Pulmonary infiltrates with eosinophilia 
Nitrofurantoin reactions 
Noncardiac pulmonary edema
Hematologic manifestations
Eosinophilia
116
Drug-induced immune cytopenias 
Thrombocytopenia 
Hemolytic anemia 
Agranulocytosis 
Hepatic manifestation 
Cholestasis
Hepatocellular damage 
Mixed pattern 
Renal manifestations
Glomerulonephritis 
Nephrotic syndrome 
Acute interstitial nephritis 
Lymphoid system manifestations 
Pseudolymphoma
Infectious mononucleosis-like syndrome 
Multisystem involvement 
Immediate generalized reactions 
Anaphylaxis 
Anaphylactoid reactions 
Serum sickness 
Drug fever
Drug-induced autoimmunity (lupus erythematosus)
Vasculitis
Of all the organ system affected by drug allergies, the most frequently involved is the skin 
(Box 12-3).
Box 12-3. Dermatologic Manifestations Are the Most Common Symptoms of Allergic 
Drug Reactions
Most Common
Exanthematous eruptions or morbilliform eruptions
Urticaria
Angioedema
Contact dermatitis
Less Common
Fixed drug eruptions
Erythema multi forme
Sevens-Johnson syndrome
Generalized exfoliative dermatitis
Photosensitivity
Uncommon
Purpura
Toxic epidermal necrolysis (Lyell's syndrome)
Erythema nodosum
DIAGNOSIS OF DRUG ALLERGIES
Occasionally, diagnosis o f drug allergy is fairly straightforward, but this is not usually the 
case. As indicated in Box 12-4, the most important diagnostic tool is the history.
Box 12-4. Guidelines for Diagnosis of Drug Allergy
History
Careful, complete drug history
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Clinical manifestations consistent with drug allergy; a temporal relationship between drug 
exposure and onset of clinical manifestations consistent with drug allergy.
In vitro Testing (Table 12-3)
Research tool 
Generally no clinical value 
In  vivo Testing
Clinically indicated in selected cases 
Cutaneous testing 
Provocative test dosing
Table 12-3. Testing for drug allergy
Immediate tests Later tests
• Mast cell tryptase, СЗ, C4, as soon after the 
reaction as possible and at 24 hours
• Serum albumin
• Refer to immunologist/allergist for 
investigation
• Specific IgE, SPT and intradermal testing: 
Flow-CAST; drug challenge (DBPC)
First, it is imperative to have a complete and accurate list of all the drugs taken by the patient 
over the previous month. If a physician does not specifically ask about such nonprescription drugs 
as aspirin, the patient may not volunteer this information. Second, it is necessary to study the 
patient's manifestations to see if they are consistent with known drug allergies. As discussed above, 
it is important to recognize the protean nature of drug allergy and that it is not confined to rashes. 
Finally, it is important to consider the temporal relationship between exposure(s) to the drug and 
onset of clinical manifestations. If a patient is receiving a drug for the first time allergy generally 
does not occur until several days have passed. However, it usually occurs within several months. 
That is, if patient has been receiving a drug on a daily basis for over a year, that drug is not likely to 
be the cause of drug allergy. If a patient has received a drug in the past, sensitization may already 
have occurred, and drugs allergy may appear immediately upon readministration.
There are numerous in vitro tests that have been utilized in the investigation of drug allergy. 
Among these are histamine release, drug-specific IgE radioallergosorbent tests (RASTs), 
immunoassays for specific IgG or IgM, lymphocyte reactivity as measured by lymphokine 
production or lymphocyte transformation, and agglutination and lysis of blood cells in the presence 
of the suspected drug and the patient's serum. With the exception of the last, which may be 
clinically useful in the evaluation o f immunologically mediated cytopenias, in vitro tests are rarely 
of clinical value, even though they may be valuable research tools. Studies indicate that elevated 
levels o f perform, granzyme B, tumor necrosis factor-а, and Fas-L are found with delayed 
cutaneous reactions to drugs. It is possible that these markers may be used in the future to monitor 
cytotoxic T-cell response in delayed drug reactions.
In vivo testing for drug allergy—that is, cutaneous testing or provocative test dosing—may be 
clinically indicated in selected cases. It must be recognized that a serious limitation of cutaneous 
testing is the dearth of appropriate multivalent test reagents or drug metabolites. This is primarily 
because the antigenic determinants responsible for drug allergy are unknown for most drugs. If a 
patient has a history compatible with drug allergy, cutaneous tests are negative, and there is a clear 
indication for a drug reaction, provocative test dosing may be Considered. In this method of testing, 
the initial dose is one that would not cause a serious reaction. Subsequent doses represent 
incremental increases. An example is given in Table 12-4. At each dose increment, it is imperative 
to ascertain whether or not any symptoms have occurred before proceeding to the subsequent dose.
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Table 12-4. Typical protocol for provocative test dosing in a patient with history of 
penicillin allergy*
I f  a  patient has negative prick and intradermal tests to Penicilloyl-polylysine (Pre-Pen), the 
major determinant, and to the minor determinant mixture (if available) or to penicillin G 
potassium, you may lest dose as follows:
Route Amount
IV 1/1000 of full dose
IV 1/100 of full dose
IV 1/10 of full dose
IV full dose
* - Following each dose increment, it is necessary to assess the patient and determine whether 
any symptoms of allergy have developed.
It is important to appreciate the difference between provocative test dosing and 
desensitization. The former describes the incremental administration of a drug to which a patient 
probably does not have an IgE-mediated allergy, even though the history is somewhat suggestive of 
an allergic reaction. On the other hand, if true IgE-mediated allergy exists, the incremental 
administration of the drug is termed desensitization, as it converts the patient from a stale of 
sensitivity to that o f nonsensitivity to the drug. The mechanism is not entirely clear, but it may be 
the result of graded antigen binding of specific IgE or of controlled mediator release. Box 12-5 
indicates agents for which desensitization can be carried out.
Box 12-5. Agents for which drug desensitization protocols are published
Allopurinol
Aminoglycosides
Aspirin
Dapsone
Furosemide
Heterologous antisera
Insulin
Measles mumps rubella vaccine
Penicillin
Sulfa
Tetanus toxoid 
Vancomycin
Conclusion
• Diagnosis o f drug reactions requires a good history.
• Investigation of an acute reaction requires confirmation of the nature of the reaction.
• Ideally, it should be possible to measure complement breakdown products (C3d, СЗа, C5a) 
and urinary methylhistamine but, due to the withdrawal of appropriate commercial assays and the 
need for usually unobtainable stabilizers in blood tubes (Futhan-EDTA), these additional tests are 
not usually done.
• Reliable specific TgE tests are available to only a few drugs (thiopentone, suxamthonium, 
major determinants of penicillin).
• Skin prick testing followed by intradermal testing is required
• Challenge tests are of more value but are time-consuming and potentially dangerous.
Treatment of drug allergies
• Treatment o f all drug reactions involves immediate cessation o f the drug and, if the reaction 
is severe, resuscitation as for anaphylaxis (Chapter 4).
Prevention of drug allergy is obviously a desirable goal (Box 12-6).
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Box 12-6. Key Measures for the Prevention of Drug Allergy
Prescribe drugs only if essential.
Prior to prescribing drugs, obtain a thorough, careful drug history; drugs to which patients 
have had reactions or cross-reacting drugs should not be prescribed.
Perform cutaneous tests prior to administration of foreign antisera.
If an allergic drug reaction occurs, fully inform the patient; medical records should reflect the 
incident.
Report adverse drug reactions, such as drug allergy, to the Food and Drug Administration; 
this is especially important for newly introduced drugs.
Penicillin allergy
• Penicillin allergy is very common, perhaps occurring in up to 8% of treatment courses. Most 
o f the reactions are trivial. Severe reactions are rare and occur mainly after parenteral 
administration.
• Occasional patients react on apparent first exposure and it has been suggested that 
sensitization may occur through antibiotics occurring in food.
• All four types of Cell and Coombs' hypersensitivity reactions may occur with penicillin, 
together with reactions of uncertain significance such as Stevens-Johnson syndrome.
• There are major antigenic determinants (benzylpenicilloyl nucleus) and minor determinants 
(benzylpenicillin, benzylpenicilloate, and others), although both are capable of causing severe 
immediate reactions.
• Currently available tests (RAST and SPT/IDT) detect only major determinants, 
although benzylpenicillin may detect some minor-determinant-only reactions if suitably 
diluted and used for SPT.
• Tests for IgE (i.e. RAST and SPT) have no predictive value for other types of reactions. Up 
to 3% of SPT-negative patients may subsequently have reactions, although the reaction rate falls if 
both major and all minor antigens are used for testing. Some recent studies have claimed very few 
false-negative results with SPT. Conversely, not all SPT-positive patients will react when 
subsequently challenged.
• There have been difficulties in obtaining skin test reagents containing minor determinants, 
which makes accurate testing difficult.
• Up to 75% of patients who have had a reaction to penicillin will tolerate the drug 
subsequently. This probably applies to patients with non-specific reactions of dubious allergic 
aetiology (nausea, vomiting, diarrhoea) but more care should be taken in patients with a history of 
angioedema, Stevens-Johnson syndrome, etc.
• There is a high level of cross-reactivity with other semisynthetic penicillins with a p-lactam 
ring, such as the carbapenems and the monobactams (up to 50% in the case of imipenem), for IgE- 
mediated reactions.
• Cephalosporins and cephacarbams also cross-react, but at a lower level: up to 5.6% of 
penicillin-allergic (SPT positive) patients may also react to cephalosporins. Older figures are higher, 
but may relate to first-generation cephalosporins. Anaphytaxis to cephalosporins is said to be very 
unlikely if there are no responses to major or minor determinants o f penicillin. In some cases the 
IgE is directed not at the nucleus but at the side-chain, which may be shared between a penicillin 
and a cephalosporin (e g. aztreonam and ceftazidime).
• The specific morbilliform rash associated with the administration of amoxycillin to patients 
with acute EBV infection does not indicate a likelihood of subsequent true penicillin allergy.
Management
• The management of the penicillin-allergic patient depends on obtaining a clear history from 
the patient
• For patients with severe reactions, avoidance is the best course, including other 
semisynthetic p-lactam antibiotics.
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• If penicillin or equivalent is essential, rush desensitization schedules may be used, although 
there is a high risk of reactions, for which supportive therapy will be required. The desensitization 
must be followed by the treatment course and there is no lasting tolerance. Desensitization should 
not be attempted in those who have had a Stevens-Johnson reaction.
Other antibiotics
• Little is written about true allergy to other antibiotics.
• Patients with AIDS have a very high reaction rate to trimethoprim-
sulphamethoxazole. This has been associated with IgE to a derivative o f the 
sulphamethoxazole.
• Abnormal metabolism with generation of toxic intermediates has been proposed as a 
mechanism for the generation of erythema multiforme and Stevens-Johnson syndrome. Cross- 
reactivity to sulphonamides may also affect other drugs that are closely related such as furusemide, 
hydrochlorothiazide, and captopril.
• Skin prick and intradermal testing can be carried out where reactions are not suggestive of a 
type I reaction (but not if the reaction is Stevens-Johnson).
Insulin allergy
• Insulin allergy may occur due to changes in the tertiary structure of insulin engendered in 
the manufacturing process for human insulin, or previously due to the sequence differences in 
bovine and porcine insulin, with the production of IgE antibodies. These do not recognize natural 
human insulin.
• Other components such as protamine and zinc may also cause allergic reactions.
• There is urticaria at the site o f injections and frequently induration. Rarely, systemic 
reactions occur.
• Treatment is difficult: local reaction may be amenable to the prophylactic use of 
antihistamines or the inclusion of a tiny dose of hydrocortisone (1 -5 mg) with the insulin.
• 'Desensitizatiori regimes have been used where there are major problems and diabetic 
control has failed.
Anaesthetic allergy
• The major difficulty o f the investigation of anaesthetic reactions is that multiple drugs are 
administered nearly simultaneously.
• Patients suffering an acute reaction to anaesthetics should be referred to a specialist centre 
for investigation (the Royal College of Anaesthetists has produced guidelines on management for 
anaesthetists).
• Confirmation o f the reaction at the time requires a blood sample for mast cell tryptase, 
complement C3 and C4, and albumin (calculation of dilutional effects).
• Complex regimes of serial blood sampling have been recommended: these are impractical 
and add nothing to the subsequent investigation.
• Measurement o f specific IgE at the time of the reaction is unhelpful, as a negative result may 
be due to consumption.
• Detailed anaesthetic records must be forwarded to the drug allergy testing unit.
• Some of the drugs used (opiate derivatives) are capable of inducing mast-cell degranulation, 
while solvents such as cremophor, used to dissolve lipophilic drugs, may activate the complement 
system.
• Problems of severe reactions peroperatively may also arise from synthetic plasma expanders 
and blood products and in patients with unrecognized (or ignored) sensitivity to latex.
• There is extensive cross-reactivity between the neuromuscular blocking agents; prior 
exposure is not necessary (possibly cross-reaction with microbial products).
• RAST tests for specific IgE are currently limited commercially to suxamethonium and 
thiopentone, although research centres may have tests for IgE to other agents.
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• SPT and intradermal testing are necessary to identify causative agents and identify safe 
alternatives.
• Challenge testing should only be carried out with full resuscitation facilities to hand.
• Guidance on testing is detailed in Chapter 3.
Local anaesthetics
• Local anaesthetics may cause both type I and type IV reactions, so a careful history is 
required to identify the nature of the reaction and guide subsequent testing.
• Overdose of local anaesthetic may cause significant adverse reactions; it is essential to 
exclude this possibility.
• Local anaesthetics divide into two groups: group I are the benzoic acid esters, including 
benzocaine and procaine; group II are the amides, including lignocaine, bupivacaine, and prilocaine. 
There is little cross-reactivity between the two groups, but there is often cross-reactivity within the 
groups.
• Local anaesthetics may contain sulphites (particularly if adrenaline is present) and other 
preservatives such as parabens, which may cause adverse reactions in their own right
• Articaine appears to be the local anaesthetic least likely to cause reactions and is the drug of 
choice where there is doubt about previous reaction history.
Drug-induced Stevens-Johnson syndrome. Drugs, particularly sulphonamides and 
penicillins, may cause the Stevens-Johnson syndrome. The immunological mechanism is uncertain.
IStevens-Johnson syndrome is, however, a contraindication to any form of cutaneous 
challenge testing or further administration of the drug.
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13. LATEX ALLERGY
Latex allergy is an increasing problem in hospitals, mainly triggered by the massive increase 
in latex glove usage during the 1980s when AIDS was identified. Up to 20% of staff in high glove 
usage areas may become sensitized to latex.
PRESENTATION
Type 1 reactions occur with anaphylaxis, asthma, angioedema, rhinoconjunctivitis, and contact 
urticaria.
Typical reactions occur with gloves, condoms, and new elasticated clothing. Cause Type I 
reactions develop against a range of proteins present in the latex.
Range of latex-containing domestic and medical products is very large.
Cross-reaction to foods is frequent bananas, avocado, kiwi fruit, potato, tomato, chestnut, 
lettuce, pineapple, papaya.
Type IV reactions occur due to plasticizers used in the manufacture (not latex), and cause a 
localized dermatitis.
The medical history in latex allergy requires knowledge of personal risk factors for the 
development of the disease. Certain medical conditions predispose these subjects to development of 
latex allergy through a combination of genetic (atopy), medical condition (spina bifida), and 
environmental (occupation and personal exposure) situations. In addition, the clinician must be 
aware that allergic reactions in certain clinical settings often indicate the possibility of latex allergy 
as the cause. Anaphylaxis during or shortly after administration of barium by a latex balloon-tipped 
catheter or placement of a bladder catheter or unexplained anaphylaxis during surgical operations 
should raise the physician’s suspicions that latex allergy may be implicated. Other situations where 
latex material comes in contact with mucous membranes (dental work) or vascular systems and 
results in angioedema or other allergic manifestations are compelling and raise questions of the 
possibility of latex allergy.
In situations where latex materials are not constantly in contact with the skin, it seems that 
dermatitis is not a prominent problem. However, when the patient frequently wears latex materials, 
dermatitis is often found. The majority of health care worker with latex allergy report dermatitis at 
the site of latex glove contact. This dermatitis is often irritant in nature, which breaks down the skin 
barrier and may allow access of proteins to the immune system. This in turn may lead to the 
development of lgE-mediated latex allergy. Because 30% of health care workers without latex 
allergy may have irritant dermatitis, its presence is not diagnostic. Frequent hand washing, multiple 
glove changes, glove powder, and failure to completely dry the skin may contribute to this common 
dermatitis. Irritant dermatitis can be easily recognized by the findings of dry, cracked skin surface; 
itching; and erythema that is not accompanied by vesicles, blistering, or weeping of the skin. This 
dermatitis may respond to cotton glove liners, reduction of powder use, thorough hand drying, non- 
petroleum-based barrier creams that cause latex to degrade, as well as moisturizers.
Others may develop contact dermatitis; a type IV cell-mediated immune response. This 
dermatitis is distinguished from irritant dermatitis because of its vesicular, weeping appearance 
coupled with dermatitis extending away from the site of direct contact with latex materials. This is 
due to the fact that lymphocytes and Langerhans cells may home to remote sites away from the site 
of contact but are activated on contact with the offending allergen. Contact dermatitis from latex 
additive chemicals is most commonly induced by thiuram and mercapto-benzothiazole derivatives. 
This may be diagnosed by the use of standard patch testing. Recently, reports of contact dermatitis 
from latex protein have been described. No standardized reagent for the patch testing of latex 
proteins is available that would allow a systematic and safe evaluation of a patient. It is critical that 
the physician understand that dermatitis may or may not be present in a patient with latex allergy. 
Neither the presence nor absence of dermatitis is diagnostic of type I IgE-mediated allergy to latex 
but often may accompany it.
A number of other factors enhance the risk of developing latex allergy. These include the need 
for multiple surgeries or chronic mechanical ventilation, ventriculoperitoneal shunts in children, and
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hospitalization of premature infants. They all have remarkably similar profiles of exposure to latex, 
especially latex examination gloves.
DIAGNOSIS OF LATEX ALLERGY
Latex allergy evaluation
Medical history 
Physical exanvnaitoo
Asympi
STOP
No latex allergy 
Testing not wcbcated
Immediate symptoms
Dermatitis, urticaria, 
engioedema, rhinitis, 
asthma, anaphylaxis
Testing indicated
Anti-latex k jE  by serology 
Patch lest (dermatitis)
Delayed symptom
Acute or chronic 
dermatitis
Te s tin g  Indicated 
Patch test
Te stin g  negative  j
Irritant dermatitis*** I
'Spina brfida patients should be cared for in л  latex sale environment from birth
**S occupation woikef-pukrxxiary function testing and methachctine chalenge. in other countries outside the US. a licensed 
skin test reagent has been used as the procedure of chose* for initial diagnostic testing.
— Some reports in the medical literature implicate 'atex proteins as a cause Ы  contact dermatitis. No standardized reagent is 
available for such testing that does not indude potential contamination from additive chemicals.
МсвЬу tem* arid derived Hfm  03006 by Uoaby. Inc.
Figure 13-1. An algorithm for the diagnosis of latex allergy in the United States, where no 
diagnostic skin test reagent is cleared for use by the Food and Drug Administration.
SPT with graded concentrations (1 HEP, 10 HEP, 100 HEP; HEP = histamine equivalent 
potency) identifies 96%; pure latex solutions may also be used.
Challenge tests may be required: blind glove challenge (in a box); open glove challenge, and 
SPT with prick through a glove have all been used.
Type IV reactions are identified by patch testing.
Current specific IgE tests (RAST) identify only 85% of allergic patients.
The latex reagents for testing are ammoniated latex extracts or finished product (high-allergen 
latex glove). Unfortunately, a standardized finished product for such testing is not available to the 
clinician. Attempts to use finished materials in an office practice of allergy may result in false­
negative reactions because the source product is low in allergen or even leads to adverse reactions 
because of excessively high allergen content. To combat the latter problem, most practicing
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allergists have used sequential multiple dilutions to avoid the risk of systemic reactions. This risk 
should not deter the release and use of latex skin test reagents. Inability to confirm a diagnosis of 
latex allergy because of unavailability o f skin testing reagents may present more risk to a patient 
who would continue latex exposures (e g., health care work) that result in life-threatening reactions 
or asthma.
The second available method to detect latex-specific IgE is serologic testing. The three 
commercially available tests include the CAP radioallergosorbet test fluorescent enzyme linked 
immunoassay (FEIA) from Pharmacia, Uppsala, Sweden; AlaSTAT from Diagnostics Products 
Corporation (DPC) Los Angeles, California; and HY-TEC-EIA from Hycor Biomedical, Irvine, 
California. The sensitivity of the CAP and AlaSTAT is similar, with approximately 25% false­
negative tests. The HY-TEC has a 27% false-positive result. These tests are very useful when 
coupled with a medical history but do not demonstrate complete diagnostic reliability. Serologic 
testing in some research centers has shown high sensitivity and specificity as well.
The presence of circulating IgE in the serum alone is not sufficient to make a diagnosis of 
latex allergy. Medical history and physical examination coupled with laboratory confirmation are 
necessary to confirm a diagnosis, when possible. Insufficiently sensitive and specific diagnostic 
reagents have hindered this endeavor. This may lead to some subjects who have latex 
hypersensitivity remaining undiagnosed while some without this allergy may be overdiagnosed. The 
clinician must use clinical judgment when the tests are asynchronous to the history and exam.
Research findings indicate that specific challenges by glove provocation, hooded exposure 
chamber, and nasal provocation may result in improved diagnostic sensitivity. Currently, these are 
impractical, given the lack of standard reagents or gloves for such challenges. The clinician must 
use judgment in discerning the proper diagnosis and therapy of a patient with a positive history and 
negative serologic test, because 25% o f subjects with latex allergy have a negative serum test. Other 
tests, including flow cytometry, cell proliferation, and patch testing, have been helpful but not 
always available to the practicing clinician.
MANAGEMENT OF THE NRL ALLERGIC PATIENT
• For type I reactions avoidance is required. This requires education of patient and 
employers.
• Occupational issues are difficult, especially in the Health Service.
• Latex is a substance identified in COSHH regulations as hazardous to health. 
Employers are therefore required by law to minimize exposure and carry out risk 
assessments where latex is used.
• Consideration of management of anaphylaxis away from hospital, including self­
administration o f hydrocortisone may be desirable.
• Pharmacy will advise on latex content of drugs: latex is used in bungs in drug vials.
• Hospitals should keep identified boxes of latex-free equipment in key areas.
• A safe environment is one where there is no NRL direct skin, mucous membrane, or 
aeroallergen contact by a Person with NRL allergy. Currently, NRL products made by a 
dipping method with a powder donning lubricant are the most likely to result in serious 
reactions from either direct contact or aeroallergen inhalation. An NRL product heat 
vulcanized at 600°C for 1 hour will have considerably less allergen content than a product 
heat vulcanized at 100°C for a few minutes.
•  NRL-"safe" precautions in the operating room have allowed for uncomplicated 
anesthesia for the majority o f patients with NRL allergy. Premedication with antihistamines 
and corticosteroids may be used, but there is no documentation that this improves patient 
outcome. Occasionally, NRL-safe precautions have failed to prevent an allergic reaction in 
some individuals. Because the level o f aeroallergen in operating rooms declines when there 
is no activity, it has been suggested that operating on latex-allergic patients as the first case 
of the day to avoid aeroallergen exposure is safe.
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•  In addition to the operating room, safe care for NRL patients in an ambulance, 
emergency room, laboratory, radiology, general ward, intensive care unit, post anesthesia 
care unit, and clinic is required. Medical literature repeatedly demonstrates that powdered 
NRL gloves are the major contributor of transferable allergen. Strict avoidance of the use of 
powdered NRL gloves is necessary in all these areas, as it is impossible to predict when an 
NRL-allergic patient may present for care. Not only should the patient wear proper 
identification about the NRL allergy, but the room or area in which they receive care should 
be clearly marked to prevent accidental exposure (e.g., by bringing a powdered NRL balloon 
into the room). Policies and procedures for caring for such patients are necessary. Central 
purchasing should control ordering practices and maintain lists of alternative products.
• Successful management of the natural rubber latex (NRL)-allergic patient is critical 
to avoid untoward allergic reactions and occupational asthma. Avoiding contact with NRL 
products has remained the mainstay of therapy (Box 13-1).
Box 13-1. Latex-Safe Precautions in Hospital and Clinical Settings in Documented or 
Suspected Latex Allergy
• Only non latex glove use
• Allergy alert band for the patient
• "Latex-safe precautions" on door to patient room
• Check all medical devices for latex content
• No latex contact to skin or mucosal surfaces of patient (no source for inhalation)
• No intravenous valves inline Inject medication via stopcock devices instead of 
injector ports on tubing
• Operating room - Schedule as the first case of the day if powdered gloves in prior use 
in operating room
• Multiple-dose vials - Take top off or change needle after drawing up medication
• Premedication - Not necessary when strict latex-Safe precautions used
• Ideal - Latex gloves used should be powder free and low in allergen for nonlatex 
allergic patients
• Ban powdered latex products manufactured by dipping process from building (e.g., 
balloons).
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14. ANGIOEDEMA
Angioedema is a deep-tissue swelling that must be distinguished from urticaria. It is rarely 
itchy, and tends to give discomfort from pressure. In hereditary angioedema and sometimes in 
idiopathic angioedema, there is often a premonitory tingling before the swelling occurs. Any part of 
the body (including gut) may be involved.
Causes
• Allergic (accompanied by other features such as urticaria, anaphylaxis, etc.).
• Hereditary C l -esterase inhibitor or C4BP deficiency.
• ACE deficiency.
• Acquired Cl-esterase inhibitor deficiency (autoantibody-mediated, SLE, lymphoma). 
Lymphoma associated acquired Cl-esterase inhibitor deficiency is usually due to splenic villous 
lymphomas.
• Physical (pressure, vibration, water - often with urticaria).
• Drugs (angiotensin-converting enzyme (ACE) inhibitors; NSAIDs, statins, proton-pump 
inhibitors are the commonest drugs).
• Idiopathic (rarely involves larynx) - other causes excluded.
Immunological features
• Mechanism is thought to involve activation of the kinin system with bradykinin production, 
leading to tissue oedema. ACE inhibitors inhibit bradykinin breakdown (also cause cough due to 
excess bradykinin).
• Histamine is not involved (unless there is accompanying urticaria).
• C l -esterase inhibitor is known to be a control protein for the kinin cascade in addition to its 
role in the complement and clotting systems.
• There are polymorphisms of this enzyme but it is not known whether they correlate with the 
tendency to develop angioedema.
• Congenital ACE deficiency has also been associated with angioedema.
Diagnosis (see Fig 14-1)
• History will give useful clues: family history, connective tissue disease, lymphoma (may be 
occult), drug exposure, association with physical stimuli.
• Angioedema with urticaria will not be due to hereditary angioedema.
• In angioedema without urticaria, Cl-esterase inhibitor deficiency should be excluded. C4 
will be low, even between attacks, C l -inhibitor will be low in type I but high in type II (Chapter 1). 
Levels of C2 are said to distinguish acquired from inherited Cl-esterase inhibitor deficiency (low in 
inherited deficiency) but this test is not reliable.
• If acquired C l esterase inhibitor deficiency is suspected, check serum immunoglobulins, 
serum and urine electrophoresis, and p2-microglobulin. Examine for lymphadenopathy and 
splenomegaly and consider chest/abdominal CT scan.
•Connective tissue disease will usually be obvious, but detection of autoantibodies 
(antinuclear antibody (ANA), dsDNA, and extractable nuclear antigen (ENA) antibodies) may be 
necessary.
• Laboratory testing for angioedema see in Table 14-1.
Table 14-1. Testing for angioedema
Immediate tests Later tests
C3, C4, C l esterase inhibitor Consider immunoglobulins, electrophoresis (serum, urine), 
P2-microglobulin (immunochemical and functional) - 
urticaria not present
Tryptase (if urticaria present) ANA ds-DNA, ENA (suspected CTD)
CT scan chest/abdoment if lymphoma suspected
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Hereditary angioedema
In patients with recurrent angioedema, several disorders should be considered in the 
differential diagnosis, including hereditary angioedema (HAE), acquired deficiency o f the 
inhibitor of complement (C)l esterase, and angioedema-eosinophilia syndrome. Hereditary 
angioedema is an autosomal disorder characterized by episodic, nonpruritic, and painless 
subcutaneous swellings lasting for several hours to days. The lesions are often triggered by local 
trauma or emotional stress and are usually asymmetrical. Unlike acquired angioedema, an urticarial 
reaction pattern is not present in patients with this disorder. Also, a history of recurrent nausea, 
vomiting, and abdominal colicky pain resulting from localized intestinal edema is common in ihis 
patient population.
The onset o f HAE usually begins in childhood or young adulthood. There is often a positive 
history of other family members with similar complaints. It is important to differentiate HAE from 
other causes of angioedema, because patients with this disorder may be at greater risk for laryngeal 
edema leading to sudden death. The underlying mechanism for HAE is a genetically determined 
partial deficiency of an alpha2-glycoprotein, termed Cl esterase inhibitor (Cl INH). This serum 
protein normally inactivates the first component of complement. The absence of Cl INH results in 
excessive consumption of the complement component, C4. Thus, patients with HAE have 
chronically depressed serum levels of C4, and during acute attacks, both C4 and C2 levels are 
depressed. In approximately 85% of the patients, Cl INH levels are low, whereas in the remaining 
15%, the protein is present in normal amounts. In this latter group, the inhibitory activity of Cl INH 
is abnormal; a functional Cl INH assay is necessary to correctly identify this of HAE.
Pathogenesis o f hereditary angioedema see Fig 14-2.
Diagnosis
• Typically C4 and C2 are undetectable during an acute attack and low/absent in between.
• In type I, there will be a low Cl-inhibitor level immunochemically and this will become 
undetectable in an acute attack.
• In type II, there will be a normal or high level of inhibitor measured immunochemically, but 
function will be low or absent.
• Angioedema may be acquired secondary to SLE or lymphoma and these may be 
distinguished from HAE by the reduction in C lq, although this is not always reliable.
Treatment
• Treat major attacks with purified (steam-treated) inhibitor (1000-1500 IU, i.e. 2-3 ampoules) 
by slow intravenous injection.
• FFP may be an emergency alternative but there are the usual risks of transmitted infection 
and it is also possible for FFP to exacerbate attacks by providing more substrate.
• Tracheostomy may be required if there is significant laryngeal oedema.
• Prophylaxis may be obtained with modified androgens (danazol, 200-600 mg/day; or 
stanozolol, 2.5-10 mg/day) or anti-fibrinolytics (tranexamic acid 2-4 g/day). Regular liver function 
tests and liver ultrasounds are required for monitoring therapy with all these agents.
• Prophylactic purified inhibitor should be used before high-risk surgical procedures, although 
tranexamic acid may be adequate for minor procedures.
• Dental work should always be carried out in hospital in view of the risk of developing oral 
oedema and airway obstruction.
• Abdominal attacks respond poorly to purified inhibitor - treatment should be conservative: 
analgesia (NSAIDs), IV fluids, and avoidance of unnecessary laparotomies (unless there is good 
evidence for other pathology).
Episodic angioedema with eosinophilia
• Angioedema associated with cyclic weight gain (up to 15%), fever, urticaria, and 
eosinophilia.
• Cause unknown.
• Said to be benign.
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Box 14-1. Differencial diagnosis of angioedema
•  Hereditary angioedema
• Acquired Cl inhibitor deficiency
•  Angioedema-eosinophilia syndrome
• Panniculitus, cellulites
• Thrombophlebitis, lymphangitis
•  Cellulites granulomatosa
Treatment of angioedema (see Fig 14-1)
• Treatment is dependent on the cause.
• Acquired Cl-esterase inhibitor deficiency due to lymphoma will be improved by effective 
treatment o f the underlying disease, as will the autoimmune-associated angioedema.
• Purified Cl-esterase inhibitor may be required in acquired Cl-esterase inhibitor deficiency. 
Frequent doses may be required, due to the presence of inhibitory antibodies: in severe cases, 
plasmapheresis and immunosuppression may be required. FFP is less effective and may actually 
make the angioedema worse by providing extra substrate.
• There is no role for Cl-esterase inhibitor concentrate in idiopathic angioedema without 
evidence of deficiency.
• Control may be helped with antifibrinolytics (tranexamic acid, 2-4 g/day), or modified 
androgens (stanozolol, 2.5-10 mg/day; danazol, 200-800 mg/day). Monitor LFTs every 4-6 months 
and consider annual ultrasound liver.
• Idiopathic form (other causes excluded) responds best to tranexamic acid and less well to 
modified androgens.
•In acute attacks, adrenaline, antihistamines, and steroids are less effective than in 
anaphylaxis. Laryngeal involvement is less common in the non-hereditary forms.
• Patients with a history of angioedema for any reason should never be given ACE inhibitors, 
as these drugs may precipitate life-threatening events.
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Figure 14-1. Algorithm for the diagnosis and treatment of chronic urticaria and angioedema. 
ANA, anti-nuclear antibody; С 1, first component of complement; ESR, erythrocyte sedimentation 
rate; HAE, hereditary angioedema; Cl INH, Cl esterase inhibitor; NSAIA, nonsteroidal anti­
inflammatory agent; PMN, polymorphonuclear neutrophils; SLE, systemic lupus erythematosus.
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Figure 14-2. Pathogenesis of hereditary angioedema. Deficiency in the first component of 
complement (C l) esterase inhibitor (Cl-INH) leads to uninhibited complement activation and 
anaphylatoxin (СЗа, C5a) formation, which, in turn, stimulates mast cell mediator release. In 
addition, Hageman Factor activation also proceeds in the absence of Cl-INH activity, which may 
result in the formation of the vasodilating agent bradykinin.
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Box 15-1. Potential Mechanisms of Mast Cell Activation in Clinical Urticaria
Immunologic Mechanisms
• Antigen reaction with specific mast cell membrane IgE antibody
• Complement anaphylatoxin (C3a and C5a) stimulation of specific mast cell- 
associated receptors
• Eosinophil-derived major basic protein activation of mast cells
•  Leukocyte-derived histamine releasing factor(s), stimulation of mast cells Antibodies 
to IgE and IgE receptors
Nonimmunologic Factors That Stimulate Mast Cells
• Neuropeptides (substance P. calcitonin gene-related peptide, vasoactive intestinal 
polypeptide, neurokinin Y)
• Hormones (gastrin, estrogen, adrenocorticotropic hormone)
•  Medications (aspirin, nonsteroidal anti-inflammatory agents, codeine, curare, 
succinylcholine, polymyxin B, thiamine)
•  Physical stimuli (neat, cold, pressure, light)
•  Venoms
• Radiocontrast media
Diagnosis
• The history is everything! The appearances of the lesions may give clues (distinctive lesions 
in cholinergic urticaria). Dermographism should be sought. Physical causes can usually be 
replicated in the clinic to confirm the diagnosis: pressure tests; ice cube test (wrap ice cube in 
plastic bag to ensure that it is cold not water that causes the problem).
• Other diagnostic tests should depend on likely cause.
• Allergy testing is rarely justified in chronic urticaria as the yield is low.
• Check thyroid function, acute-phase response, full blood count, and think of infective 
causes.
• For acute urticarias, foods may play a role, exclusion diets may help but only if there is a 
strong suspicion on clinical grounds. The role of natural dietary salicylates and/or preservatives in 
chronic urticaria is controversial.
• In cold urticaria, seek family history and check for cryoglobulins and causes thereof 
(electrophoresis of serum, search for underlying diseases, infections, connective tissue disease, 
lymphoproli feration).
• Autoantibodies (ANA, ENA, dsDNA, RhF) and complement studies (СЗ, C4) may be 
relevant in some instances. In SLE with urticaria, think of autoantibodies to Clq.
• Skin biopsy should be considered if there are atypical features if  urticarial vasculitis 
suspected).
Testing for urticaria
Immediate tests Later tests
Fut blood count—check for haematinic 
deficiency - MCV
Drug monitoring as required
Thyroid function
Liver function
Infection screen - Helicobacter
Consider autoimmune serology
Differential diagnosis of urticaria
• Urticaria of pregnancy (PUPPP)
• Urticarial vasculitis
• Figurative erythemas
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•  Erythema multiforme
• Dermatitis herpetiformis
•  Bullous pemphigoid
•  Herpes simplex, herpes zoster
• Mastocytosis
PRURITIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY
The term pruritic urticarial papules and plaques o f  pregnancy (PUPPP) refers to an intense 
pruritic eruption that is occasionally observed in pregnant women. Characteristically, patients with 
this disorder develop erythematous, urticarial plaques and papules during the last trimester of 
pregnancy. Classically, these lesions begin centrally over the abdomen and extend to involve the 
thighs, buttocks, and distal extremities. The facial area is usually spared. In some patients, only the 
lower extremities are involved. Although the pathophysiologic mechanism for this disorder is 
unknown, skin biopsies o f lesional tissue show histologic changes similar to those observed in other 
urticarial reactions and therefore suggest an important role for the mast cell. The material cutaneous 
lesions usually resolve shortly after delivery, and no associated abnormalities or adverse reactions 
have been reported in infants from mothers with PUPPP. Patients who develop PUPPP with their 
initial pregnancy are not necessarily at risk for recurrence of this disorder with subsequent 
pregnancies.
Systemic lupus erythematosus and other disorders
Urticaria lesions have the typical histologic changes of urticaria, while in others, there is 
evidence of leucocytoclastic vasculitis. Some patient with essential mixed cryoglobulinemia may 
also present initially with urticaria-like lesions following cold exposure. However, the presence of 
palpable purpuric lesions (vasculitis), Raynaud's phenomenon, and cutaneous ulterations helps to 
distinguish these patients from those with uncomplicated chronic urticaria.
Most patients with serum sickness develop an urticarial reaction pattern early in the course of 
disease. Histologically, these lesions may demonstrate changes typical of urticaria or may show 
more significant inflammation in the form of vasculitis. Urticarial vasculitis is distinguished from 
ordinary urticaria by the persistence of the lesions for >24 hours. Lesions usually fade to leave 
brown staining, due to erythrocyte extravasation. The hands, elbows, ankles, and knees are most 
frequently involved, and the patient often experiences pain or tenderness of cutaneous lesions in 
conjunction with pruritus. Joint pain and stiffness are also common and usually parallel skin disease 
activity. Gastrointestinal symptoms, including abdominal pain, nausea, vomiting, and diarrhea, have 
been temporally associated with skin and joint involvement. Other symptoms encountered less 
frequently in patients with urticarial vasculitis include recurrent headaches, eye pain, and chest pain.
In addition to arthritis, other clinical signs of systemic involvement in these patients include 
generalized lymph-adenopathy, bronchospasm, uveitis, episcleritis, and, more rarely, neurologic 
findings such as pseudotumor cerebri, meningitis, and mononeuritis.
The diagnosis o f idiopathic urticarial vasculitis is established by the histologic changes in the 
skin biopsy.
Urticarial-like papules and plaques also have been reported in children with juvenile 
rheumatoid arthritis, but, unlike common hives, these lesions are characteristically nonpruritic.
Lesions, o f acute and chronic urticaria also have been reported in patients with 
hypothyroidism, hyperthyroidism, and occult lymphomas.
Recurrent episodes of urticaria and angioedema have also been described in adolescents with 
the rare hereditary disorder originally described by Muckle and Wells 's These children experience 
recurrent urticaria eruptions accompanied by chills and malaise. Progressive nerve deafness and 
amyloidosis o f the kidney develop after a variable period. Schnitzler's syndrome represents a rare 
disorder characterized by nonpruritic urticarial papules and a monoclonal gammopathy. Patients 
aiso may experience a number of other signs and symptoms, including angioedema, fever, bone 
pain, weight loss, hepatospienomegaly, and lymphadenopathy. In addition to an IgM monoclonal
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gammopathy, these patients also may have an elevated erythrocyte sedimentation rate and increased 
serum fibrinogen levels. Biopsies of lesional skin may show varying degrees of neuirophilic 
infiltrates with or without vasculitis.
Several other well-defined cutaneous diseases also should be considered in the differential 
diagnosis o f urticaria or angioedema. The annular and arcuate morphology of some urticarial 
lesions must be distinguished from a group of disorders termed the figurative erythemas. This group 
includes erythema annulare centrifugum, erythema chronicum migrans, and erythema marginatum. 
In contrast to urticaria, usually these eruptions are nonpruritic. Erythema annulare centrifugum, 
which most closely resembles an urticarial reaction pattern, can be identified by a characteristic 
scaling ring that trails its advancing red border. Individual lesions of erythema multiforme may also 
assume an urticarial morphology. However, the more typical target-like lesions are usually also 
present.
Early in their course, some of the primary blistering disorders may appear urticarial. In 
particular, the autoimmune blistering diseases such as dermatitis herpetiformis and bullous 
pemphigoid may present as pruritic papules. Similarly, herpes simplex and herpes zoster may begin 
as pruritic, slightly painful urticarial lesions, and in some instances, the full clinical expression of 
grouped vesicles may not occur. Lesion arrangement (grouped) and, a focal anatomic distribution, 
however, provide important clinical characteristics for differentiating herpetic lesions from typical 
lesions of urticaria.
Mastocytosis
Patients with mastocytosis may have dermatographism or a spontaneous urticaria-like 
eruption in foci of cutaneous mast cell infiltrates. Unlike urticaria, lesions of mastocytosis are 
persistent and readily identified by their tan (in children) or reddish-brown (in adults) color. This 
condition has been called urticaria pigmentosa because of the appearance.
Classification of mastocytosis
• Cutaneous mastocytosis:
• urticaria pigmentosa;
• solitary mastocytoma;
• diffuse cutaneous mastocytosis (rare);
• telangiectasia macularis eruptive perstans.
• Systemic mastocytosis:
• involvement of gut, bone marrow, bone.
• Mastocytosis in association with haematological disorders:
• leukaemia, lymphoma, myelodysplastic syndrome.
• Lymphadenopathic mastocytosis with eosinophilic
• Mast cell leukaemia (very rare!).
Presentation
• Cutaneous involvement with itchy brown macules; Darier's sign = urticaria on rubbing or 
scratching cutaneous lesions. Dermographism.
• Systemic symptoms include: nausea, vomiting, diarrhoea, headache, shortness o f breath, 
flushing, palpitations, loss of consciousness, malaise, and lethargy.
• Systemic attacks triggered by heat, emotion, aspirin, opiates.
• Evidence of associated haematological malignancy.
• Symptoms may be confused with carcinoid and phaeochromocytoma.
Diagnosis of mastocytosis
• Biopsy of skin, bowel; bone marrow examination if systemic form expected; endoscopy will 
be required for gut involvement.
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• Mast cell tryptase (serial measurements may be required); urinary methylhistamine is 
helpful, but not readily available. Exclude carcinoid by measurement of 5-H1AA, 
phaeochromocytoma by urinary catecholamines.
• Serum immunoglobulins and electrophoresis; urine electrophoreses.
• Blood film.
• Bone scan/MRI skeletal survey for infiltrations.
Treatment of mastocytosis
• High dose antihistamines (HI and H2).
• Aspirin may reduce prostaglandin production causing flushing, but should be used with 
caution as it can directly activate mast cells; leukotriene antagonists (monteleukast) will prevent 
leukotriene-related symptoms.
• Oral disodium cromoglycate may help bowel symptoms.
• Caution with drug use: avoid opiates and other drugs directly activating mast cells 
(radiocontrast dyes, dextrans); anaesthesia needs to be approached carefully.
• Wasp/bee stings may lead to severe reactions.
• a-interferon (disappointing in most cases) and c-kil inhibitors (mast cells express increased 
c-kit) are being used experimentally. PUVA may help in skin lesions.
Treatment of urticaria
• Urticaria may be difficult to manage, especially cold urticaria. Commonest failing is 
inadequate dosage o f antihistamines. The new antihistamines are safe in doses well above the 
recommended doses and do not interfere with cardiac potassium channels to cause prolonged QT 
interval.
• Acute urticaria should be treated with potent non-sedating antihistamines. Short-acting ones 
such as acrivastine may be appropriate for intermittent attacks. Potent long-acting non-sedating 
ones, such as fexofenadine, levocetirizine, and cetirizine (also said to have mast-cell stabilizing 
activity, o f uncertain clinical significance), are useful for prophylaxis against frequent attacks. A 
few patients may still be sedated by these drugs.
• Loratidine and desloratidine have been reported by the EMEA to be associated with a small 
increase in minor malformations if taken in pregnancy.
• Doses up to 4 times the normal dose may be required in difficult cases.
• If these are unsuccessful alone, then the addition of an H2-blocker may be helpful, although 
the evidence is weak. There is no evidence to suggest whether ranitidine or cimetidine is preferable.
• Other therapeutic options include the following:
•  doxepin, an antidepressant with potent HI- and H2-blocking activity, and ketotifen 
and which has mast-cell stabilizing activity in addition to anti-Hl activity (it increases 
appetite and is sedating);
•  mirtazipine is also a valuable third-line agent and has antihistaminic properties;
• calcium-channel blockers may have some beneficial effect as they stabilize mast 
cells (nimodipine is said to be better than nifedipine);
• p2-agonists (terbutaline) and phosphodiesterase inhibitors (theophylline) may help in 
rare cases;
•  oxypentifylline has been reported to reduce cytokine synthesis by macrophages and 
may bebelpful;
•  colchicine is helpful in delayed pressure urticaria but is poorly tolerated;.
• leukotriene antagonists may also be helpful in some patients;
•  resistant urticaria may respond to low dose warfarin (mechanism unknown).
• Non-familial cold urticaria may respond to cyproheptadine, calcium-channel blockers, p2- 
agonists, and phosphodiesterase inhibitors, although responses tend to be poor.
• Familial cold urticaria does not respond to antihistamines, but may respond to NSAfDs.
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• Steroids may be effective but should be used as a last resort as chronic therapy is not 
justified by the side-effects; danazol and stanozolol may be used as alternatives (with varying 
benefit). Short courses may be helpful for acute disease.
• Cyclosporin A may also be helpful, but the disease relapses once the drug is withdrawn. The 
side-effects (hypertension, nephrotoxicity) make it an undesirable drug for urticaria.
• High-dose IVlg has been used in resistant cases but the benefits are variable.
• Whenever chronic therapy is started, it is important to withdraw it at intervals to see 
whether it is still required in the light of possible spontaneous remission.
• Consider stress management programme
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QUESTIONS AND ANSWERS
1. How do CD8+T-cell subsets differ from CD4+ subsets?
CD8+ T cells are also divided into subsets based upon their cytokine profiles. CD8+ T cells that 
produce cytokines similar to CD4+ Thl cells are designated T cytotoxic 1 (Tel) cells, whereas 
those that produce cytokines similar to CD4+ Th2 cells are called T cytotoxic 2 (Tc2) cells.
2. Which T-cell subset is associated with oral tolerance?
Another type of Th cell, known asTh3, is preferentially induced by chronic oral administration of 
low doses of antigens. These cells synthesize large amounts o f transforming growth factor-f), 
produce IL-10, and induce oral tolerance.
3. Explain the mechanisms by which CD8+ cells mediate cytotoxity.
CD8+ T cells exhibit two distinct mechanisms for inducing cytotoxicity: Fas ligand and perforin. 
Fas ligand on CD8+ cells engages Fas on the target cell, thereby initiating apoptotic pathways that 
lead to activation o f caspase 8 (exogenous pathway) and caspase 9 (endogenous pathway). Both 
caspase pathways activate caspase 3, which induces apoptosis.
Alternatively, cytotoxic cells may interact with perforin, a membrane pore-forming molecule, to 
create pores in the target cell. Cytotoxic enzymes such as granzyme В and granulysin are 
transferred from the cytotoxic cell into the cytosol o f the target cell, leading to cell death. In 
addition, granzyme В induces apoptosis by activating caspase 8, caspase 9, and caspase-activated 
DNAse (CAD), an endonuclease that cleaves DNA.
4. How does allergen-specific IgE testing compare with other tests for 
aeroallergens?
Allergen-specific IgE tests have been compared to skin testing. Modified RAST testing was found 
to be equivalent to skin prick testing and better than intradermal testing in predicting clinical 
reactivity to cat dander. The allergen-specific IgE testing was also found to have a sensitivity of 
69%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 73% 
compared to cat allergen inhalation testing. A correlation was found between the concentration of 
dust mite-specific IgE and the concentration of dust mite allergen in the patient’s bedding. There 
was a 77% chance of high dust mite allergen exposure when the concentration of dust mite allergen- 
specific IgE was > 2 kUa/L In general, allergen-specific IgE testing is comparable to allergic skin 
prick testing.
5. What is the prick-prick test?
The prick-prick test is a skin prick test in which the fresh food is pricked before pricking the 
patient's skin. This method may introduce proteins from the fresh food that is not available in the 
commercial extract. A prick from the fresh food must also be pricked on a patient without the 
pertinent history as a control. Spices may also be used after the material is ground into a power and 
solubilized with diluent.
6. What are the shock organs in anaphylaxis?
The clinical course o f anaphylaxis is determined by organ system involvement. It is based on the 
immune response and the location of the smooth muscles affected by the release of the chemical 
mediators. In humans, the major organs affected by the anaphylaxis are heart and lung, with 
common and potentially fatal clinical reactions of cardiovascular compromise, respiratory failure, 
and laryngeal edema.
7. What common clinical conditions may mimic anaphylaxis/anaphylactoid 
reaction?
• Shock
• Hemorrhagic (massive gastrointestinal blood loss)
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•  Cardiogenic (acute myocardial infarction)
•  Septic
•  Vasovagal reaction
•  Carcinoid syndrome
• Systemic mastocytosis
• Pheochromocytoma
• Hereditary angioedema
• Nonorganic causes
•  Panic disorder
•  Vocal cord dysfunction
•  Globus hystericus
8. How can you differentiate a vasovagal reaction from true anaphylaxis or 
anaphylactoid response?
Vasovagal reactions may occur after an injection, and the usual clinical manifestations include 
dizziness, diaphoresis, pallor, weakness, sweating, nausea, hypotension, and bradycardia Patients 
lack pruritus, urticaria, angioedema, tachycardia, and bronchospasm.
9. Which reactions are mediated by non-IgE mechanisms?
Complement activation and generation of anaphylotoxins (СЗа, C4a, C5a): human plasma and 
blood products, gamma globulin.
Direct activation of mast cells or basophil mediators release: opiates, tubucurare, dextran, 
radiocontrast materials, fluorescein dye for angiography, and some chemotherapeutic agents. 
Modulators o f arachidonic acid metabolism: nonsteroidal anti-inflammatory drugs (e.g., 
aspirin, ibuprofen, indomethacin).
10. Which reactions are mediated by an unknown mechanism?
Sulfites: food additives
Steroids: progesterone and hydrocortisone
Physical triggers: EIA, food-dependent EIA, systemic cold-induced urticaria, and systemic 
heat-induced urticaria 
Systemic mastocytosis 
Idiopathic anaphylaxis
11. What symptoms may be seen with overdose of first-generation antihistamines? 
Contrast the toxic effects in young children and adults.
Overdose in adults typically causes severe lethargy. Coma and death may occur. Anticholinergic 
effects may include dry mucous membranes, urinary retention, tachycardia, and decreased intestinal 
motility. The QTc interval may be prolonged, predisposing the patient to torsade de pointes.
In contrast, infants and young children may show paradoxical central nervous system stimulation 
with irritability, hyperactivity, hallucinations, and seizures.
12. What are the two basic classes of decongestants?
Oral decongestants include pseudoephedrine and phenylephrine; topical decongestants include 
oxymetazoline, xylometazoline, naphazoline, tetrahydrozoline, and phenylephrine.
13. What is the most effective class of medication used to treat allergic rhinitis?
A meta-analysis o f 16 studies comparing intranasal steroids sprays to antihistamines showed a 
highly significant superiority of nasal steroids in controlling sneeze, itch, congestion, nasal dis­
charge, and total nasal symptom score. In addition, compared to antihistamines, nasal steroids were 
equally effective at controlling ocular symptoms. The authors' conclusion based on efficacy, safety,
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and cost was that intranasal steroids are preferred as first-line therapy for allergic rhinitis. Nasal 
steroids have also been shown to be more efficacious than cromolyn and montelukast.
14. Describe the mechanism of action of cromolyn sodium nasal spray. What is 
role in the treatment of allergic rhinitis?
Cromolyn sodium (Nasatcrom) inhibits mediator release from mast cells, reducing the allenii 
reaction ratherthan alleviating symptoms once they have begun. The protective effect of a single 
dose of cromolyn lasts for 4-8 hours. It is best to start cromolyn before the onset of the allergy 
season (e g., spring) because the onset of sustained benefit takes several days to 2 weeks.
Suggested dosing is 1 spray in each nostril every 4 hours during the day. Cromolyn may also be 
used as an intermittent medication to pretreat infrequent exposures to the patient's known allergic 
triggers. Like antihistamines, cromolyn is more effective for reducing sneeze, itch, and rhinorrhea 
than it is for nasal congestion. In general, cromolyn is less effective than antihistamines and nasal 
steroids.
15. What should be considered first-line controller therapy for patients with 
moderate and severe persistent asthma?
The updated 2002 NAEPP guidelines stress that the combination controller regimen of low-to- 
moderate dose inhaled corticosteroids plus a long-acting 02 agonist is equally or more efficacious in 
maintaining asthma control than high-dose inhaled steroids alone. This statement is supported by 
several recent clinical trials showing that the combination regimen best improves quality of life and 
symptoms and most effectively diminishes the number of exacerbations. This recommendation 
agrees with the recommendation to minimize dosing of inhaled steroids because of the possible, but 
as yet unproven, long-term side effects of high-dose inhaled steroids.
16. How can nocturnal awakenings be better controlled?
Since many medications lose their effect at these hours, nocturnal symptoms often become 
challenging to control. Moving the dose of inhaled corticosteroids to the afternoon hours, adding an 
inhaled long-acting 02 agonist or anticholinergic bronchodilator, or offering a trial of a leukotriene 
inhibitor or theophylline before the patient retires to sleep are appropriate measures. A stepwise 
approach is often needed, and if one intervention does not ameliorate the symptoms, another agent 
should be added to the regimen.
17. What are the effects of pregnancy on asthma?
Asthma is the most commonly encountered lung disease during pregnancy. Approximately 1 % of 
pregnancies are complicated by asthma, and 1 of 500 pregnant women experience life-threatening 
consequences. In general, approximately one-third of pregnant women experience worsening of 
asthma during gestation, one-third remain the same, and one-third actually improve.
18. When should antibiotics be prescribed in acute exacerbations of asthma?
Common triggers of acute exacerbations of asthma include allergen exposure (e.g., dust mite, mold, 
pollens, cats), viral infections, and exercise. Evidence suggests that viral upper respiratory tract 
infections, namely rhinovirus, cause > 80% of asthma exacerbations in adults. The need for 
diagnostic chest radiographs or antibiotics for treatment of exacerbations is very uncommon. The 
2002 NAEPP guidelines state that antibiotics are not indicated for the treatment of acute asthma 
exacerbations except when comorbid conditions dictate such use. Indications for antibiotic use 
include concomitant acute pyogenic sinusitis or acute bacterial bronchitis in patients with 
underlying COPD. In general, treatment focus is on appropriate steroid and bronchodilator therapy 
and trigger avoidance. Recent trials, however, have shown the benefits o f macrolide therapy 
(clarithromycin, 1000 mg/d for 6 weeks or equivalent) in some severe asthmatics who have 
serologic evidence of Chlamydia pneumoniae or Mycoplasma pneumoniae Infection.
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19. Explain the benefit of dry-powder inhalers (DPIs).
Dry-powder, brea'h-activated delivery devices are available for both inhaled steroid and bron- 
chodilator medications, and combination formulations will soon be manufactured. They have 
gained favor among patients and physicians because of their ease of use and the elimination of 
CFC-containing MDls. DPIs may benefit patients unable to master the hand-breath coordination of 
an MDI and improve airway deposition of drug in many patients with poor MDI technique. In 
addition, the automatic doses counter and simple packaging of DPIs make them appealing to 
patients and physicians. However, as with MDIs, the success of DPI delivery to the lower respi­
ratory tract is still heavily dependent on patient effort.
20. What causes nocturnal awakenings in asthmatic patients?
Nocturnal symptoms of sleep wakefulness, cough, and wheezing are signs of poorly controlled 
asthma. The chronobiology of asthma in adults and children is well documented. Typically, PEFRs 
decrease significantly between 2 am and 6 am because of a natural diminution in circulating 
catecholamines and corticosteroids and a rise in vagal tone.
21. Describe hereditary angioedema.
Hereditary angioedema is a dominantly inherited disorder characterized by recurrent attacks i ii 
angioedema involving the skin, mucous membranes, and respiratory and gastrointestinal tracts. It is 
associated with a functional deficiency of the inhibitor of the first component of the complement 
system, the Cl esterase inhibitor About 85% of patients have decreased levels of the inhibitor; the 
remaining patients have a normal level of the inhibitor, but it is nonfunctional. The condition can be 
diagnosed by clinical presentation, positive family history, and a characteristic complement profile 
(normal Cl, C3, decreased C4) during attacks.
22. What is autoimmune urticaria?
Autoimmune urticaria designates a subset of patients with chronic urtiaria who have autoantibodies 
with histamine-releasing activity. The existence of these autoantibodies was recognized initially by 
the observation that sera from affected patients induced an immediate urticarial response on 
injection into their own skin It was then shown that the sera induced histamine release from 
basophils and mast cells It is now well established the autoantibodies responsible for this activity 
are those recognizing FceRI and, less commonly, IgE.
23. Describe contact urticaria (allergic or pseudoallergic).
Contact urticaria refers to lesions that develop following skin contact with substances ranging from 
low-molecular-weight organic compounds to macromolecules. Nonimmunoiogicai contact urticaria 
(NICU) occurs without previous sensitization. Inducing substances include preservatives and 
fragrances in foods, cosmetics, and topical medicaments Immunologic (allergic) contact urticaria is 
due to immediate-type hypersensitivity and involves IgE specific for the contact allergens. It may 
be associated with systemic and potentially life-threatening symptoms. Natural rubber latex is one 
of the most notable allergens.
24. What is the role of foods in urticaria?
Foods are a common cause of acute urticaria, which is often identified by the patients themselves 
through association of the development of the lesions in proximity to ingestion of a particular kind 
of foods on several occasions Symptoms begin within minutes to several hours after ingestion. GI 
and respiratory symptoms may accompany or precede the urticarial reaction IgE antibodies to food 
components are implicated However, other mechanisms exist, for example, red wines may contain 
high concentrations of vasoactive amines, which can cause urticaria. The role of foods as a cause of 
chronic urticaria is controversial.
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25. Do children outgrow IgE-mediated food allergies?
New data suggest that about 10% of children with peanut allergy become tolerant by age 5-6 years; 
however, if they are not tolerant by then, the allergy appears to be persistent through adulthood. 
Approximately 85% of children allergic to milk, soy, and egg tolerate the implicated food by age 3- 
5 years. If the reaction was anaphylactic and the level of IgE antibody is high, the development of 
tolerance is less likely. Most reactions to cow's milk are поп-IgE-mediated G1 reactions. In general, 
if a child has a low level of IgE to a food, there is a greater chance of developing tolerance when 
rechallenged later compared with children with high IgE levels. Incremental food challenges are 
quite useful and allow liberalization of the diet after 1-3 years ni avoidance. A child may still have a 
positive skin test or in vitro specific IgE assay and yet tolerate the food.
26. What is the immediate cause of death from food allergy?
Severe bronchospasm is frequently reported in the few available case series examining food allergy 
mortality. Symptoms can start out mild (hives) and then progress. Severe symptoms can persist for 
many hours before death. However, any of the following manifestations can result in death within 
minutes:
• Laryngoedema
• Oral angioedema blocking the airway
• Bronchospasm
• Hypotension/cardiovascular collapse
27. What are the risk factors for death from anaphylaxis to foods?
Failure to administer epinephrine early in the reaction. Many patients do not have self- 
injectable epinephrine because of failure of physicians to prescribe epinephrine or their own 
failure to carry it with them or keep the prescription up to date In addition, many states do not 
allow all levels of emergency medical technicians to administer epinephrine in the field.
• Underlying asthma
• Peanut, tree nut, or seafood allergy
• Adolescent or young adult (may be related to denial of symptom severity)
• History of previous severe reactions
• Failure to activate the emergency medical system after recognizing a reaction due to denial 
of its potential severity
• Failure to recognize biphasic anaphylaxis, which occurs when a systemic reaction initially 
seems to respond completely to therapy, only to recur within an hour or two.
• Patient taking beta blockers and perhaps ACE inhibitors may have more severe anaphylaxis.
28. How is food allergy diagnosed?
A combination of history, physical examination, laboratory evaluation, skin prick testing, 
elimination diets, sometimes endoscopy and/oral food challenges. The history, which is most 
important, should focus on the age of onset, symptoms, time between ingestion and reaction, 
reproducibility (do the reactions occur every time the food is eaten?), presence of atopic dermatitis, 
asthma, allergic rhinitis, or other atopy. The history should also focus on conditions that may be in 
the differential diagnosis of food allergy or intolerance, such as gastrointestinal conditions (hiatal 
hernia, pyloric stenosis, gallstones). Subsequent evaluation is driven by the suspected 
pathophysiology of the reported adverse reaction.
29. Describe the role of aeroallergens and household allergens in atopic dermatitis.
Aeroallergens play more of a role as the atopic child grows older. Studies have shown worsening of 
symptoms with patch testing of aeroallergens Inhalation of aeroallergens may exacerbate the skin 
disease Sera from 95% of patients with atopic dermatitis had IgE to house dust mites compared 
with 42% of asthmatic patiente. House dust mite-specific lymphocyte stimulation is greatly elevated
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in infants with atopic dermatitis. Recommendation of empiric avoidance of dust mite and animal 
dander may be warranted because avoidance improves symptoms.
30. What role do infectious agents play in flares of atopic dermatitis?
Patients with atopic dermatitis have an increased tendency for development of bacterial and fungal 
skin infections. In general, dry skin creates small fissures that can serve as an entry to skin 
pathogens. However, compared with other dry skin conditions, such as psoriasis, there is still an 
increased susceptibility for infections. A deficiency in antimicrobial peptides was found in the skin 
of patients with atopic dermatitis compared to the skin of patients with psoriasis, leading to a 
susceptibility to S. aureus. S. aureus is colonized on the skin of 90% of patients with atopic 
dermatitis compared with only 5% of healthy people. Empirical treatment with oral antibiotics often 
results in improvement, even if no active infection is seen. Observation of pustules indicates that S. 
aureus may be present.
31. How are bacterial skin infections treated?
An antibiotic with good staphylococcal coverage, such as cephalexin or dicloxacillin should be 
administered for 3-4 weeks. Some patients may require longer treatment (6-12 weeks). Bictroban 
can be used for early topical treatment and also can be applied to the nares of staphylococcal 
carriers who experience frequent relapses when antibiotics are discontinued. However, other topical 
antibiotics are of little therapeutic value and can lead to sensitization to the agents, particularly 
neomycin.
32. What mechanisms of immune damage have been associated with drug 
hypersensitivity?
The Gell and Coombs classification of human hypersensitivity provides models for understanding 
immunologic drug reactions. Type I reaction is IgE-mediated and constitutes an immediair 
hypersensitivity response. Type II hypersensitivity involves antibody-mediated cytotoxicity. 
Immune complex reactions are temied type III. Cell-mediated immunity causes type IV 
hypersensitivity. For the majority of suspected lDHRs, the exact mechanism of involvement o f the 
immune system is not fully known, and some drug reactions may involve multiple pathways.
33. Describe the pathogenesis of type I hypersensitivity reactions.
Type I hypersensitivity reactions are true dnig allergies. They are elicited by the binding of some 
from of the drug to specific IgE attached to Fee receptors on mast cells. Degranulation and 
activation of the mast cell occur with release of histamine and other preformed and newly 
synthesized mediators of inflammation. Clinical findings include urticaria, angioedema, 
bronchospasm, and anaphylaxis.
34. Give examples of agents that may cause type I reactions.
Beta-lactams such as penicillin that can bind to human proteins and create allergenic haptens are the 
most common cause of type I drug hypersensitivity. Other drugs that may produce this type of 
reaction include proteins, generally of large molecular weight, such as:
•  Antithymocyte globulin
• Chymopapain
• ' Heterologousantiserum
• Insulin
• Protamine
•  Recombinant granulocyte-macrophage colony-stimulating factors (GM-CSF)
•  Streptokinase
• Tetanus toxoid
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35. Describe the mechanism of a type II hypersensitivity reaction.
Toxicity due to type II hypersensitivity is caused by antibodies directed against antigens on or near 
the cell surface. Specific antibodies are necessary to initiate this form o f cytotoxic reaction, but in 
contrast to type I reactions, the antibodies are typically of the IgG or IgM class.
36. Give examples of type II reactions.
A major example of type II reaction is Coombs'-positive hemolytic anemia, in which penicillin 
exposure results in the production of antibodies directed against penicillin-coated erythrocytes, 
causing lysis of the cells. Other examples are:
• Granulocytopenia due to phenothiazines and sulfonamides
• Immune-induced thrombocytopenia due to sulfonamides, quinidine or heparin
• Methacillin-induced interstitial nephritis
• Methyldopa-induced immunohemolytic anemia
37. Give examples of a type III reaction.
Medications such as heterologous antiserum and other proteins with a tong half-life in the body may 
elicit a type III reaction. The clinical manifestations typically resemble serum sickness (skin rash, 
fever, lymphadenopathy, and arthralgia) and occur between 1 and 3 weeks after drug 
administration. Penicillin and cefaclor have been associated with a serum sickness-like illness, 
although the mechanism of this syndrome appears to be more complex and, in the case of cefaclor, 
seems not to involve significant antigen-antibody reactions.
38. Describe the proposed pathogenesis of a type IV hypersensitivity reaction.
In type IV hypersensitivity, or delayed hypersensitivity, cell-mediated cytotoxicity is responsible 
for the various clinical symptoms. Both CD4+ and CD8+ T cells mediate type IV responses. The 
proposed mechanism involves binding of drug haptens to intracellular or extracellular proteins for 
presentation by MHC molecules to drug-specific T cells. Subsequent cytokine release by T cells, 
together with the production of other mediators of cytotoxicity, creates the inflammatory response 
that is seen in conditions such as delayed-type hypersensitivity skin disease. Subtypes of the 
delayed hypersensitivity response may account for a variety of IDMRs, including maculopapular 
erythematous (morbilliform) eruptions, pustular exanthems, and some bullous reactions.
39. Give examples of a type IV reaction.
Examples of delayed hypersensitivity include contact dermatitis induced by:
• Ethylenediamine
• Neomycin
• Topical anesthestics
•  Topical antihistamines
• Topical corticosteroids
40. Define systemic mastocytosis.
Systemic mastocytosis is a clinical syndrome caused by the accumulation of mast cells in multiple 
organs, including skin, bone marrow, liver, and gastrointestinal tract. Clinical features of flushing, 
pruritus, and anaphylactic response may be associated with urticaria pigmentosa and may develop 
spontaneously or after taking NSAIDs, opiates, or alcohol. Other common features are osteoporosis, 
bone demineralization, and anemia due to bone marrow involvement.
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